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Upper urinary tract stones are a major determinant of pain and is suggested to accelerate 
disease progression in patients with autosomal dominant polycystic kidney disease 
(ADPKD). For these reasons, stones should be optimally managed in patients with 
ADPKD. However, the kidney distortions may make managing stones challenging in 
patients with ADPKD. Understanding of the epidemiology of upper urinary tract stones 
and stone intervention and the outcomes of stone interventions is limited. The aim of this 
thesis is to understand the epidemiology of upper urinary tract stones and stone 
interventions and consequences of stone management in patients with ADPKD. 
To address this knowledge gap, we conducted two systematic reviews to understand the 
current knowledge on the prevalence and incidence of upper urinary tract stones, and the 
success and complication rate of the three common stone interventions (shockwave 
lithotripsy [SWL], ureteroscopy, and percutaneous nephrolithotomy [PCNL]) in patients 
with ADPKD. We conducted a chart review to validate International Classification of 
Diseases, 10th revision (ICD-10) codes related to ADPKD. We then conducted two cohort 
studies using ICES data to determine and compare the rate of stones and rate of stone 
intervention, and the complication rate of the most common stone intervention 
(ureteroscopy) in patients with ADPKD to patients without ADPKD with similar baseline 
health.  
Chapter 2 showed that that there is poor consensus on how often patients with ADPKD 
develop or undergo intervention for upper urinary tract stones.  
Chapter 3 showed that the efficacy and safety of stone interventions in patients with 
ADPKD remains uncertain. 
Chapter 4 summarized the limitations of the existing literature based on the findings of 
the two systematic reviews. 
Chapter 5 showed that majority of the patients with ICD-10 codes related to ADPKD 





Chapter 6 showed that patients with ADPKD presented to the hospital with upper urinary 
tract stones more, and that urologist were not managing stones in patients with ADPKD 
in a similar manner to comparable patients without ADPKD. It also showed that 
ureteroscopy is the most commonly performed stone intervention. 
Chapter 7 showed ADPKD is associated with a statistically significant increase 
emergency department visits in selected patients with ADPKD who received 
ureteroscopy for upper urinary tract stones compared to patients without ADPKD.  
Results can inform the use of ICD-10 codes to build ADPKD cohorts, inform clinical 
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Summary for Lay Audience 
Autosomal dominant polycystic kidney disease is a condition where the kidneys are filled 
with many cysts. Over time, the cysts grow in size and number and cause the kidneys to 
fail. Upper urinary tract stones are a major reason for pain and may cause kidneys to fail 
faster in these patients. For these reasons, stones should be managed well in patients with 
ADPKD. However, the kidney cysts in these patients may make this challenging. A 
thorough review of the literature shows that little is known about the rate of upper urinary 
tract stones and stone interventions, and the outcomes of ureteroscopy (a common 
procedure to treat upper urinary tract stones). The aim of this thesis was to fill this 
knowledge gap. 
We did this by conducting large, follow-up studies using administrative databases. Our 
validation studies show that we can confidently use administrative codes to identify 
patients with ADPKD. This thesis confirms that hospital encounters with upper urinary 
tract stones are a manifestation of ADPKD. From the administrative data, urologists 
approach stones in ADPKD in a similar manner compared to patients without ADPKD, 
despite the distorted kidney anatomy potentially making stone interventions more 
challenging. Of all three commonly used interventions (SWL, ureteroscopy, and PCNL), 
ureteroscopy is the most common intervention used to manage stones in both patients 
with and without ADPKD. Our final thesis study shows that patients with ADPKD do not 
experience more ureteroscopic complications and hospital admission for any reason. 
However, they did experience more hospital presentation and emergency department visit 
for any reason compared to patients without ADPKD. This may be a consideration for 
patient counselling.  
The knowledge gained from this thesis identifies knowledge gaps, and lays the 
foundation for future studies on ADPKD using healthcare administrative databases. It 
also clarifies the rate of hospital encounters with upper urinary tract stones and the rate of 






All studies included in this thesis was primarily conceived, designed, and executed by 
Vinusha Kalatharan. Vinusha Kalatharan also wrote the initial draft of all manuscripts 
included in this thesis, and integrated feedbacks from co-authors and reviewers. The data 
for chapters 5, 6, and 7 were provided by ICES. The supervisory committee, Drs. Amit 
Garg, York Pei, Blayne Welk, and Sisira Sarma, and other research team members 
provided feedback, data cuts according to ICES regulations, and/or methodological or 
content expertise on an as needed basis and were listed as co-authors accordingly. All co-
authors contributed and approved the manuscripts. The contributions of Vinusha 
Kalatharan and each of the co-authors is detailed below, and  recognized as footnotes in 
the beginning of each chapter.  
Chapter 2: Vinusha Kalatharan and Amit X Garg conceived and actively participated in 
the design and coordination of the study. Vinusha Kalatharan developed the 
comprehensive search strategy with the help of the librarian, John Costello. Vinusha 
Kalatharan and Gary Grewal screened all relevant citations, abstracted information using 
a standardized data abstraction form developed by Vinusha Kalatharan, and assessed the 
risk of bias of each included study. Danielle M Nash resolved any disagreement between 
the two reviewers. Vinusha Kalatharan wrote the first draft of the manuscript, and 
integrated all co-authors’ and reviewers’ comments. All authors read and approved the 
final article. 
Chapter 3: Vinusha Kalatharan and Amit X Garg conceived and actively participated in 
the design and coordination of the study. Vinusha Kalatharan developed the 
comprehensive search strategy with the help of the librarian, John Costello. Vinusha 
Kalatharan and Racquel Jandoc screened all relevant citations and abstracted information 
using a standardized data abstraction form developed by Vinusha Kalatharan. Vinusha 
Kalatharan and Gary Grewal assessed the risk of bias of each included study. Danielle M 
Nash resolved any disagreement between the two reviewers. Vinusha Kalatharan 
conducted the analysis, wrote the first draft of the manuscript, and integrated all co-




Chapter 5: Vinusha Kalatharan, York Pei, and Amit X Garg conceived and actively 
participated in the design and coordination of the study. Vinusha Kalatharan was the 
main reviewer, conducted the main analysis, wrote the first draft of the manuscript, and 
integrated the comments of all co-authors and reviewers. Kristin Clemens assisted with 
the data collection, and Rebecca K McTavish was the second reviewer. Matthew Rochon 
reviewed images of patients that required additional information. Stephanie Dixon 
conducted analysis and provided analytical support for the ICES proportion of the data. 
All authors read and approved the final article.  
Chapter 6: Vinusha, Amit, Blayne, Danielle, and Stephanie actively participated in the 
design of the study. Vinusha executed the study, conducted the analyses, and wrote the 
first draft of the manuscript as first-author. Stephanie and Justin provided analytical 
support. All authors read, critically revised, and approved the final article. Vinusha 
integrated the feedbacks of all authors and reviewers.   
Chapter 7: Vinusha, Amit, Blayne, Danielle, and Eric actively participated in the design 
of the study. Vinusha executed the study, conducted the analyses, and wrote the first draft 
of the manuscript as first-author. Eric and Justin provided analytical support. All authors 
read, critically revised, and approved the final article. Vinusha integrated the feedbacks 





First, I would like to express my sincerest gratitude to my thesis advisor, Dr. Amit Garg, 
for his continual support throughout my doctoral training. I will forever be grateful for 
his guidance and the ample amount of opportunities that he provided me that enriched my 
training. Being trained under his supervision was an amazing learning experience and I 
am a better, and more independent researcher today because of his training and 
opportunities.  
I would also like to thank my committee members, Drs. Blayne Welk, Sisira Sarma, and 
York Pei for their insights and perspective on my research. My sincerest thanks to Dr. 
Blayne Welk for going above and beyond while providing me guidance with urological 
and epidemiological concepts. Blayne was always generous with his time and provide 
answers to all my questions, and I am truly grateful for all that he has done during my 
PhD. I also thank Dr. Sisira Sarma for taking time to meet with me and for providing me 
with his insights. Dr. Pei was very helpful with providing feedback pertaining to 
ADPKD. 
I am truly grateful for the opportunity to work alongside the staff at ICES. I’m forever 
thankful to Danielle Nash for training me on the ICES processes, and providing guidance 
and support in many ways. Danielle has always been generous with her time, and I am 
forever grateful for everything she has helped me with. My sincerest thanks to Stephanie 
Dixon, Eric McArthur, and Justin Slater for taking the time to clarify any conceptual 
doubts and sharing their expertise in biostatistics and SAS programming. I also thank 
Jessica Sontrop for providing me with writing resources and tips on how to become a 
better writer. I am also grateful for all the other ICES Western graduate students and 
post-doctoral fellows for their advice, continued friendship, and for supporting me. A 
special thanks to Kristin Clemens, Rey Acedillo, Alvin Li, Ahmed Al-Jaishi, Kyla 
Naylor, Steven Habbous, Rebecca McTavish, Aiden Liu, Sebastian Przech, Owen 
Litwen, Carina Iskander, and Flory Muanda. Flory has always encouraged me to keep 




concepts, provide advice, and hear out my thoughts. Thank you for all the kind words and 
motivation. 
Many thanks to the Department of Epidemiology and Biostatistics for laying a strong 
foundation in Epidemiology and Biostatistics. I am also very thankful for the friends I 
met at the Department of Epidemiology and Biostatistics during my graduate training that 
enriched my graduate experience. 
I would also like to acknowledge the financial support provided by Western Graduate 
Research Scholarship, Schulich Graduate Scholarship, Ontario Graduate Scholarship, 
Canadian Institute of Health Research Doctoral Scholarship, and the Kidney Research 
Scientist Core Education and National Training [KRESCENT] award. 
I am very grateful to have met researchers with a diverse background across Canada 
through the KRESCENT training program. The training program, mentors (Drs. Adeera 
Levin, Sunny Hartwig, and Todd Alexander), and other KRESCENT fellows fostered my 
growth as a researcher.  
My sincerest thanks and appreciation to my parents (Kalatharan Nagesu and Shasikara 
Kalatharan), late grandparents, sisters (Venusha Kalatharan and Abisha Kalatharan) who 
constantly encouraged and supported me throughout this process; I would not be where I 
am today without them. I also thank my new set of parents and siblings (my in-laws) that 
I gained during my PhD for being very supportive. Lastly, my sincerest thanks to my 




Table of Contents 
Abstract i 
Summary for Lay Audience ........................................................................................ iv 
Co-Authorship Statement.............................................................................................. v 
Acknowledgments...................................................................................................... vii 
Table of Contents ........................................................................................................ ix 
List of Tables .............................................................................................................. xv 
List of Figures ......................................................................................................... xviii 
List of Appendices .................................................................................................... xix 
Abbreviations .............................................................................................................. xx 
 Introduction ............................................................................................. 1 
1.1 BURDEN OF UPPER URINARY TRACT STONES IN THE GENERAL 
POPULATION .................................................................................................. 1 
1.2 AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
 ........................................................................................................................... 1 
1.3 UPPER URINARY TRACT STONES IN ADPKD ......................................... 3 
1.4 UPPER URINARY TRACT STONE MANAGEMENT IN THE GENERAL 
POPULATION .................................................................................................. 4 
1.4.1 Shockwave lithotripsy (SWL) in the general population ........................ 4 
1.4.2 Ureteroscopy in the general population ................................................... 5 
1.4.3 Percutaneous nephrolithotomy (PCNL) in the general population.......... 5 
1.5 UPPER URINARY TRACT STONE MANAGEMENT IN ADPKD ............. 6 
1.6 OVERALL AIMS ............................................................................................. 6 
1.7 STUDY OBJECTIVES ..................................................................................... 7 
1.8 STRUCTURE OF THESIS ............................................................................... 8 




 Stone prevalence in autosomal dominant polycystic kidney disease: a 
systematic review and meta-analysisa .................................................................... 15 
2.1 INTRODUCTION........................................................................................... 16 
2.2 METHODS ..................................................................................................... 16 
2.2.1 Design and study selection .................................................................... 16 
2.2.2 Identifying relevant articles ................................................................... 17 
2.2.3 Data abstraction ..................................................................................... 19 
2.2.4 Data analysis .......................................................................................... 25 
2.3 RESULTS ....................................................................................................... 25 
2.3.1 Study selection ....................................................................................... 25 
2.3.2 Description of included studies ............................................................. 26 
2.3.3 Patient population .................................................................................. 39 
2.3.4 Quality assessment of studies ................................................................ 45 
2.3.5 Prevalence and characteristics of stones and prevalence of stone 
intervention ......................................................................................... 47 
2.3.6 Stone incidence ...................................................................................... 55 
2.4 DISCUSSION ................................................................................................. 55 
2.5 CONCLUSION ............................................................................................... 58 
2.6 ADDENDUM ................................................................................................. 58 
2.7 REFERENCES ................................................................................................ 59 
 Efficacy and safety of surgical upper urinary tract stone interventions in 
autosomal dominant polycystic kidney disease: a systematic reviewb .................. 65 
3.1 INTRODUCTION........................................................................................... 66 
3.2 METHODS ..................................................................................................... 67 
3.2.1 Design and study selection .................................................................... 67 




3.2.3 Data abstraction ..................................................................................... 68 
3.2.4 Data analysis .......................................................................................... 69 
3.3 RESULTS ....................................................................................................... 77 
3.3.1 Quality assessment of studies ................................................................ 89 
3.3.2 Shockwave lithotripsy ........................................................................... 89 
3.3.3 Ureteroscopy .......................................................................................... 91 
3.3.4 Percutaneous nephrolithotomy (PCNL) ................................................ 93 
3.4 DISCUSSION ................................................................................................. 98 
3.5 CONCLUSION ............................................................................................. 101 
3.6 ADDENDUM ............................................................................................... 101 
3.7 REFERENCES .............................................................................................. 102 
 Limitations of the existing literature.................................................... 106 
4.1 Limitations of the existing literature ............................................................. 107 
4.2 REFERENCES .............................................................................................. 110 
 Positive predictive value of international classification of diseases, 10th 
revision coding algorithms to identify patients with autosomal dominant polycystic 
kidney diseasec ..................................................................................................... 111 
5.1 INTRODUCTION......................................................................................... 112 
5.2 METHODS ................................................................................................... 113 
5.2.1 Study design ........................................................................................ 113 
5.2.2 Ethics approval and consent to participate .......................................... 113 
5.2.3 Data sources and database algorithms ................................................. 114 
5.3 METHODS SPECIFIC TO CHART ABSTRACTION STUDY ................. 115 
5.3.1 Patient selection ................................................................................... 115 




Abbreviations: family history, Fam Hx; International Classification of Diseases, 
10th revision, ICD-10; left kidney, LK; polycystic kidney disease, PKD; right 
kidney, RK; ultrasound, U/S ......................................................................... 120 
5.3.3 Clinical definition of ADPKD ............................................................. 121 
5.3.4 Data analysis ........................................................................................ 122 
5.4 METHODS SPECIFIC TO ICES STUDY ................................................... 123 
5.4.1 Patient Selection .................................................................................. 123 
5.4.2 Data analysis ........................................................................................ 123 
5.5 RESULTS ..................................................................................................... 123 
5.5.1 Chart abstract study sample ................................................................. 123 
5.5.2 Chart abstraction patient characteristics .............................................. 124 
5.5.3 Coding algorithm positive predictive value and frequency ................. 125 
5.6 DISCUSSION ............................................................................................... 125 
5.7 CONCLUSION ............................................................................................. 127 
5.8 ADDENDUM ............................................................................................... 128 
5.8.1 Rationale for sampling 201 patients .................................................... 128 
5.8.2 Recommended algorithm for future studies ........................................ 128 
5.9 REFERENCES .............................................................................................. 129 
 Risk of hospital encounters with upper urinary tract stones in autosomal 
dominant polycystic kidney disease: a cohort studyd ........................................... 131 
6.1 INTRODUCTION......................................................................................... 132 
6.2 MATERIALS AND METHODS .................................................................. 133 
6.2.1 Designs and setting .............................................................................. 133 
6.2.2 Sample size calculations ...................................................................... 133 
6.2.3 Data sources ......................................................................................... 134 




6.2.5 Outcomes ............................................................................................. 137 
6.2.6 Data analysis ........................................................................................ 142 
6.3 RESULTS ..................................................................................................... 147 
6.3.1 Cohort selection & baseline characteristics ......................................... 147 
6.3.2 Follow-up period for stone event ......................................................... 153 
6.3.3 Follow-up period for stone intervention event .................................... 153 
6.3.4 Outcomes ............................................................................................. 153 
6.3.5 Multi-variable risk factor analysis ....................................................... 162 
6.4 DISCUSSION ............................................................................................... 164 
6.5 CONCLUSION ............................................................................................. 165 
6.6 REFERENCES .............................................................................................. 167 
 Ureteroscopic complications in patients with autosomal dominant 
polycystic kidney diseasee .................................................................................... 176 
7.1 INTRODUCTION......................................................................................... 177 
7.2 PATIENTS AND METHODS ...................................................................... 178 
7.2.1 Design and setting ............................................................................... 178 
7.2.2 Data sources ......................................................................................... 178 
7.2.3 Population and timeline ....................................................................... 186 
7.2.4 Outcomes ............................................................................................. 188 
7.2.5 Data analysis ........................................................................................ 189 
7.3 RESULTS ..................................................................................................... 191 
7.3.1 Cohort selection and baseline characteristics ...................................... 191 
7.3.2 Follow-up ............................................................................................. 195 
7.3.3 Outcome ............................................................................................... 195 
7.4 DISCUSSION ............................................................................................... 197 




7.6 REFERENCES .............................................................................................. 199 
 Discussion and conclusions ................................................................. 202 
8.1 SUMMARY OF KEY FINDINGS ............................................................... 203 
8.2 IMPLICATIONS........................................................................................... 205 
8.2.1 Laid the foundation for future research in ADPKD using administrative 
databases ........................................................................................... 205 
8.2.2 Implications for clinical practice guidelines ........................................ 206 
8.2.3 Clinical prognostication ....................................................................... 207 
8.3 STRENGTHS ................................................................................................ 208 
8.4 LIMITATIONS ............................................................................................. 209 
8.5 FUTURE DIRECTIONS .............................................................................. 210 
8.6 CONCLUSION ............................................................................................. 211 
8.7 TAKE HOME MESSAGE ............................................................................ 212 





List of Tables 
Table 2-1. Search strategy used to identify relevant articles. ........................................... 17 
Table 2-2. Data abstraction form ...................................................................................... 20 
Table 2-3. Modified Downs and Black Checklist for observational studies .................... 22 
Table 2-4. Study Characteristics ....................................................................................... 28 
Table 2-5. Patient characteristics ...................................................................................... 40 
Table 2-6. Ravine ultrasonographic criteria for diagnosing autosomal dominant 
polycystic kidney disease .................................................................................................. 45 
Table 2-7. Pei ultrasonographic criteria for diagnosing autosomal dominant polycystic 
kidney disease (ADPKD) .................................................................................................. 46 
Table 2-8. Prevalence of stones and stone intervention in patients with autosomal 
dominant polycystic kidney disease and controls ............................................................. 48 
Table 2-9. Symptoms and characteristics of stones .......................................................... 52 
Table 3-1. Search strategy used to identify relevant articles related to thesis .................. 69 
Table 3-2. Data abstraction form ...................................................................................... 71 
Table 3-3.  Modified Downs and Black checklist............................................................. 74 
Table 3-4. Study and patient characteristics of included studies. ..................................... 80 
Table 3-5. Outcomes of stone interventions. .................................................................... 83 
Table 3-6. Characteristics of shockwave lithotripsy (SWL). ............................................ 90 
Table 3-7. Characteristics of ureteroscopy. ...................................................................... 92 




Table 5-1. International classification of diseases, 10th revision codes relevant for 
autosomal dominant polycystic kidney disease. ............................................................. 115 
Table 5-2. Combination of International Classification of Diseases, 10th revision of the 
nine administrative coding algorithms evaluated to identify patients with autosomal 
dominant polycystic kidney disease................................................................................ 115 
Table 5-3. Data abstraction form to collect relevant clinical information required to 
elucidate whether patients have ADPKD or not according to the reference standard. ... 118 
Table 5-4. Number and percentage of patients that satisfied each criterion for autosomal 
dominant polycystic kidney disease................................................................................ 124 
Table 5-5. Positive predictive values and the number of Ontarians identified by each 
administrative database coding algorithm. ..................................................................... 125 
Table 6-1. Databases and coding definitions for restriction criteria, baseline 
characteristics and outcome measurements. ................................................................... 137 
Table 6-2. Characteristics of the autosomal dominant polycystic kidney disease 
(ADPKD) cohort and controls at the time of cohort entry before and after inverse 
probability exposure weighting based on propensity scores and truncating extreme 
weights. ........................................................................................................................... 150 
Table 6-3. Comparison of the hazards of (i) time to first hospital encounter with stone, 
and (ii) time to first stone intervention between patients with autosomal dominant 
polycystic kidney disease cohort (ADPKD) and patients without ADPKD with similar 
baseline health. ................................................................................................................ 156 
Table 6-4 Hazard ratio of hospital encounter with upper urinary tract stone and stone 
intervention among patients with autosomal dominant polycystic kidney disease versus 





Table 6-5. Risk factors for hospital encounter with upper urinary tract stones and stone 
interventions in patients with autosomal dominant polycystic kidney disease (ADPKD) 
and patients without ADPKD with similar indicators for baseline health when each group 
was analyzed separately. ................................................................................................. 163 
Table 7-1. Database and coding definitions for restriction criteria, baseline characteristics 
and outcome measurements. ........................................................................................... 178 
Table 7-2. List of baseline characteristics that were present in one study group but not the 
other group. ..................................................................................................................... 188 
Table 7-4. Characteristics of patients with and without autosomal dominant polycystic 
kidney disease at the time of cohort. ............................................................................... 193 
Table 7-5. Unadjusted, and adjusted 30-days risk of ureteroscopic complications, hospital 
presentation, hospital admission, and emergency department visits in patients with 






List of Figures 
Figure 2-1. Study selection ............................................................................................... 26 
Figure 2-2. Calculated unadjusted prevalence ratio of stones in patients with autosomal 
dominant polycystic kidney disease compared to unaffected family members ................ 54 
Figure 3-1. Study selection. .............................................................................................. 78 
Figure 5-1. Definition of positive predictive value used for the first (chart review) study.
......................................................................................................................................... 122 
Figure 6-1. Total sample size required to detect a clinically significant difference with an 
effect size (Hazard Ratio) varying between 1.5 to 5.0 when the prevalence of upper 
urinary tract stone is 1%, 5%, 10%, 15%, and 20%. ...................................................... 134 
Figure 6-2. Cohort selection of patients with autosomal dominant polycystic kidney 
disease (ADPKD) using International Classification of Diseases codes for ADPKD. ... 148 
Figure 6-3. Cohort selection of patients without autosomal dominant polycystic kidney 
disease using International Classification of Diseases, 10th revision codes. .................. 149 
Figure 6-4. Cumulative incidence function of (A) time to first hospital encounter with 
upper urinary tract stone; and (B) time to first stone intervention. ................................. 155 
Figure 6-5. Log-minus-log curve of the hospital encounter with upper urinary tract stone 
outcome. .......................................................................................................................... 158 
Figure 6-6. Log-minus-log curve of the hospital encounter with stone intervention 
outcome ........................................................................................................................... 159 





List of Appendices 
APPENDIX A: Detailed descriptions of ICES data sources used in Chapters 5 to 
7 ...................................................................................................................................... 216 






ACEi angiotensin converting enzyme inhibitors 
AKI acute kidney injury 
AMOSO Academic Medical Organization of Southwestern Ontario 
ARBs angiotensin II receptor blockers 
CCI Canadian Classification of Health Intervention  
CCI Canadian Classification of Health Intervention  
CI confidence interval 
CIHI Canadian Institute for Health Information 
CIHI-DAD Canadian Institute for Health Information Discharge Abstract Database 
CKD chronic kidney disease 
CT computed tomography scan 
ESKD end-stage kidney disease 
Fam Hx family history 
HR hazards ratio 
ICD-10 International Classification of Diseases, 10th revision 
ICD-9 International Classification of Diseases, 9th revision 
ID identification number 
IPDB ICES Physician Database 
IPTW inverse probability treatment weighting 
IQR interquartile range 
IV intravenous 
KUB kidney, ureter, bladder 
kV kilovolts 




LHRI Lawson Health Research Institute 
MOHLTC Ministry of Health and Long-Term Care 
N/A not applicable 
NACRS National Ambulatory Care Reporting System 
NR not reported 
NSAIDs nonsteroidal anti-inflammatory drugs  
OHIP Ontario Health Insurance Plan 
PCNL percutaneous nephrolithotomy 
PHIPA Personal Health Information Protection Act 
PKD polycystic kidney disease 
PRISMA Preferred Reporting Items for Systematic Review and Meta-Analysis 
RD risk difference 
RPDB Registered Persons Database   
RR relative risk 
SDS same day surgery 
SSMD Schulich School of Medicine and Dentistry 
SWL shockwave lithotripsy 
U/S ultrasound 
UTI urinary tract infection 






1.1 BURDEN OF UPPER URINARY TRACT STONES IN 
THE GENERAL POPULATION 
Upper urinary tract stones are a common occurrence in the general population 
(prevalence ranging between 0.1% and 14.8% and the incidence ranging between 24.2 
and 81.0 individuals per 100,000 person-years) with its prevalence increasing globally.1 
The prevalence of upper urinary tract stones is higher in men than in women, with the 
difference in stone prevalence between men and women decreasing overtime.2 
Approximately half of the patients experience a recurrent upper urinary tract stone event 
within seven years of the first stone occurrence, if left untreated.3  
Upper urinary tract stone events impose a significant burden on the healthcare system.4 In 
the United States in 2009, there were 1.3 million emergency department visits for upper 
urinary tract stones, of which 20% resulted in a hospitalization.4 The number of 
emergency department visits increased 20%, and the rate of hospitalization increased 
14% between 2005 and 2009.4 This clinical demand translates to a significant economic 
burden on the healthcare system, with annual estimates greater than $5 billion.4 Upper 
urinary tract stones impose both a direct cost and an indirect cost via lost work 
productivity.4   
 
1.2 AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY 
DISEASE (ADPKD) 
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic kidney disorder 
with no cure.5,6 It has an estimated prevalence of 1 in 1000 to 1 in 400 worldwide, and is 
characterized by focal cyst development in both kidneys.7–11 It is primarily diagnosed 
using ultrasound according to the Ravine criteria (Table 1-1) prior to 2009, and according 
to the Pei criteria (Table 1-2) after 2009.12,13 In early stages of ADPKD, the cysts cause 
structural deformation to the kidney and damage adjacent nephrons, but overall kidney 





the number and size of cysts increase progressively, more nephrons become damaged, 
and overall kidney function starts to decline.16 The level of kidney function is indicated 
by chronic kidney disease (CKD) stages in patients with ADPKD (Table 1-1).17 The 
earlier stages of CKD are defined by kidney damage (determined by albuminuria 
(albumin type proteins in the urine)), and mild-to-moderate reductions in how well the 
kidney clears the blood of waste products, which is indicated by the estimated glomerular 
filtration rate (eGFR).17,18 Further decrements in eGFR defines more advanced stages of 
CKD.17,18 By the age of 55, about half of the patients with ADPKD reach end-stage 
kidney disease (ESKD) and require kidney transplantation or dialysis to sustain life.19,20 
Currently, tolvaptan is the only drug approved to delay progression to ESKD, and much 
of current research on patients with ADPKD is focused on identifying other therapeutic 
agents. However, kidney failure is not the only manifestation of ADPKD; patients with 
ADPKD are affected with other morbidities that warrant attention to prevent loss of 
health-related quality of life.21 One such morbidity is upper urinary tract stones.22 
Table 1-1. Ravine ultrasonographic criteria for diagnosing autosomal dominant 
polycystic kidney disease 
Age 
Positive Family History Negative Family history 
< 30 years 2 cysts bilaterally or 
unilaterally 
5 cysts bilaterally 
30 to 60 years 4 cysts bilaterally 5 cysts bilaterally 
> 60 years 8 cysts bilaterally 8 cysts bilaterally 
 
Table 1-2. Pei ultrasonographic criteria for diagnosing autosomal dominant polycystic 
kidney disease (ADPKD) among patients with a positive family history 
Age (years) Diagnostic Criteria 
15 to 39 At least 3 cysts (unilateral or bilateral) 
40 to 59 2 cysts/kidney 
> 60 4 or more cysts/kidney  
*Note: Fewer than 2 cysts in individuals > 40 years old and are at risk of ADPKD is sufficient to rule out 






Table 1-3. Chronic kidney disease stages categorized based on the classification system 
established by the National Kidney Foundation outcome Quality initiative 
Chronic Kidney Disease Stage Clinical Characteristics 
Stage 1 Persistent albuminuria & eGFR > 
90 mL/min/1.73m2 
 
Stage 2 Persistent albuminuria & 60 > 
eGFR > 90 mL/min/1.73m2 
 
Stage 3 30 > eGFR > 60 mL/min/1.73m2 
 
Stage 4 15 > eGFR > 30 mL/min/1.73m2 
 
Stage 5 eGFR < 15 mL/min/1.73m2 
Abbreviations: eGFR, estimated glomerular filtration rates 
 
1.3 UPPER URINARY TRACT STONES IN ADPKD 
Many popular educational materials and clinical practice guidelines indicate patients with 
ADPKD are at higher risk of upper urinary tract stones.23,24 Although the exact 
mechanism underlying stone formation in patients with ADPKD is unknown, this makes 
clinical sense based on our speculation of the pathophysiology of stone disease in patients 
with ADPKD. In general, supersaturation of salts causes crystals to form in the urine 
(crystallization).25 There are inhibitors to prevent crystallization in our urine (e.g. 
citrate).25 However, as salts become more and more supersaturated, clusters of crystals 
start to form (nuclei).25 Nucleation often needs a surface or a seed (e.g. epithelial lining, 
other crystal, cell debris).25 Over time, these microscopic nuclei aggregate together to 
form stones.25 In patients with ADPKD, the kidney cysts lead to urinary stasis, which 
along with metabolic abnormalities, such as hyperoxaluria (high urinary excretion of 
oxalate), hyperuricosuria (high uric acid level in urine), hypocitraturia (low citrate 
concentration, an inhibitor of crystallization in urine), may promote stone formation.26–28 
The kidney cysts in these patients may also impede stone passage promoting stone 
growth. Although the idea that the cystic burden in patients with ADPKD may make 
them more susceptible to upper urinary tract stones makes clinical sense, a systematic 





ADPKD, and to give insight into whether patients with ADPKD have a higher risk of 
upper urinary tract stones compared to non-ADPKD patients of similar baseline health. 
Understanding the burden of upper urinary tract stones in patients with ADPKD would 
inform future clinical practice guidelines and guide prognostication.  
Upper urinary tract stones in patients with ADPKD are associated with significant pain 
and morbidity.29 In the general CKD population, patients with stones are at higher risk of 
ESKD compared to patients without stones, with the suggestion that this is also true in 
patients with ADPKD.30,31 For these reasons, stones should be optimally managed in 
patients with ADPKD. A clinical practice guideline on recommended upper urinary tract 
stone management in patients with ADPKD states that similar approaches are being taken 
to manage stones as the general population. The interventions appear safe and efficacious 
based on limited evidence.24 
 
1.4 UPPER URINARY TRACT STONE MANAGEMENT IN 
THE GENERAL POPULATION 
Most stones usually do not require a urological intervention, and will often pass within 
four weeks upon presenting symptoms.32 Pain may be managed with narcotics or 
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).32 However, urgent intervention is 
often required in the presence of infection/urosepsis, intractable pain, vomiting, 
impending acute renal failure, and/or obstruction.25 Prior to the 1980s, open stone surgery 
or nephrectomy (i.e. partial or full removal of a kidney) was performed to remove stones 
in anatomically abnormal kidneys.33,34 However, recently less invasive procedures are 
used.35 These procedures are shock wave lithotripsy (SWL), ureteroscopy, and 
percutaneous nephrolithotomy (PCNL).35 
1.4.1 Shockwave lithotripsy (SWL) in the general population 
SWL is the least invasive treatment option and is one of the recommended first-line 
treatments for proximal ureteral or renal stones less than 1 cm.36,37 SWL emits 





stones to fragment by either exerting mechanical stress or by causing the cavitation 
bubbles within the stones to collapse.32,38 SWL is non-invasive and associated with few 
short-term or long-term complications; the rate of major (0.4%) and minor (5.8%) 
complications for SWL is low in the general population.36 Some SWL related 
complications include transient hematuria, pain, perirenal hematoma, and acute kidney 
injury.39 SWL is contraindicated for pregnant women and for patients with uncontrolled 
hypertension, uncontrolled coagulopathy, or a distal urinary obstruction to where the 
stone is located.36 
1.4.2 Ureteroscopy in the general population 
Ureteroscopy is an alternative first-line therapy for stones in the ureter or kidney 
(generally < 2cm). It is performed by inserting a rigid, semi-rigid, or flexible 
ureteroscope through the urethra, and by positioning it close to the stone.40,41 Various 
instruments, such as a laser or a pneumatic intracorporeal lithotripter, are then used to 
fragment the stones.42 Other instruments, such as stone baskets, can be used to remove 
the stone fragments.43 Ureteral stents are often used with ureteroscopy to prevent 
obstruction from ureteral oedema or residual stone fragments  (especially in the presence 
of ureteric injury, stricture, solitary kidney, CKD, or a large stone).43 Ureteral stents are 
associated with patient discomfort.36 In the general population, the percentage of patients 
that are stone free after ureteroscopy is approximately 90%.36  
1.4.3 Percutaneous nephrolithotomy (PCNL) in the general 
population 
PCNL is recommended for large stones (>2cm), or in cases where retrograde access to 
the ureter or kidney is not possible. During PCNL, a renal calyx is punctured with the 
guidance of fluoroscopy and/or ultrasound to gain access to the stone.42 Various 
instruments, such as lasers, can then be introduced to fragment the stone, and instruments 
such as suction, graspers, or baskets are introduced to remove the stones.23 Although this 
procedure is relatively more invasive than the other procedures for stone removal, it is 







1.5 UPPER URINARY TRACT STONE MANAGEMENT IN 
ADPKD 
Optimal stone management requires proper access to upper urinary tract stones. The 
structural kidney deformation in patients with ADPKD may make gaining optimal access 
challenging leading to potentially lower stone free rates following SWL, ureteroscopy, 
and PCNL. The kidney distortion may also increase complication rates in patients with 
ADPKD. For example, the kidney distortion may impede passage of residual stones, and 
may lead to urinary tract obstruction; this may cause an acute kidney injury (AKI) event. 
Additionally, patients with ADPKD are more likely to develop a urinary tract infection 
(UTI).45,46 During a UTI event, a coexisting stone may passively trap bacteria and 
provide an environment that protects the bacteria  from the host immune system and 
antibiotics allowing it to grow easily.47,48 The passively trapped bacteria may be released 
upon fragmentation resulting in a UTI event post-discharge.47 Preoperative obstruction 
may limit drainage of the urine infected by the released bacteria and sepsis may also 
result.48 Therefore, patients with ADPKD may also be at higher risk for sepsis post-
intervention. Overall, stone interventions may be associated with lower success rate (i.e. 
lower stone free rate), and higher post-operative complication rate. However, a 
systematic review on the outcomes of SWL, ureteroscopy, and PCNL to understand the 
current state of knowledge and to identify knowledge gaps on this topic is lacking.  
 
1.6 OVERALL AIMS 
Understanding of the epidemiology of upper urinary tract stones and stone intervention 
and the outcomes of stone interventions is limited. The overarching aim of this thesis is 
to understand the epidemiology of upper urinary tract stones and stone interventions, and 
consequences of upper urinary tract stone management, in patients with ADPKD. We 







1.7 STUDY OBJECTIVES 
My thesis consists of five manuscripts, and the first two manuscripts are systematic 
reviews of the literature. My five thesis manuscripts and their respective objectives are 
outlined below: 
STUDY 1 - Stone prevalence in patients with ADPKD: a systematic review and 
meta-analysis 
Objective 1: To review English-language studies reporting the incidence and 
prevalence of stones and stone interventions in adults with ADPKD.  
STUDY 2 – Efficacy and safety of surgical upper urinary tract stone interventions 
in patients with ADPKD: a systematic review.  
Objective 2: To systematically review studies describing being stone free after 
the intervention and post-operative complications as reported by each study of the 
three main stone interventions in adults with ADPKD: shockwave lithotripsy 
(SWL), ureteroscopy, and percutaneous nephrolithotomy.  
STUDY 3 – Positive predictive values of International Classification of Diseases, 10th 
Revisions coding algorithms to identify patients with ADPKD 
Objective 3: To determine whether different International Classification of 
Diseases, 10th, revision coding algorithms in large healthcare databases identify 
adult patients who meet strict clinical criteria for ADPKD as assessed through 
medical chart review. 
Secondary objective: To assess the number of patients identified with different 
ADPKD coding algorithms in Ontario.  
STUDY 4 – Risk of hospital encounters with upper urinary tract stones in patients 





Objective 4: To describe the rate of hospital encounters (emergency department 
visits or hospital admissions) with upper urinary tract stones, and the rate and type 
of stone intervention in patients with ADPKD.  
 Secondary objectives: 
a) To compare the rate of hospital encounters (emergency department visits or 
hospital admission) with stones in patients with and without ADPKD with 
otherwise similar indicators for baseline health.  
b) To determine whether the association between ADPKD (yes, no) and the 
outcomes are modified by age, sex, and hospital encounters with stones or 
stone interventions in the prior five years. 
c) To identify risk factors for hospital encounters with stones and stone 
interventions in patients with ADPKD. To also do the same in patients 
without ADPKD with otherwise similar baseline health as those with 
ADPKD.  
STUDY 5 – Complications in patients with ADPKD undergoing ureteroscopy 
Objective 5: To describe the 30-day cumulative incidence of ureteroscopic 
complications, (composite of urinary tract infection, acute kidney injury, and 
sepsis), all-cause hospital presentation (either an emergency room visit or hospital 
admission), all-cause hospital admission, and all-cause emergency department 
visit following ureteroscopy in patients with ADPKD compared to patients 
without ADPKD. 
 
1.8 STRUCTURE OF THESIS 
An integrated manuscript-based format will be used to present the work of this thesis in a 





Chapter 2 addresses objective 1 of the thesis, and it identifies knowledge gaps and 
summarizes the prevalence and incidence of upper urinary tract stone and stone 
intervention reported in the literature. This chapter contains a part of the literature review, 
and a version of this chapter has been published the Canadian Journal of Kidney Health 
and Diseases as the first manuscript: “Stone prevalence in autosomal dominant 
polycystic kidney disease:  a systematic review and meta-analysis.” 
Chapter 3 addresses objective 2 of the thesis, and it summarizes the outcomes of the three 
commonly used stone interventions (SWL, ureteroscopy, and PCNL) in patients with 
ADPKD. This chapter contains the second part of the literature review and a version of 
this chapter has been published the Canadian Journal of Kidney Health and Diseases as 
the second manuscript: “Efficacy and safety of surgical upper urinary tract stone 
interventions in autosomal dominant polycystic kidney disease: a systematic review.” 
Chapter 4 discusses the limitations of the existing literature based on results from 
Chapters 2 and 3.  
Chapter 5 addresses objective 3 of the thesis, and provides insight into whether patients 
with hospital encounter codes related to ADPKD truly have ADPKD. A version of this 
chapter has been published in the Canadian Journal of Kidney Health and Diseases: 
“Positive predictive values of International Classification of Diseases, 10th Revision 
coding algorithms to identify patients with autosomal dominant polycystic kidney 
disease.” 
Chapter 6 addresses objective 4 of the thesis, and it describes the rate of upper urinary 
tract stones and rate of stone interventions compared to non-ADPKD patients with 
similar indicators for baseline health. A version of this chapter has been submitted for 
publication as the fourth manuscript: “Risk of hospital encounters with upper urinary 
tract stones in autosomal dominant polycystic kidney disease: a cohort study”.  
Chapter 7 addresses objective 5 of the thesis, and it provides an interim perspective on 
whether ADPKD is associated with an increased risk of post-operative outcomes 





the fifth manuscript: “Ureteroscopic complications in patients with autosomal dominant 
polycystic kidney disease” 
The last chapter (Chapter 8) of this thesis is the discussion. This chapter summarizes the 
major findings of this thesis, links all the chapters of the thesis together, states strengths 
and limitations of the thesis, and discusses future directions.  
Additional details on the healthcare administrative databases used for my thesis are 
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Autosomal dominant polycystic kidney disease (ADPKD) is the most commonly 
inherited kidney disease and is characterized by focal cyst development in both kidneys.1 
In early stages of ADPKD, the cysts cause structural deformation to the kidney and 
damage adjacent nephrons, but overall kidney function is maintained by compensatory 
hyperfiltration of functioning nephrons.2,3 As the number and size of cysts increase 
progressively, more nephrons become damaged, and overall kidney function starts to 
decline.4 By the age of 55, about half of the patients reach end-stage kidney disease 
(ESKD) and require kidney transplantation or dialysis to sustain life.5,6  
ESKD is not the only kidney manifestation of ADPKD. Previous studies suggest that 
upper urinary tract stones are more prevalent in patients with ADPKD compared to the 
general population; however, there remains uncertainty about the incidence and 
prevalence of upper urinary tract stone in patients with ADPKD.7–12 Upper urinary tract 
stones in patients with ADPKD are associated with significant morbidity. For example, 
stones are a significant determinant of pain, and may accelerate disease progression to 
ESKD in patients with ADPKD.13,14  
We conducted this systematic review to critically appraise and summarize studies which 
reported the incidence and prevalence of upper urinary tract stones and stone 
interventions in patients with ADPKD. This encompassed studies which also included 
patients without ADPKD as a comparator.  
 
2.2 METHODS 
2.2.1 Design and study selection 
We conducted this systematic review using a pre-specified protocol not previously 
published but detailed below, and report this review according to the Preferred Reporting 





The following studies met our eligibility criteria for review: a) published English full-text 
articles and conference proceedings; b) any study design (for example, cross-sectional, or 
cohort study); c) mean age of studies population 18 years or older; d) study populations 
not solely restricted to patients with ESKD; e) reported prevalence or incidence of stones; 
and f) studies published any time after 1970 (the resolution of imaging modalities in older 
studies would be different from current ones). In some studies, patients without ADPKD 
were included as a comparator to patients with ADPKD, and in such cases we abstracted 
information on both groups of patients.   
2.2.2 Identifying relevant articles 
We performed a comprehensive search of bibliographic databases from 1970 to February 
2019 (MEDLINE, EMBASE, Web of Science, BIOSIS Preview, and CINAHL) to 
identify all relevant journal articles and conference proceedings (detailed in Table 2-1). 
To identify further relevant articles, we also used the ‘cited by’ function on Web of 
Science and Google Scholar, and ‘related article’ function on Google Scholar and 
‘similar article’ function on PubMed to identify other relevant articles. We also reviewed 
the reference lists of all relevant articles.  
Two reviewers (VK and GG) independently removed duplicates and rated the title and 
abstract of each citation as “relevant”, “possibly relevant” or “not relevant”. We then 
retrieved the full-text of “relevant” and “possibly relevant” articles to assess study 
eligibility. The two reviewers resolved any disagreement through discussion and 
consensus.  
Table 2-1. Search strategy used to identify relevant articles. 
Database Search Strategy 
MEDLINE 
1. Polycystic Kidney Diseases/ or Polycystic Kidney, 
Autosomal Dominant/  
2. (((polycystic or "type 2" or "type II" or "type 1" or "type I" 
or "autosomal dominant" or pkd) adj3 (kidney* or renal)) or 
adpkd).mp.  
3. 1 or 2  





5. (nephrolith* or urolith* or ureterolith* or lithias* or urolyt 
or urolyts or ((kidney* or renal or urin* or ureter*) adj3 
(calculus or calculi or stone*))).mp.  
6. 4 or 5  
7. 3 and 6  
EMBASE 
1. kidney polycystic disease/  
2. (((polycystic or "type 2" or "type II" or "type 1" or "type I" 
or "autosomal dominant" or pkd) adj3 (kidney* or renal)) or 
adpkd).mp.  
3. 1 or 2  
4. urolithiasis/ or calcium oxalate stone/ or calcium stone/ or 
nephrolithiasis/ or staghorn stone/ or uric acid stone/ or 
ureter stone/  
5. (nephrolith* or urolith* or ureterolith* or lithias* or urolyt 
or urolyts or ((kidney* or renal or urin* or ureter*) adj3 
(calculus or calculi or stone*))).mp. 
6. 4 or 5 
7. 3 and 6  
CINAHL 
1. (MH "Kidney, Cystic") OR (MH "Polycystic Kidney, 
Autosomal Dominant")   
2. (((polycystic or "type 2" or "type II" or "type 1" or "type I" 
or "autosomal dominant" or pkd) N3 (kidney* or renal)) or 
adpkd)   
3. S1 OR S2   
4. (MH "Urolithiasis+")  
5. (nephrolith* or urolith* or ureterolith* or lithias* or urolyt 
or urolyts or ((kidney* or renal or urin* or ureter*) N3 
(calculus or calculi or stone*)))   
6. S4 OR S5   
7. S3 AND S6   




(((((((((polycystic OR "type 2") OR "type II") OR "type 1") OR 
"type I") OR "autosomal dominant") OR pkd) NEAR (kidney* OR 
renal)) OR adpkd) AND (((((((((nephrolith* OR urolith*) OR 
ureterolith*) OR lithias*) OR uralyt) OR uroliths) OR ((((kidney* 
OR renal) OR urin*) OR ureter*) NEAR ((calculus OR calculi) OR 
stone*))) OR ((((ESWL OR eswls) OR SWL) OR lithotrips*) OR 
litholapax*)) OR ((((ureteroscop* OR ureterorenoscop*) OR RIRS) 
OR retrograde intrarenal surgery) OR FURS)) OR ((PCNL OR 







2.2.3 Data abstraction 
Two reviewers (VK and GG) independently abstracted data from all included articles, 
recorded the data on the standardized abstraction form (Table 2-2), and resolved any 
disagreements through discussion, or with the help of a third reviewer (DMN). We 
collected data on study characteristics, patient characteristics, incidence or prevalence of 
stones, and stone characteristics. We abstracted the prevalence of stone intervention from 
the included studies that reported it.  
We assessed the methodological quality of included studies using a modified Downs and 
Black checklist (Table 2-3). We assigned all included studies a score between 0 and 22 
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Table 2-3. Modified Downs and Black Checklist for observational studies 
  Description of Criteria 
Probable 
Answers 
1 Is the hypothesis/aim/objective of the study clearly described? 1-Yes; 0-No 
2 Are the main outcomes to be measured clearly described in the 
Introduction or Methods section? 
1-Yes; 0-No 
3 Are the inclusion and exclusion criteria of the populations 
clearly described? 
1-Yes; 0-No 
4 Is the case definition for ADPKD clearly described? 1-Yes; 0-No 
5 Is the ADPKD case definition valid or reliable? After 2009, Pei 
criteria; between 1994 and 2009 Ravine criteria; before 1994 other 
definitions that sounds reasonable 
1-Yes; 0-No 
6 Is the distribution of age, sex, and baseline kidney function in 
each group of subjects to be compared clearly described?  
1-Yes; 0-No 
7 Are the main findings of the study clearly described? Simple 
data (including denominators and numerators) should be reported 
for all major findings so that the reader can check the major 
analyses and conclusions. 
1-Yes; 0-No 
8 Does the study provide estimate of the random variability in the 
data for the main outcome? In non-normally distributed data, the 
inter-quartile range of results should be reported. In normally 
distributed data the standard error, standard deviation, or 
confidence intervals should be reported. If the distribution of the 
data is not described, it must be assumed that the estimate used 
were appropriate and the question should be answered yes. 
1-Yes; 0-No 
9 Have the characteristics of patients lost to follow-up been 
described? This should be answered YES where there were no 
losses to follow-up or where losses to follow-up were so small that 
findings would be unaffected by their inclusion. This should be 
answered nowhere a study does not report the number of patients 
lost to follow-up. If LOF <15% then NO. 
1-Yes; 0-
No; 0-N/A 
10 Have actual probability values been reported (e.g. 0.035 rather 
than <0.05) for the main outcomes except where the probability 







11 Were the subjects asked to participate in the study 




12 Were those subjects who were prepared to participate 
representative of the entire population from which they were 
recruited? The proportion of those asked who agreed should be 
stated. Validation that the sample was representative would include 
demonstrating that the distribution of the main confounding factors 
was the same in the study sample and the source population. 
1-Yes; 0-
No; 0-UTD 
13 Was the prevalence of stone estimated at a place or facility that 
is representative of where most of the source population would 
attend? If recruited from tertiary care center, then NO. If recruited 
from outpatient clinic, then YES. 
1-Yes; 0-
No; 0-UTD 
14 There are no unplanned retrospective analyses performed (i.e. 
data dredging)? Any analyses that had not been planned at the 
outset of the study should be clearly indicated. If no retrospective 
unplanned subgroup analyses were reported, then answer yes. If 
authors report any outcomes/clinical characteristics that were not 
explicitly referenced in the intro/method section, then my answer to 
this question is NO; If methods section too brief/not detailed 
enough, then UTD) 
1-Yes; 0-
No; 0-UTD 
15 In cohort studies, do the analyses adjust for different length of 
follow-up of patients, or in case-control studies is the time 
period between the intervention and outcome the same for cases 
and controls? Where follow-up was the same for all study patients, 
the answer should be yes. If different lengths of follow-up were 
adjusted for by, for example, survival analysis the answer should be 





16 Were the statistical tests used to assess the main outcome 
appropriate? The statistical techniques used must be appropriate 
to the data. For example, non-parametric methods should be used 
for small sample sizes. Where little statistical analysis has been 
undertaken but where there is no evidence of bias, the question 
should be answered yes. If the distribution of data (normal or not) 
is not described it must be assumed that the estimates used were 










18 Was the case definition for stones accurate and reliable? For 
studies where the outcome measures are clearly described, the 
question should be answered yes. For studies which refer to other 
work or that demonstrate the outcome measure are accurate, the 
question should be answered as yes. If authors reference a 
validation study for their stone definition, or comment on the 
sensitivity/specificity of the method they used to identify stone, then 
answer yes  
1-Yes; 0-
No; 0-UTD 





20 Were the ADPKD population and the controls recruited from 
the same time period? For a study which does not specify the time 
period over which patient were recruited, the question should be 




21 Was there adequate adjustment for confounding in the analyses 
from which the main finding was drawn?  Should be answered 
no if: 1) the distribution of known confounders in the different 
treatment group was not described;or 2) the distribution of known 
confounders differed between the two groups but was not taken into 




22 Were losses of patients to follow-up taken into account? If the 
number of patients lost to follow-up are not reported, the question 
should be answered as unable to determine. If the proportion lost to 
follow-up was too small to affect the main findings, the question 










2.2.4 Data analysis 
We used a Fischer Exact test for studies with controls that did not statistically compare 
the prevalence of stones between patients with ADPKD and controls. We also calculated 
the prevalence ratio of upper urinary tract stones for each of the studies with controls 
using Cochrane Review Manager 5.3. We assessed for heterogeneity across all studies 
using the I2 test. I2 values of 25%, 50%, and 75% corresponds to low, moderate and high 
levels of heterogeneity, respectively.17 We conducted a meta-analysis to combine the 
results if I2 was less than 75%. We calculated the meta-analyzed prevalence ratio 
estimates for upper urinary tract stones using a random effects model and Cochrane 
Review Manager 5.3.  
 
2.3 RESULTS 
2.3.1 Study selection 
A schematic diagram of the study selection process is presented in Figure 2-1. Our search 
yielded 1812 citations, and we identified 29 eligible articles that met our eligibility 
criteria. We identified an additional 20 eligible articles through our further search 
strategy described above, which resulted in a total of 49 eligible articles (a total of 9,396 
patients with ADPKD) 7–12,14,18–59. The chance corrected agreement between two 






Figure 2-1. Study selection 
2.3.2 Description of included studies 
The characteristics of included studies are summarized in Table 2-1. The 49 eligible 
studies were published between 1977 and 2019, and the studies were conducted in 





(3 studies), India (3 studies), Spain (3 studies), Canada (2 studies), Italy (2 studies), and 
Japan (2 studies). A single study was conducted in Bulgaria, China, Cyprus, Greece, 
Ireland, Korea, Pakistan, Philippines, Republic of Macedonia, Saudi Arabia, Senegal, 
Taiwan, Tunisia, and the United Kingdom, and one was a multi-national study. The 
country where the study was conducted was unknown for one study. The number of 
centres participating in a study was unclear in 19 of 49 studies; of the remainder, 21 
studies were single center, and 9 were multi-center. Among the 49 included studies, 12 
were cohort studies, 33 were cross-sectional studies, and the study design was unclear for 






























(1995)                            
Saudi 
1 ADPKD NR N/A 30 1. 5+ renal cysts 
distributed between 
both kidneys                         
(U/S, intravenous 
pyelogram, or CT) 
None 4 
Baishya (2012)                
India 
Unclear ADPKD Since 1992 N/A 452 NR 
(NR) 
None 6 
Bajrami (2016)   
Albania 
Unclear ADPKD 2011 to 2014 N/A 100 Ravine criteria 
(x-ray or U/S) 
None 9 
Chang (2013)             
Taiwan 
1 ADPKD October 2008 
to May 2011 
N/A 46 1. Ravine criteria; 
OR 
2. No fam hx + 
bilateral kidney 
enlargement + at 









ADPKD Since April 
2007 






























(2000)            
Cyprus 
1 1. Alive 
2. Has an 
affected family 
member with a 
PKD2 mutation 
up to August 
1998 
N/A 106 1. 1+ cyst in 
one kidney for 
patients aged 5 
to 14 years;  
2. 2+ unilateral 
cysts or one in 
each kidney for 
patients aged 
15 to 19;  




20 to 29; 4. 2+ 
cysts in each 
kidney for 
patients aged 
30 to 59; AND  
5. 4+ cysts in 
each kidney for 
patients aged 




members                     
(105) 
11 
Duli (2013)            
Albania 
Unclear ADPKD NR N/A 180 Unclear 
(NR) 
None 7 
Ekin (2014)                            
Turkey 
1 ADPKD 1995 to 2014 N/A 144 1. 5+ renal cysts in 
both kidneys  
(NR) 
None 9 
Gall (2017)                         
France 
22 1. Genkyst study 
participants 
2. 18+ years old 
3. Mutation in 
PKD2 gene 
January 2010 
to March 2016 
N/A 293 1. Pei criteria; OR 
2. 10+ cysts in both 
kidneys combined + 





























Galliani (2015)           
Italy 
28 ADPKD February 2013 
to April 2014 
N/A 462 NR 
(NR) 
None 2 
Gonzalo (1995)               
Spain 
Unclear 1. At-risk of 
ADPKD 
2. Asymptomatic 
3. 13+ years old 
June 1993 to 
December 
1994  
N/A 65 1. 1+ cysts in each 
kidney; OR 








(2000)         
United States 
1 1. ADPKD 










(1981)             
Japan 
1 ADPKD May 1972 to 
September 
1980 
N/A 118 NR 
(U/S or CT) 
None 3 
Ka (2010)                     
Senegal 
1 1. ADPKD 
2. Black 












































Kaygis (2018)          
Turkey 
1 1. Referred and 
diagnosed with 
ADPKD at a 
tertiary care 
center  
2. Not on dialysis 
3. eGFR >30 
mL/min 




(2011)          
Turkey 










Kim (NR)                        
Korea 
9 1. Korean 
2. ADPKD and 
CKD 
3. Pre-dialysis 





6. Not a 
transplant 
recipient 
7. Without heart 
failure, liver 
cirrhosis, or 
current or past 
history of cancer 
8. Not pregnant 
9. No single 
kidney due to 
trauma or kidney 
donation 
April 2011 to 
February 2016 





























Kumar (2012)                
India 
1 ADPKD November 
2011 to 
October 2012 




Memili (2007)           
Turkey 
1 1. ADPKD 






N/A 136 NR 
(NR) 
None 8 
Meng (2018)                
China 













(1984)              
United States 













(1990)              
United States 
Unclear 1. Fam hx of 
ADPKD 
2. 50+ years old 
NR N/A 32 1. Bilateral renal 




members          
(25)                 
12 
Nikolov (2012)              
Unclear 
1 ADPKD referred 
to center 
1998 to 2008 N/A 208 NR 
(NR) 
None 4 
Nishiura (2009)               
Brazil 
1 1. Referred to 








NR N/A 125 Ravine criteria 
(U/S or CT) 
None 14 
Parfrey (1990)                
Canada 
NR Family members 
of index ADPKD 
cases 
NR N/A Unclear 1. Reported on 
autopsy report, 
surgical report or of 
a death due to CKD 

































2. 1+ in each kidney; 
OR 
3. 1+ in one kidney 
(excretory 
urography, CT, U/S) 
Romao (2006)      
Brazil 
1 ADPKD January 1985 
to December 
2003 
N/A 92 1. Ravine criteria; 
OR  




Roscoe (1993)‡              
Canada 
Unclear ADPKD  NR N/A 80 NR 
(NR) 
None 9 
Segal (1977)              
United States 




(2006)                
Albania 
NR ADPKD NR N/A 180 NR 
(NR) 
None 5 
Torra (1996)                 
Spain 
Unclear ADPKD or at-
risk of ADPKD 
NR N/A PKD1: 
146                  
PKD2: 
20      


































Torres (1988)                    
United States 
1 1. ADPKD 







1976 to 1986 N/A 751 1. Bilateral 
polycystic kidneys + 
fam hx; OR  
2. No fam hx + 
bilaterally enlarged 
and polycystic 
kidneys + exclusion 
of other disorders 




Vikrant (2017)          
India 
1 1. ADPKD 
2. Attending renal 
clinic 
April 2009 to 
March 2015 
N/A 208 1. Pei criteria; OR 
2. Fam hx + hepatic 
cyst 
(U/S) 
None  13 
Yildz (2016)               
Turkey 
Unclear 1. ADPKD 
2. Not on renal 
replacement 
therapy 
3. eGFR > 
30mL/min 










Gonzalo (1990)            
Spain 
1 ADPKD June 1977 to 
June 1988 
6 years 3 
months (NR) 
107 1. 3+ cysts in each 
kidney + fam hx 
(excretory 
urography or U/S) 








































and the United 
Kingdom  
7 ADPKD NR NR 624 1. Ravine criteria; 
2. DNA linkage test; 
OR 
3. Report of ADPKD 
on medical records 
(U/S) 
None 14 
Idrizi (2009)      
Albania        
Unclear ADPKD                                     NR NR 180 NR 
(NR) 
None 10 
Ozkok (2013)       
Turkey 









(1999)                      
Greece 
Unclear At-risk of 
ADPKD 
NR NR 85 1. 2+ cysts in one 
kidney and one cyst 




Rabbani (2008)         
Pakistan 
1 ADPKD January 1997 
to December 
2003 
7.6 (4.2) years 56 1. Fam hx + 2+ cysts 
in either kidney + 
hypertension or renal 
insufficiency;   
2. Bilateral cysts + 
no fam hx; OR  
3. Unilateral 
polycystic kidney + 
liver cyst, berry 
aneurysm, arterio-
venous malformation 
or evidence of prior 
cerebrovascular 
accident on 






























(2014)             
Republic of 
Macedonia 




Senal (2016)                 
Turkey 
Unclear ADPKD January 1990 
to January 
2015 
NR 300 NR 
(NR) 
None 6 
Tantoco (1986)              
Philippines 
1 ADPKD May 1973 to 
January 1986 
3 (NR) years 60 1. Signs and 






tomogram, U/S or 
CT) 
None 3 
Thong (2013) ‡                  
United Kingdom 
Unclear 1. ADPKD 
2. In research 
database 
3. Have at least 
five years of renal 
function tests at 
the time of 
analysis 





Wright (1993)                           
Ireland 
Unclear Belonging to 
PKD1 family 
NR NR PKD1: 
49            
Non-
PKD1: 




following ways:  1) 
by post-mortem 
examination;  
2) by report of a 
death due to chronic 
renal failure with a 





























3) by operative 
report during 
abdominal surgery;  
4) by excretory 
urography or CT 
scan;  
5) by unequivocal 
findings on 
ultrasonography; OR  
6) 1+ cyst in in at 
least one kidney 
(diagnostic data files 
or ultrasound)  
Study Design Unclear 




1947 to 1980 12 (NR) years 53 1. History and 
physical 
examination; OR  
2. Diagnosis 
confirmed with 










(1994)              
Bulgaria 
Unclear ADPKD NR N/A 82 Unclear 
(echography, venous 





























(1992)    Japan 
38 ADPKD January 1988 
to December 
1988 
N/A 316 NR 
(U/S or CT) 
None 11 
Idrizi (2011)      
Albania        
Unclear ADPKD 2002 to 2009 N/A 200 Ravine criteria 
(U/S) 
None  7 
Abbreviations: autosomal dominant polycystic kidney disease, ADPKD; computed tomography, CT; family history, Fam Hx; intravenous, IV; not 
applicable, N/A; not reported, NR; standard deviation, SD; ultrasound, U/S 
‡Data was abstracted and methodological quality was assessed for the portion of the multi-component study that reported the prevalence of stones 
ɶ A modified Downs and Black checklist was used to assess the methodological quality of each included study. The methods quality score ranged 





2.3.3 Patient population  
The sample size of patients with ADPKD ranged from 30 to 1139 (Table 2-4). The mean 
age of patients with ADPKD ranged from 26 to 61 years, 35% to 71% of the patients with 
ADPKD were male, up to 51% developed ESKD, 5% to 88% were hypertensive, and 1% 
to 73% experienced at least one prior urinary tract infection (UTI) (Table 2-5).  
 Six studies compared the prevalence of stones in patients with ADPKD to 
unaffected family members as controls.7–12 The mean age of controls ranged from 35 to 
60 years, 36% to 48% of the controls were male, 4% to 36% were hypertensive, and 2% 



































(1995)                           
Saudi 
45 (10) 13 (43) 2 (7) 2 (7) 4 (13) 17 (57) 22 (73) NR 
Baishya 
(2012)                
India 
NR NR NR NR NR NR NR NR 
Bajrami 
(2016)   
Albania 
NR 42 (42) NR NR NR NR NR NR 
Chang (2013)             
Taiwan 
48 (13) 24 (52) NR NR  NR 31 (67) 17 (37) NR 
Corradi 
(2009)                     
Italy 
48 (NR) 58 (58) NR 6 (6) 29 (29) 75 (75) NR NR 
Demitriou 








(0)          
CONTROL: 
NR (NR)   
ADPKD: 1 













Duli (2013)            
Albania 
NR NR NR NR NR NR NR NR 
Ekin (2014)                            
Turkey 
45 (NR) 61 (42) NR (11) NR NR (11) 117 (82) 14 (2)* 168 (186) 
Gall (2017)                         
France 
61 (NR) 123 (42) NR NR Unclear 221 (75) NR NR 
Galliani 
(2015)           
Italy 
NR 194 (42) NR NR NR NR (60) NR (28) NR 
Gonzalo 







(40)                         
CONTROL: 
28 (47) 
NR NR NR 
ADPKD: 19 
(29)             
CONTROL: 3 
(5) 





































(2000)         
United States 
NR 17 (35) NR NR NR 23 (48) NR NR 
Ishibashi 
(1981)             
Japan 
44 (NR) 54 (46) NR NR NR NR 57 (54)* NR 
Ka (2010)                     
Senegal 
47 (5) 30 (57) 10 (19) NR 27 (51) 36 (68) 7 (13) NR 
Kaygis (2018)          
Bursa 
NR 54 (46) 0 (0) NR 0 (0) 72 (61) 29 (25) NR 
Kazancioglu 
(2011)          
Turkey 
NR 548 (48) 108 (11) 8 (1) NR 828 (73) 228 (23)* 194 (194) 
Kim (NR)                        
Korea 
47 (11) 184 (51) 0 (0) 0 (0) NR 319 (88) 8 (2) 119 (79) 
Kumar (2012)                
India 
NR 29 (71) NR NR 13 (32) 27 (66) 6 (40) 398 (283) 
Memili (2007)           
Turkey 
47 (16) 65 (48) 16 (12) 1 (1)  NR 98 (72) 22 (16) NR 
Meng (2018)                
China 
49 (NR) 72 (43) NR NR NR 84 (50) 41 (25) 309 (290) 
Milutinovic 











(18)            
CONTROLS
: 0 (0) 
NR 
ADPKD: 28 






































(2012)              
Unclear 
NR NR NR NR NR NR NR NR 
Nishiura 
(2009)               
Brazil 


































(1990)                
Canada 
NR NR NR NR NR 
ADPKD: 118 








Romao (2006)      
Brazil 
35 (15) 34 (37) NR NR 27 (29) 61 (63) 33 (36) 212 (247) 
Roscoe (1993) 
‡              
Canada 
NR NR NR NR 22 (28) NR NR NR 
Segal (1977)              
United States 
NR NR NR NR NR NR NR NR 
Strakosha 
(2006)                
Albania 
NR NR NR NR NR NR NR NR 













(46)            
CONTROL: 
23 (15)  
ADPKD: 57 




Torres (1988)                    
United States 
NR 393 (52) NR NR NR NR NR NR 
Vikrant 
(2017)          
India 
46 (15) 126 (61) 5 (2) NR 20 (10) 145 (70) 81 (39) 292 (318) 
Yildz (2016)               
Turkey 
41 (13) 49 (53) 0 (0) 0 (0) 0 (0) NR (72) NR NR 
Gonzalo 
(1990)            
Spain 
46 (14) 58 (54) NR NR NR 73 (68)* 33 (31)* NR 
Hajji (2019)                                              
Tunisia 
49 (14) 297 (52) 298 (52) 13 (2) NR 321 (59) NR (24) 459 (NR) 
Hateboer 







































Idrizi (2011)      
Albania        
NR 97 (49) NR NR NR NR 108 (54) NR 
Ozkok (2013)       
Turkey 
53 (15) 149 (46) 46 (14) NR 48 (14) 255 (79)* 64 (21)* NR 
Papadopoulou 
(1999)                      
Greece 
26 (12) 44 (52) NR NR NR 
 ADPKD: 4 
(5)               
ADPKD: 1 (1)                  NR 
Rabbani 
(2008)         
Pakistan 
NR 40 (71) NR NR 7 (13) 38 (68) NR 398 (282) 
Ritovska 
(2014)             
Republic of 
Macedonia 
43 (13) NR NR NR NR NR NR NR 
Senal (2016)                 
Turkey 
NR 143 (48) NR NR NR 231 (83)* 52 (19)* 203 (221) 
Tantoco 
(1986)              
Philippines 
44 (NR) 30 (50) NR NR 17 (28) 40 (67) 17 (28) NR 
Thong (2013) 
‡                  
United 
Kingdom 
46 (16) 102 (49) NR NR NR 147 (70) 57 (27.2) NR 
Wright (1993)                           
Ireland 
NR NR NR NR 12 (18) 16 (24) 5 (8) NR 
Delaney 
(1985)             
United States 
NR 21 (40) 9 (17) NR NR 11 (21) 10 (19) NR 
Dimitrakov 
(1994)              
Bulgaria 
NR 34 (41) NR NR NR NR NR NR 
Idrizi (2009)      
Albania        


































(1992)     
Japan 
51 (13) 167 (53) 72 (23) NR 72 (23) 201 (64)* NR 354 (380) 
Abbreviations: autosomal dominant polycystic kidney disease, ADPKD; not reported, NR; standard deviation, SD; urinary tract infection, UTI 
‡Data was abstracted for the portion of the multi-component study that reported the prevalence of stones. 





2.3.4 Quality assessment of studies 
The methodological quality of the studies was limited as the methods quality score 
ranged from 2 to 14 out of 22 (where higher scores indicates higher methodological 
quality).  
The internal validity of studies’ results is affected by the definition of the exposure being 
investigated and the outcome of interest. Of the 49 studies, 29 specified the definition for 
ADPKD. Patients with ADPKD were identified using the Ravine’s criteria in 6 studies, 
Ravine’s criteria or another additional criterion such as family history and liver cysts in 3 
studies, Pei’s criteria in 3 studies, Pei’s criteria and an additional criterion in 2 studies, at 
least 5 cysts in each kidney in 3 studies, and other criteria in the remaining 13 studies; the 
definition for ADPKD was unclear or not reported in the remaining 19 studies.  Ravine 
and Pei criteria to diagnose ADPKD are summarized in Table 2-6 and Table 2-7, 
respectively.61,62  Some studies used a definition different from the most accepted 
diagnostic criteria at the time the study was published. For example, Ekin et al. (2014) 
and Kazancioglu et al. (2011) defined patients with at least five cysts in each kidney as 
patients with ADPKD, although Pei’s criteria were the most commonly used diagnostic 
criteria for ADPKD during the time period in which the studies were conducted.29,46  
Table 2-6. Ravine ultrasonographic criteria for diagnosing autosomal dominant 
polycystic kidney disease 
Age 
Positive Family History Negative Family history 
< 30 years 2 cysts bilaterally or 
unilaterally 
5 cysts bilaterally 
30 to 60 years 4 cysts bilaterally 5 cysts bilaterally 





Table 2-7. Pei ultrasonographic criteria for diagnosing autosomal dominant polycystic 
kidney disease (ADPKD) 
Age (years) Diagnostic Criteria 
15 to 39 At least 3 cysts (unilateral or bilateral) 
40 to 59 2 cysts/kidney 
> 60 4 or more cysts/kidney  
*Note: Fewer than 2 cysts in individuals > 40 years old and are at risk of ADPKD is sufficient to rule out 
the disease.  
Thirty of the 49 studies described how they identified patients with stones, while the 
remaining 19 studies did not. Among the 30 studies that specified how the stones were 
detected, 3 studies relied on patient self-report of a history of stones, 14 solely relied on 
radiological evidence of stone, and 13 studies relied on combination of radiological 
evidence of stone and at least one other criterion (i.e. stone passage and recovery, 
surgical removal of stone and self-report of stone). Among the 27 of the 30 studies that 
used radiological evidence of stones as one of their diagnostic criteria, 9 reviewed 
historic imaging, 10 reviewed recent imaging, and the nature of considered imaging was 
unclear in 8 studies. Eight of the 27 studies thoroughly described what they were looking 
for on the radiological image to identify stones. Amongst the five studies that reported 
asymptomatic stones, the percentage of patients ranged between 1% and 68%.18,19,22,38,49  
The setting and source population from which the samples are recruited affects the study 
generalizability. For 21 of the studies, the setting or population from which the sample 
was recruited from was unclear or not reported. Patients were recruited from hospitals in 
18 studies, outpatient clinics in 7 studies, solely from an inpatient setting in 1 study, an 
outpatient ADPKD specialty clinic in 1 study, and from both an inpatient and outpatient 
setting for 1 study. It is unclear if patients were recruited from an inpatient or outpatient 
setting for 20 studies and setting was not reported for one study.  
Six of the 49 studies compared the prevalence of stones in patients with ADPKD to 





sectional. Only two of the six studies statistically compared the prevalence of stones in 
patients with ADPKD to controls. Both of these studies used univariate analyses and did 
not adjust for any confounders.  
2.3.5 Prevalence and characteristics of stones and prevalence of 
stone intervention 
In patients with ADPKD, the prevalence of stones ranged between 3% and 59% (Table 2-
8). Of those patients with stones, 2% to 47% underwent at least one stone intervention. 
UTI and flank pain were the predominant precursor to diagnosis of stones in patients with 
ADPKD.18,22,25,38,41,49 In most patients, stones were solely located in the renal calyces 
18,19. Most stones were composed of uric acid according to six studies7,19,21,22,38,49, and 





Table 2-8. Prevalence of stones and stone intervention in patients with autosomal dominant polycystic kidney disease and 
controls 
Author (Year) Country Stone Definition (Modality) 
No. of unique 
patients with stones 
(%)                   
No. of unique patients 
who underwent stone 
intervention (%) 




5 (17) NR 




19 (4) 9 (2) 
Bajrami (2016)   
Albania 




(U/S; or plain abdominal KUB film, intravenous 
pyelography and non-contrast helical CT in cases where 
stones were not observed on U/S or KUB film) 
58 (58) NR 




19 (41) NR 




24 (24) NR 
Demitriou (2000)            
Cyprus 
Passage of stone or presence of stone on a plain KUB film or 
U/S 𝜓                   
(Plain KUB film or U/S) 
ADPKD: 21 (20) 
CONTROL: 4 (4) 
NR 
Duli (2013)            
Albania 
Image of stone within the urinary collecting system
 Ɍ
                       
(U/S, renal radiography, CT) 
106 (59) NR 
Ekin (2014)                            
Turkey 
Presence and absence of stone on U/S 𝜓 and/or history of 
passing stone               
(U/S) 
24 (17) NR 




57 (20) NR 




102 (22) NR 
Gonzalo (1995)               
Spain 
Hyperechogenic image with posterior shadowing
 Ɍ
                 
(U/S or plain roentgenogram with tomograms) 
ADPKD: 7 (11) 
CONTROL: 2 (3) 
NR 
Grampsas (2000)         
United States 
Echogenic focus with posterior acoustic shadowing within 
the kidney but outside an identifiable cyst
 Ɍ
 + with or 
without a clinical history of stone                       
(U/S) 





Author (Year) Country Stone Definition (Modality) 
No. of unique 
patients with stones 
(%)                   
No. of unique patients 
who underwent stone 
intervention (%) 




10 (13) NR 




6 (11) NR 
Kaygis (2018)          
Bursa 
History of stone or positive imaging
 Ɍ
                  
(U/S, non-contrast CT) 
28 (24) 10 (8) 
Kazancioglu (2011)          
Turkey 
Presence or absence of urinary tract stones on U/S
 Ɏ
 and/or 
history of passing stone                  
(U/S) 
278 (27)* NR 




92 (29)* NR 





Memili (2007)           
Turkey 
Presence and absence of upper urinary tract stone 𝜓                   
(U/S) 
39 (29) NR 




65 (39) NR 
Milutinovic (1984)              
United States 
Stones apparent on radiogram
 Ɏ or passed in urine                
(radiogram) 
ADPKD: 16 (11) 
CONTROL: 5 (4) 
NR 
Milutinovic (1990)              
United States 
Stone apparent on radiograms
 Ɍ
 or were found in urine                                
(radiogram) 
ADPKD: 5 (17) 
CONTROL: 3 (12) 
NR 




29 (14) NR 
Nishiura (2009)               
Brazil 
Image of stone within the renal collection system
Ɍ
                          
(U/S and CT) 
35 (28) NR 
Parfrey (1990)                
Canada 
Self-report history of upper urinary tract stones during 
interview  
(NR) 
ADPKD: 16 (15) * 
CONTROL: 20 (10) 
* 
NR 
Romao (2006)      Brazil 
NR  
(NR) 
15 (16) NR 
Roscoe (1993)
 ‡
              
Canada 
Acoustic shadowing on radiologic imaging 𝜓                   
(NR) 
8 (10) NR 









Author (Year) Country Stone Definition (Modality) 
No. of unique 
patients with stones 
(%)                   
No. of unique patients 
who underwent stone 
intervention (%) 




                  
(ultrasound or abdominal x-ray) 
81 (45) 2 (1) 
Torra (1996)                 
Spain 
Passage of stone with recovery of stone or evidence of stone 
within the collecting system as reported by the radiologist 𝜓                   
(unclear) 
ADPKD: 29 (18) 
CONTROL: 15 (10)* 
NR 
Torres (1988)                    
United States 
Historical evidence of passage, recovery, surgical removal of 
stone, evidence of stone within the collecting system, or 
renal papillary tips as reported by radiologist 𝜓               
(excretory urogram for a subset [79 patients]; unclear for 
remaining patients) 
151 (20) 31 (4) 
Vikrant (2017)          
India 
History of stone passage, removal of stone or calcific 
foci/nephrocalcinosis seen on imaging 𝜓                      
(unclear) 
81 (39) NR 
Yildz (2016)               
Turkey 
Self-reported history of stone 
(NR) 
23 (25) NR 
Gonzalo (1990)            
Spain 
Passage or surgical removal of stones or presence of radio-
opaque deposits on x-ray
 Ɏ












Hateboer (1999)        
The Netherlands, Spain, 
Bulgaria, and the United 
Kingdom 
Radiological evidence of upper urinary tract stone
 Ɏ
                 




Idrizi (2009)      Albania 
An echogenic focus with posterior acoustic shadowing 
within the kidney but outside an identifiable cyst and with or 
without clinical history of stone
 Ɍ
      
(U/S and X-ray) 
76 (42)
 ɶ
 2 (1) 
Ozkok (2013)       
Turkey 
Self-reported hx of passing stone or presence or absence of 





Papadopoulou (1999)                      
Greece 





Rabbani (2008)         
Pakistan 









Author (Year) Country Stone Definition (Modality) 
No. of unique 
patients with stones 
(%)                   
No. of unique patients 
who underwent stone 
intervention (%) 
Ritovska (2014)             
Republic of Macedonia 
Evidence on imaging
 Ɍ
                       











Tantoco (1986)              
Philippines 
Presence of radiopaque stone on radiographic ultrasound
 Ɏ
                     




















Delaney (1985)             
United States 
Passage of stone or surgical removal of stones from urinary 
tract or presence of radio-opaque deposits on x-ray
 Ɏ
                      
(x-ray) 
18 (34) 1 (2) 
Dimitrakov (1994)              
Bulgaria 
Presence or absence of upper urinary tract stone on imaging
 
Ɏ
                       
(echography, venous urography, CT) 
23 (28) NR 




53 (18)* NR 
Idrizi (2011)      Albania 




(U/S; or plain abdominal KUB film, intravenous 
pyelography and non-contrast helical CT in cases where 
stones were not observed on U/S or KUB film) 
116 (58) 4 (2) 
Abbreviations: computed tomography scan, CT; kidney, ureter, bladder, KUB; not reported, NR; ultrasound, U/S 
* The denominator only includes a subset of the study population 
‡Data was abstracted for the portion of the multi-component study that reported the prevalence of stones 
Ɍ Patients underwent prospective abdominal imaging. 
𝜓 Authors reviewed historic images to ascertain stone event.  
Ɏ Unclear whether investigators prospectively imaged abdomen or reviewed past abdominal images or imaging report to identify stone event. 
ɶ Stone event was ascertained at baseline; therefore, the percentage is a prevalence estimate. 
κ Stone was ascertained at baseline and during follow-up; therefore, the percentage is a prevalence estimate. 






Table 2-9. Symptoms and characteristics of stones 
Author (Year) 
Country 
Symptoms Location Composition 
Baishya (2012)                
India 
• Anorexia: 3 (16%) 
• Fever: 1 (5%) 
• Fluid Overload: 2 (11%) 
• Hematuria: 5 (26%) 
• Pain: 6 (32%) 
• Vomiting: 3 (16%) 
• Weakness: 2 (11%) 
Location of stones in the 23 kidneys with 
stones among 19 patients (denominator is 
23): 
• Renal calyces: 10 (28%) 
• Renal pelvis: 2 (9%) 
• Both renal pelvis and calyces: 5 (22%) 
• Ureter: 5 (22%) 
• Staghorn: 1 (4%) 
NR 
Bajrami (2016)   
Albania 
NR NR • Calcium oxalate: NR (39%) 
• Urate: NR (47%) 
• Other compounds: NR (14%) 
Demitriou (2000)            
Cyprus 
NR NR Majority were uric acid 
Kaygis (2018)          
Bursa 
Lower back pain: 10 (36%) NR NR 
Nishiura (2009)               
Brazil 
Low back pain NR NR 
Strakosha (2006)                
Albania 
• 40% of patients with stone associated 
with a history of UTI and flank pain 
NR • Calcium oxalate: NR (39%) 
• Urate: NR (47%) 
• Other Compounds: NR (14%) 
Torres (1988)                    
United States 
NR Among the 71 patients where details 
about stone location is available: 
• Only renal calyces: 63 (89%) 
• Renal pelvis/Staghorn: 4 (6%) 
• Ureter: 4 (6%) 
Composition examined in 30 patients: 
• Calcium carbonate: 3 (10%) 
• Calcium oxalate: 14 (47%) 
• Calcium phosphate: 6 (20%) 
• Struvite: 3 (10%) 
• Uric Acid: 17 (57%) 
Idrizi (2009)      
Albania 
History of UTI and flank pain: NR (40%) NR • Calcium oxalate: NR (39%) 
• Urate: NR (47%) 
• Other compounds: NR (14%) 
Idrizi (2011)      
Albania        
• UTI and Flank pain: 70 (60%) 
• Gross Hematuria: 65 (56%) 
NR Among the 63 patients with information 
on stone composition: 
• Calcium oxalate: 25 (39%) 
• Uric acid: 30 (47%) 







Symptoms Location Composition 
Delaney (1985)             
United States 
NR NR • Calcium oxalate: 3 (50%) 
• Uric Acid stones: 1 (17%) 
• Calcium oxalate stones in one occasion 
and uric acid or calcium phosphate stones 
on the other occasion: 2 (33%) 
Dimitrakov 
(1994)              
Bulgaria 
NR NR • Oxalate: 12 (52%) 
• Urate: 6 (26%) 
• Mixed composition: 5 (22%) 
Abbreviation: not reported, NR; urinary tract infection, UTI  





The prevalence of stones ranged from 3% to 12% in family members confirmed not to be 
affected with ADPKD (Table 2-3). None of the studies described the characteristics of 
stones in unaffected family members. All six studies that compared the prevalence of 
stones in patients with and without ADPKD reported stones were more prevalent in 
patients with ADPKD; however, four studies did not statistically analyze the prevalence 
of stones between the two groups, and the remaining two studies found no statistical 
difference. When we statistically compared the prevalence of stones in patients with 
ADPKD to unaffected family members in the four studies that did not conduct any 
statistical analyses, we found that only one out of the four studies found a significant 
difference. Meta-analysis of the calculated prevalence ratios across six cross-sectional 
studies show that patients with ADPKD had a higher prevalence of upper urinary tract 
stones compared to unaffected family members (unadjusted prevalence ratio: 1.8, 95% 
confidence interval: 1.3 to 2.6, p=0.0007; test for heterogeneity: I2 = 0%, p=0.8) (Figure 
2-2). 
 
Figure 2-2. Calculated unadjusted prevalence ratio of stones in patients with autosomal 
dominant polycystic kidney disease compared to unaffected family members 
Note: The prevalence ratios were calculated using prevalence estimates obtained from studies and 





Six studies reported the prevalence of stone intervention in patients with ADPKD, which 
ranged between 1% and 8% (Table 2-8). None of the studies with controls reported the 
prevalence of stone intervention in unaffected family members. 
2.3.6 Stone incidence 
No study clearly reported the incidence of upper urinary tract stones and the incidence of 
stone intervention in patients with ADPKD. Most cohort studies included in this review 
assessed upper urinary tract stones at cohort entry and not during follow-up. Whether the 
reported percentage was a prevalence or incidence estimate was unclear for three of the 
included cohort studies.  
 
2.4 DISCUSSION 
Many popular educational materials and clinical practice guidelines state that upper 
urinary tract stones are common in patients with ADPKD, and its prevalence may be five 
to ten times higher than the general population.63,64 This makes clinical sense based on 
our knowledge of the pathophysiology of ADPKD; the kidney cysts in patients with 
ADPKD leads to urinary stasis which promotes stone formation.24 Our review of the 
literature, however, indicates that the evidence to support these assertions is weak, and 
illuminates several knowledge gaps about the clinical epidemiology of stones in ADPKD. 
No study has clearly reported the incidence of stones in ADPKD. Prevalence estimates in 
ADPKD varied widely ranging from 3% to 59% for upper urinary tract stones, and from 
1% to 8% for stone interventions. UTI and flank pain were the predominant precursors to 
diagnosis of stones; however, UTI and flank pain are not specific to stones and are also 
manifestations of ADPKD independent of stones. It is likely that UTI and flank pain was 
associated with ADPKD itself rather than stones because most of the stones in ADPKD 
were located in the renal calyces where they would be less likely to be symptomatic. Uric 
acid stones are the most prevalent stone composition in patients with ADPKD. The wide-





reported stone incidence, confirms that how often patients with ADPKD develop upper 
urinary tract stones remains uncertain. 
There are several reasons why prevalence estimates of stones varied drastically across 
studies. These include inconsistent stone definitions, different distributions of stone risk 
factors, potential recall bias in studies that relied on patient self-report to identify stone 
events, and relying on past imaging reports done for reasons other than stone 
identification. Self-report is particularly problematic because the symptoms of flank pain 
and hematuria are common with ADPKD in the absence of stone disease. Patients with 
ADPKD may be more likely to undergo renal imaging, which would lead to over-
detection of potentially clinically insignificant stones which may also exist undetected in 
the general population. The variability in imaging modalities used across studies and 
even between patients in the same study may also explain the variable prevalence 
estimates across studies. For example, computed tomography (CT) is a more sensitive 
method of stone detection than ultrasound and would provide a more accurate estimate of 
stone prevalence.65,66 Most of the studies published to date on stones in ADPKD were 
conducted in a single-center, and are of poor methodological quality. Additionally, only 
six studies compared the prevalence of stones in patients with ADPKD to controls.7–12 
Among these six studies, only two statistically compared the prevalence of stones 
between the two groups,9,10 and none of these studies adjusted for confounders.7–12 
Additionally, not all patients with ADPKD were hospitalized; as a result, prevalence 
estimates obtained from patients recruited from an inpatient setting must be generalized 
to the broader ADPKD population with caution. Similarly, the prevalence estimates 
obtained from patients recruited from an outpatient specialty clinic must also be 
generalize to the broader ADPKD population with caution due to increased surveillance. 
Also, only 8 of 49 of the included studies described the composition of stones in patients 
with ADPKD; none of the eight studies compared the composition of stones in patients 
with ADPKD to patients without ADPKD. 
This review serves as a call to action for better research in this field. We recommend 
conducting large, multi-center studies that compare the risk of stones and risk of stone 





characterize the magnitude of upper urinary tract stone and stone intervention risk in 
patients with ADPKD. We also recommend such studies adjust for important 
confounders, such as hypertension, to better characterize the true association between 
ADPKD and upper urinary tract stones and stone intervention. Imaging tests are much 
more advanced, widespread, and frequent over time; this may lead to the possibility of 
detecting stones in ADPKD that may not be clinically relevant. Examining risk of upper 
urinary tract stone diagnosis and upper urinary tract stones that require intervention 
separately would provide insight into whether there is a potentially higher burden of 
asymptomatic stone that were detected incidentally on imaging. More reliable estimates 
of the magnitude of risk of stones and stone intervention would provide insight into 
clinical management practices and help patients with ADPKD and their physicians better 
prognosticate. If patients with ADPKD are truly at higher risk for upper urinary tract 
stones, then nephrologists may want to consider preventative measures for upper urinary 
tract stones. For example, if patients with ADPKD are at higher risk of upper urinary 
tract stones and hypocitraturia, then nephrologists may want to screen for hypocitraturia 
and treat patients with potassium citrate. Nephrologists may also want to consider 
treating large cysts that obstruct the urinary system and cause urinary stasis. Preventing 
stone formation would alleviate pain due to upper urinary tract stones and potentially 
slow down disease progression in patients with ADPKD. We also recommend comparing 
the composition of stones observed in patients with ADPKD compared to patients 
without ADPKD. New medications used in ADPKD, such as vasopressin receptor 2 
antagonists, may alter the urine composition and change the types of renal stones that 
these patients get. Future ADPKD-specific risk factors, such as mutation type, of upper 
urinary tract stone studies may help identify patients at high-risk for stones and provide 
further insight into the pathophysiology of upper urinary tract stones in patients with 
ADPKD.  
Our study is the first to systematically review and summarize the prevalence of stones in 
patients with ADPKD. Unlike past narrative reviews, we used a comprehensive search 
strategy across five different databases, and two reviewers independently screened all 
citations retrieved from the search strategy to identify all relevant articles. We also 





for systematic reviews. Two independent reviewers abstracted the data to minimize 
human error and bias.  
There are some limitations inherent in our systematic review. First, we only included 
original journal articles and conference proceedings published in English. However, 
studies show that language-restricted meta-analysis does not lead to biased estimates.67 
Second, the definitions for ADPKD and stones varied across studies; therefore, the 
pooled estimate must be interpreted with caution. 
 
2.5 CONCLUSION 
Our systematic review highlights that there is poor consensus on the prevalence of stones 
in patients with ADPKD. A more methodologically robust study is needed to better 
characterize the magnitude of risk of stones and stone intervention in patients with 
ADPKD. This information can help patients with ADPKD and physicians with their 
prognostication, and might inform the use of interventions to reduce the risk of stones.  
2.6 ADDENDUM 
There has been quite some time between when we initially searched for relevant studies 
(February 2019) and when we completed the thesis (July 2020). Since the time from the 
last search (February 2019), an additional conference proceeding of 241 patients with 
ADPKD was published which described disease progression and renal and extrarenal 
manifestations.68 135 of the 241 (56%) of the patients with ADPKD experienced a upper 
urinary tract stone over a span of 18 years, and the methods quality score for this 
conference proceeding was 8.68 Findings from this study does not change the conclusion 
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Autosomal dominant polycystic kidney disease (ADPKD) is a genetic kidney disorder 
with no cure.1,2 It is characterized by focal cyst development leading to a progressive 
enlargement of both kidneys and kidney failure.3,4 The prevalence of stones in patients 
with ADPKD ranges from 3 to 59%. The wide range of upper urinary tract stone 
prevalence reported in the literature can be explained by several factors including 
inconsistent stone definitions, different distributions of stone risk factors, potential recall 
bias in studies that relied on patient self-reported data to identify stone events, and 
relying on past imaging reports for reasons other than stone identification.5 Upper urinary 
tract stones in patients with ADPKD are associated with significant morbidity. For 
example, stones are a major determinant of pain and may accelerate chronic kidney 
disease progression.6,7 For these reasons, effective stone management is important in 
patients with ADPKD. However, the distorted kidneys and the reduced kidney function in 
patients with ADPKD may make active stone removal more challenging. For example, 
the cysts in patients with ADPKD may hinder optimal stone access and hence the success 
rate of stone interventions.  
A published clinical practice guideline states that stone management in patients with 
ADPKD should not differ from the general population, and recommends that if necessary 
that stone interventions be considered.8 The guideline authors also indicated that their 
recommendation was based on limited evidence.  
Irrespective of whether a patient has ADPKD or not, urgent intervention is often required 
in the presence of infection/urosepsis, intractable pain, vomiting, impending acute renal 
failure, and/or obstruction.9 Currently, shock wave lithotripsy (SWL), ureteroscopy, and 
percutaneous nephrolithotomy (PCNL) are commonly used procedures to remove stones.8 
The choice of stone intervention to treat stone is primarily dependent on stone 
characteristics such as, stone location and size, and availability of equipment. In some 
instances, a combination of interventions may be required to remove stones. SWL emits 
shockwaves from an external device, which then propagate through the body and cause 





subsequent weeks. SWL is least invasive stone intervention, and is not recommended for 
pregnant women, and for patients with uncontrolled hypertension, uncontrolled 
coagulopathy, or a distal urinary obstruction to where stone is located.12 Ureteroscopy is 
performed by inserting a rigid, semi-rigid, or flexible ureteroscope through the urethra 
and into the ureter, and positioning it close to the stone.13,14 Instruments, such as laser, are 
used to fragment the stones, and these stone fragments can be left to pass or can be 
removed using instruments such as stone baskets or graspers.15 During PCNL, a renal 
calyx is punctured percutaneously with fluoroscopy and/or ultrasound guidance to gain a 
access to the stone.16 Stones are then fragmented using instruments, such as lasers or 
pneumatic lithotripters, and removed using tools such as graspers or suction devices.9 
PCNL is relatively the most invasive stone intervention.9  
We undertook this systematic review to critically appraise and summarize the results of 
studies which described the efficacy and safety outcomes of the three main stone 
interventions (SWL, ureteroscopy, and PCNL) in adults with ADPKD. The outcomes of 
interest were the proportion of patients who were stone-free after the intervention, and the 
proportion who experienced at least one post-operative complication.  
 
3.2 METHODS 
3.2.1 Design and study selection 
We conducted this systematic review using an internal pre-specified protocol and 
reported this review according to the Preferred Reporting Items for Systematic Review 
and Meta-Analysis (PRISMA) statement.17  
We included studies that met the following eligibility criteria: (1) published English 
language full-text articles and conference proceedings; (2) any study design; (3) at least 
two patients with ADPKD included in the study; (4) with and without a comparator 
group; and (5) described any efficacy or safety outcome following at least any one of 
SWL, ureteroscopy, and/or PCNL in adults with ADPKD and upper urinary tract stones. 





abstracted data on the study published more recently. We only included studies with 
comparators if outcomes of a stone intervention were compared between ADPKD and 
non-ADPKD populations who underwent the same stone intervention; we did not include 
studies if outcomes of two different interventions were compared in patients with 
ADPKD.  
3.2.2 Identifying relevant articles 
With an experienced librarian, we developed a comprehensive search strategy (Table 3-1) 
to identify eligible published, original journal articles and conference proceedings on 
upper urinary tract stone interventions performed in adults with ADPKD. We retrieved 
all citations using MEDLINE (1947 to February 2019), EMBASE (1947 to February 
2019), Web of Science, BIOSIS Preview (1955 to February 2019), and CINAHL.  
Two reviewers (VK and RJ) removed duplicates and rated the remaining title and 
abstracts obtained from the search syntax. We retrieved the full text of all “relevant” and 
“potentially relevant” articles to further assess study eligibility. To identify additional 
eligible articles, we also manually searched the reference list of all included articles, used 
the “cited by” function in Google Scholar and Web of Science, and the “similar article” 
feature of PubMed. The two reviewers resolved any disagreement by consensus. 
3.2.3 Data abstraction 
One author (VK) developed a standardized form to abstract data from each study 
including information on study, patient and stone characteristics, interventions, and 
outcomes. Two authors (VK and RJ) pilot-tested and improved the form by 
independently extracting data from five eligible articles. Using the final data abstraction 
form (see Table 3-2), two abstractors independently extracted data from remaining 
studies, recorded the data, and resolved any disagreement by consensus.   
Two authors (VK and GG) assessed the methodological quality of each of the included 
studies using a modified Down’s and Black checklist (Table 3-3). We assigned a score 
between 0 and 22 for all included studies, with a higher score indicating better 





3.2.4 Data analysis 
Results were described qualitatively. The heterogeneity of included studies precluded a 
formal meta-analysis.  
Table 3-1. Search strategy used to identify relevant articles related to thesis 
DATABASE SEARCH STRATEGY 
MEDLINE 1. Polycystic Kidney Diseases/ or Polycystic Kidney, 
Autosomal Dominant/  
2. (((polycystic or "type 2" or "type II" or "type 1" or "type I" 
or "autosomal dominant" or pkd) adj3 (kidney* or renal)) or 
adpkd)  
3. 1 or 2   
4. lithotripsy/ or lithotripsy, laser/  
5. (ESWL or ESWLs or SWL or lithotrips* or litholapax*) 
6. 4 or 5 
7. 3 and 6  
8. Ureteroscopy/  
9. (ureteroscop* or ureterorenoscop* or RIRS or retrograde 
intrarenal surgery or FURS) 
10. 8 or 9  
11. 3 and 10  
12. Nephrostomy, Percutaneous/  
13. (PCNL or mPCNL or (percutaneous adj3 (nephrostom* or 
nephrolithotom*))) 
14. 12 or 13  
15. 3 and 14  
16. 7 or 11 or 15  
EMBASE 1. kidney polycystic disease/   
2. (((polycystic or "type 2" or "type II" or "type 1" or "type I" 
or "autosomal dominant" or pkd) adj3 (kidney* or renal)) or 
adpkd)  
3. 1 or 2  
4. extracorporeal lithotripsy/  
5. (ESWL or ESWLs or SWLs or lithotrips* or litholapax*) 
6. 8 and 9  
7. 3 and 6  
8. ureteroscopy/  
9. (ureteroscop* or ureterorenoscop* or RIRS or retrograde 
intrarenal surgery or FURS) 
10. 8 or 9  
11. 3 and 10  
12. percutaneous nephrolithotomy/  






14. 12 or 13  
15. 3 and 14  
16. 7 or 11 or 15   




1. (((((polycystic or "type 2" or "type II" or "type 1" or "type I" 
or "autosomal dominant" or pkd) NEAR/3 (kidney* or 
renal)) or adpkd))) 
2. (ESWL or ESWLs or SWL or lithotrips* or litholapax*)) 
3. ((ureteroscop* or ureterorenoscop* or RIRS or retrograde 
intrarenal surgery or FURS)) 
4. ((PCNL or mPCNL or (percutaneous NEAR/3 (nephrostom* 
or nephrolithotom*)))) 
5. #4 OR #3 OR #2 
6. #5 AND #1 
CINAHL 7. (MH "Kidney, Cystic") OR (MH "Polycystic Kidney, 
Autosomal Dominant") 
8. (((polycystic or "type 2" or "type II" or "type 1" or "type I" 
or "autosomal dominant" or pkd) N3 (kidney* or renal)) or 
adpkd)  
9. S1 OR S2  
10. (MH "Lithotripsy+")  
11. (ESWL or ESWLs or SWL or lithotrips* or litholapax*)  
12. S4 OR S5  
13. S3 AND S6 
14. (MH "Ureteroscopy")  
15. (ureteroscop* or ureterorenoscop* or RIRS or retrograde 
intrarenal surgery or FURS) 
16. S8 OR S9 
17. S3 AND S10 
18. (MH "Nephrostomy, Percutaneous")  
19. (PCNL or mPCNL or (percutaneous adj3 (nephrostom* or 
nephrolithotom*))) 
20. S12 OR S13 
21. S3 AND S14 






Table 3-2. Data abstraction form 
UID Author Title 
Study 
No. 
Type of Stone 
Intervention 
Country Study Design Centre 
                
 
Sample size 







% of patients lost 









Stone Free Status 
(SFS) Definition 
Modality Used 
to Assess SFS 
Time since treatment 
to assess SFS 
No. (%) of patients 
stone free after one 
session 
          
 
No. (%) of patient stone 
free after all sessions 
No. (%) of kidney units 
stone free after one session 
No. (%) of kidney unit stone 
free after all session 






























No. (%) of patients who had 
stent placed after procedure 
        
 
PCNL 





Instrument Used to 
Fragment Stone 
Instrument Used to 
Remove Stone 
No. (%) of patients 
with multiple 
access tract 
            
 
Type of Lithotripter 
No. of Shockwaves 
[Mean (SD; range)] 
Voltage of Shockwaves 
(kV) 
Type of Ureteroscopy 






          





Table 3-3.  Modified Downs and Black checklist 
 Description of Criteria 
Probable 
Answers 




2 Are the main outcomes to be measured clearly described in 
the Introduction or Methods section? 
If assessing being stone-free or any complication are first 








4 Is the case definition for ADPKD clearly described? 1-Yes;  
0-No 
5 Is the ADPKD case definition valid or reliable?  
If the case definition of ADPKD was not reported, then UTD. 
After 2009, Pei criteria; between 1994 and 2009 Ravine criteria; 




6 Is the distribution of age, sex, and baseline kidney function in 
each group of subjects to be compared clearly described?  
1-Yes;  
0-No 
7 Are the main findings of the study clearly described?  
Simple data (including denominators and numerators) should be 
reported for all major findings so that the reader can check the 
major analyses and conclusions. 
1-Yes; 
0-No 
8 Does the study provide estimate of the random variability in 
the data? 
In non-normally distributed data, the inter-quartile range of 
results should be reported. In normally distributed data the 
standard error, standard deviation, or confidence intervals 
should be reported. If the distribution of the data is not 
described, it must be assumed that the estimate used were 
appropriate and the question should be answered yes. 
1-Yes; 
0-No 
9 Have any post-operative adverse events of the intervention 
been reported?  
If study reports no patient experience of any complications, or 
list any post-operative adverse events, then YES; if the results do 
not mention anything about complications, then answer NO.  
1-Yes; 
0-No 
10 Have the characteristics of patients lost to follow-up been 
described?  
If no loss to follow-up, then YES. If authors describe any 
characteristics of those loss to follow-up then answer YES. If 
authors do not describe any characteristics and just state 
number of follow-up, then NO. If author does not mention 








outcome for all patients, then YES. If the author does not report 
number of patients’ loss to follow-up, but only report outcome in 
a subset of the patients, then NO.  
11 Have actual probability values been reported (e.g. 0.035 
rather than <0.05) for the main outcomes except where the 
probability value is less than 0.001?  





12 Were the subjects asked to participate in the study 
representative of the entire population from which they were 





13 Were those subjects who were prepared to participate 
representative of the entire population from which they were 
recruited?  
The proportion of those asked who agreed should be stated. 
Validation that the sample was representative would include 
demonstrating that the distribution of the main confounding 





14 Were the staff, places, and facilities where the patient was 





15 There are no unplanned retrospective analyses performed 
(i.e. data dredging)?  
Any analyses that had not been planned at the outset of the study 
should be clearly indicated. If no retrospective unplanned 
subgroup analyses were reported, then answer yes. If authors 
report any outcomes/clinical characteristics that were not 
explicitly referenced in the intro/method section, then my answer 
to this question is NO; If methods section too brief/not detailed 





16 In cohort studies, do the analyses adjust for different length 
of follow-up of patients, or in case-control studies is the time 
period between the intervention and outcome the same for 
cases and controls?  
If length of follow-up was the same for all study patients, the 
answer should be YES. If different lengths of follow-up were 
account for by, survival analysis for example, the answer should 
be yes. Studies where differences in follow-up are ignored 













18 Were the ADPKD population and controls recruited from 
the same population?  





19 Were the ADPKD population and the controls recruited 
from the same time period?  
For a study which does not specify the time period over which 
patient were recruited, the question should be answered as 





20 Was there adequate adjustment for confounding in the 
analyses from which the main finding was drawn?   
If the distribution of known confounders in the different 
treatment group was not described or the distribution of known 
confounders differed between the two groups but was not 
considered in the analysis, then NO. If effect of the main 
confounders was not investigated or confounding was 
demonstrated but no adjustment was made in the final analyses 





21 Were losses of patients to follow-up considered?  
If the number of patients lost to follow-up are not reported, the 
question should be answered as unable to determine. If the 
proportion lost to follow-up was too small to affect the main 













Figure 3-1 summarizes the study selection process. Our search strategy yielded 221 
citations that we reviewed and identified 24 eligible articles. We identified an additional 
article when manually searching the reference lists of the study conducted by Delakas et 
al. (1997).18 This yielded a total of 25 relevant articles (311 patients with ADPKD) 
published between 1993 and 2019. Studies were conducted in India (n=7), United States 
(n=6), China (n=3), Greece (n=2), and Kuwait (n=2). One study was conducted in each of 
the following countries:  Azerbaijan, Denmark, Iran, Romania, and Taiwan. Of the 25 
included articles, 24 studies were case series (96%), and one (4%) was a cohort study. 







Figure 3-1. Study selection. 
The number of patients in each study ranged from 2 to 29 cases (2 to 30 kidneys), and the 





performed between October 1981 and January 2017. It was unclear whether the 
interventions were emergent or elective in all included studies. The study and patient 
characteristics of each included study are summarized in Table 3-4, and overall outcomes 





Table 3-4. Study and patient characteristics of included studies. 
Author (Year) 
Country (Citation) 
















Shockwave Lithotripsy - Case Series   
Baishya (2012) *              
India 14 
3 (3) Unclear Since 1992 1.5 (1.3) years NR NR 9 
Cass (1995) *                       
United States 30 
4 (NR) 1 NR 3 months‡ 61 (12) 2 (50) 7 
Chen (1993) *                
Taiwan 31 
2 (2) 1 June 1986 to 
December 1989 
NR NR NR 9 
Delakas (1997)               
Greece 18 




55 (NR) 7 (54) 9 
Deliveliotis (2002) *              
Greece 26 
4 (Unclear) Unclear NR 1 month‡ 49 (NR) 3 (75) 8 
Ng (2000) *                  
United States 32 
3 (3) 1 Since 1993 NR NR NR 9 
Singh (2019) *        
India 24     
3 (3) 1 January 1990 to 
July 2014 
NR NR NR 12 
Ureteroscopy - Case Series   
Baishya (2012) *                   
India 14 
2 (3) Unclear Since 1992 7.3 (1.2) 
months 
NR NR 9 
Franke (2010) *                
Denmark 33 
9 (NR) 1 NR NR NR NR 7 
Geavlete (2017) *        
Romania 28     
11 (Unclear) 1 January 2007 to 
January 2017 
NR 61 (NR) NR 8 
Ng (2000) *                  
United States 32 
2 (3) 1  Since 1993 NR NR NR 9 
Singh (2019) *        
India 24     
5 (6) 1 January 1990 to 
July 2014 
NR NR NR 12 
Yili (2012)                  
China 13 
13 (15)  1 2005 to 2010 3 (NR) 35 (NR) 9 (69) 11 























Khorrami (2012)                    
Iran 29 















Percutaneous Nephrolithotomy - Case Series         
Al-Kandari (2009)      
Kuwait 23 
19 (20) 2 1995 to 2007 NR 42 (9) 12 (63) 11 
Al-Kandari (2008)                
United States 34 
29 (30) 2 NR NR NR 21 (72) 4 
Baishya (2012) *        
India 14     
3 (3) Unclear Since 1992 2.2 (0.8) years NR NR 9 
Bendigeri (2016)       
India 35     
13 (17) NR NR NR NR 10 (77) 8 
Boaz (2016)       
India 36     
19 (23) Unclear January 2003 to 
July 2015 
NR NR NR 6 
Enganti (2017)       
India 37     
22 (Unclear) Unclear January 2014 to 
April 2016 
NR 42 (NR) NR 4 
Ismayil (2014) *                       
Azerbaijan 38 
3 (NR) NR 2004 to 2014 NR NR NR 6 
Khadgi (2016)                       
Kuwait 25 
7 (NR) NR March 2010 to 
September 2012 
NR 42 (8) 3 (43) 12 
Lei (2014)                  
China 19 
23 (23) Unclear January 2007 to 
December 2012 
NR 43 (11) 17 (74) 12 
Sabnis (2016)                        
United States 22 
10 (NR) NR NR NR NR 8 (80) 7 
Singh (2013)                   
India 39 
22 (26) 1 2002 to 2011 35 (NR) 
months 
38 (NR) NR 8 
Singh (2019) *        
India 24     
6 (6) 1 January 1990 to 
July 2014 
NR NR NR 12 
Srivastava (2012)          
India 40 
22 (25) 1 January 2000 to 
January 2010 























Umbreit (2010)                   
United States 21          




32 (NR) 7 (78) 9 
Wang (2017)                         
United States 41 
11 (13) Unclear Since 2010 NR 50 (13) 8 (73) 7 
Zhang (2014)                    
China 27 
11 (12) 1 January 2002 to 
December 2012 
36 months‡ 42 (11) 7 (64) 11 
Abbreviations: not reported, NR; standard deviations, SD 
*The described cases are a subset of a larger case series. 
‡The reported length of follow-up is not the average but rather constant for all included patients.  
± A modified Downs and Black checklist was used to assess the methodological quality of each included study. The methods quality score ranged 






















Complications, No. of 
Patients (%) 
Post-operative 















Shockwave Lithotripsy - Case Series 
Baishya (2012)               
India 
0 (0) 2 (67) NR NR NR NR 
Cass (1995)                      
United States 
2 (50) Unclear NR None NR NR 
Chen (1993)               
Taiwan 
0 (0) NR NR None NR NR 
Delakas (1997)               
Greece 
9 (69) 2 (15) None • At least one complication: 
Unclear 
• Colic pain that improved 
with oral analgesics: 3 (23) 
• Transient Gross Hematuria: 
8 (62)  
NR NR 
Deliveliotis 
(2002)             
Greece 
1 (25) NR NR None NR NR 
Ng (2000)                 
United States 
NR 1 (33) NR None 76.6 (10.2; 
70.7 to 88.4) 
79.6 (25.0; 
61.9 to 97.2) 
Singh (2019)       
India      
NR 1 (33) NR • At least one complication: 2 
(33) 
• Fever: 2 (33) 
NR NR 
Ureteroscopy - Case Series 
Baishya (2012)                  
India 
2 (100) 0 (0) NR None NR NR 
Franke (2010)               
Denmark 
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Geavlete (2017)       
Romania      
8 (73) Unclear NR • At least one complication: 3 
(27) 
• Fever: 1 (9) 
• Hematuria: 1 (9) 
• Renal colic: 1 (9) 
NR NR 
Ng (2000)                 
United States 
NR 0 (0) NR None  556.9 (399.6; 
274.0 to 
839.8) 
 300.6 (75.0; 
247.5 to 
353.6) 
Singh (2019)       
India      
NR 0 (0) NR • At least one complication: 1 
(20) 
• Fever: 1 (20) 
NR NR 
Yili (2012)                  
China 
11 (85) 2 (15) None • At least one complication: 3 
(23) 
• Low-grade fever: 1 (8) 
• Flank pain: 1 (8) 
• Moderate stent pain: 1 (8) 
NR (NR; 70.7 
to 291.7)  
NR 
Percutaneous Nephrolithotomy - Cohort 







NR • ADPKD: None 
• CONTROL: None 
• Urinary leakage from 
nephrostomy tube was longer 
in patients with ADPKD (31 + 
4 hours) vs. controls (6 + 1.5 
hours)  
NR NR 





















Complications, No. of 
Patients (%) 
Post-operative 
















(2009)      Kuwait 
16 (84)  3 (16) Unclear • At least one complication: 3 
(15) 
• Mild hematuria with low-
grade fever: 1 (5) 
• Bleeding through 
nephrostomy tube after 
declamping: 1 (5) 






(2008)                
United States 
NR 2 (7) •At least one complication: 3 
(10) 
• Renal Pelvic Tear: 2 (7) 
• Intraoperative bleeding: 1 
(3) 
None NR NR 
Baishya (2012)       
India      
2 (67) 1 (33) NR • At least one complication: 2 
(67) 
• Post-operative fever: 1 (33) 
• Pain in operating site: 1 (33) 
NR NR 
Bendigeri (2016)       
India      
NR 3 (23) NR • At least one complication: 
Unclear 
• Fever: 3 (23) 
• Blood transfusion: 1 (8) 
NR NR 
Boaz (2016)       
India      
NR 4 (21) • At least one complication: 
1 (5) 
• Blood transfusion: 1 (5) 
• At least one complication: 4 
(21) 
• Fever: 4 (21) 
• Sepsis: 1 (5) 
179.5 (84.2; 
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Enganti (2017)       
India      
NR NR NR • At least one complication: 5 
(23) 
• Renal pelvic perforation: 1 
(5) 
• Hematuria requiring blood 
transfusion: 2 (9) 
• Perirenal fluid collection: 2 
(9) 
NR NR 
Ismayil (2014)                      
Azerbaijan 
2 (67) 1 (33) NR • At least one complication: 3 
(100) 
• Blood transfusion: 3 (100) 
NR NR 
Khadgi (2016)                       
Kuwait 
7 (100) 0 (0) NR • At least one complication: 3 
(43) 
• Fever: 1 (14) 
• Urinary tract infection: 1 
(14) 
• Bleeding: 1 (14) 
NR NR 
Lei (2014)                  
China 
16 (70) 6 (26) NR • At least one complication: 
Unclear 
• Fever: 4 (17) 
• Urinary tract infection: 3 
(13) 
• Blood transfusion: 2 (9) 
• Selective renal artery 
embolization: 1 (4) 
148.2 (110.1; 
































Complications, No. of 
Patients (%) 
Post-operative 















Sabnis (2016)                        
United States 
NR 0 (0) NR • At least one complication: 2 
(20) 
• Fever: 2 (20) 
NR NR 
Singh (2013)                   
India 
12 (55) 10 (45) • At least one complication: 
4 (18) 
• Hypotension requiring 
resuscitation but did not 
require termination of 
procedure: 4 (18) 
• At least one complication: 
Unclear 
• Blood transfusion: 9 (32) 
• Fever due to cyst infection: 4 
(18) 
• Perirenal hematoma 
collection: 4 (18) 
• Renal failure that worsened: 
3 (14)  
• Hydrothorax:  2 (9) 
• Hemothorax: 1 (5) 
• Pneumothorax: 1 (5) 
• Paralytic ileus: 3 (14) 
NR NR 
Singh (2019)       
India      
NR Unclear NR • At least one complication: 
Unclear 
• Fever: 2 (33) 
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Srivastava (2012)          
India 
Unclear 3 (14) NR • At least one complication: 
Unclear 
• Fever: 4 (18) 
• Blood transfusion: 3 (14) 
• More than one transfusion: 1 
(5) 
• Positive fungal culture with 
antibiotic treatment for 3 
months: 1 (5) 
NR NR 
Umbreit (2010)                   
United States          
NR 2 (18) None None 123.8 (NR; 




Wang (2017)                         
United States 
NR 7 (64) NR • At least one complication: 
Unclear 
• Severe hematuria: 1 (9) 
• Fever: 5 (45) 
• Paralytic ileus: 1 (9) 






Zhang (2014)                    
China 
5 (45) 4 (36) NR • At least one complication: 
Unclear 
• Bleeding: 3 (27) 
• Fever: 4 (36) 
• Blood transfusion: 2 (18) 













3.3.1 Quality assessment of studies 
The methods quality score was highly variable and ranged between 4 to 12 out of 22 
(where higher scores indicates studies of higher methodological quality).  
The ADPKD and outcome definitions affect the internal validity of a study. Only one 
study reported the case definition of ADPKD, which defined ADPKD using the 
validated, Ravine ultrasonographic criteria.19,20   
The definition of stone free status post-intervention was highly variable across studies. 
Seven of the 25 studies specified and defined stone free status as complete clearance or 
residual fragments less than a prespecified size. The prespecified size for an acceptable 
residual fragment was less than four millimeters for five studies, less than two 
millimeters for one study, and less than one millimeter for one study.  
The sampling strategy and the source population influenced the generalizability of the 
findings to the broader ADPKD population who underwent stone intervention. Seven of 
the 25 studies specified how cases were recruited, and all seven studies included 
consecutive or all patients within a specified time frame.13,14,21–25 One study recruited 
patients from an outpatient setting26, and four studies recruited patients from a hospital 
setting.18,19,27,28 For the latter, it was unclear whether the cases were recruited from a same 
day surgery setting, emergency department, inpatient, or an outpatient hospital-based 
clinic.    
One conference proceeding described the efficacy outcomes of PCNL performed in 
patients with ADPKD compared to non-ADPKD controls, without adjustment for any 
covariates.29  
3.3.2 Shockwave lithotripsy 
We identified seven case series describing the outcomes and experience of treating stones 
in patients with ADPKD with SWL (in total 32 patients).14,18,24,26,30–32 The characteristics 





Table 3-6. Characteristics of shockwave lithotripsy (SWL). 
Author (Year)             
Country 








Modality used to assess 




Baishya (2012)               
India 
Dornier Compact Delta <1500 <13 X-ray, U/S of the KUB 
region  
NR 
Cass (1995)                      
United States 
Medstone STS Lithotripter 2050 (700; 
1000 to 2400) 
24 Plain radiograph NR 
Chen (1993)               
Taiwan 
Dornier HM-3 Lithotripter 2500 (NR; 
2000 to 3000) 
20 KUB x-ray and 
excretory urography  
NR 
Delakas (1997)               
Greece 
Dornier HM-4 Lithotripter 1800 (NR; 
1400 to 2500) 
15 to 21 Plain x-ray film and U/S NR (35 to 
88) 
Deliveliotis (2002)             
Greece 
Dornier HM-4 Lithotripter Unclear 23 Plain KUB x-ray film 
and U/S  
NR 
Ng (2000)                 
United States 
Dornier HM-3 or MFL 5000 
Lithotripter  
4333 (3402; 
1800 to 8200) 
NR Plain x-ray film and 
kidney U/S or non-
contrast CT 
NR 
Singh (2019)       
India      
NR < 1500 < 13 U/S or KUB x-ray 100 (80 to 
120) 





None to 69% of the patients were stone free after a single SWL session, and 15% to 67% 
of the patients received additional follow-up procedures to achieve stone-free 
status.14,18,24,26,30–32 In four of the six case series that examined at least one post-operative 
SWL complication, no patients experienced any complications post-operatively.26,30–32 
The percentage of patients that experienced at least one complication was unclear in one 
study18, and 33% of the patients described by Singh (2019) experienced fever post-
operatively.24 The reported post-operative complications of SWL in patients with 
ADPKD included colic pain and fever.18,24 Delakas and colleagues specified that none of 
the patients experienced any post-operative complications18, whereas the remaining six 
case series did not report any intraoperative complications.14,24,26,30–32   
3.3.3 Ureteroscopy 
We identified six case series reporting stone treatment in patients with ADPKD using 
ureteroscopy (in total 42 patients) 13,14,24,28,32,33. The characteristics of ureteroscopy are 





Table 3-7. Characteristics of ureteroscopy. 




Instrument used to 
Fragment Stones 
Modality used to Assess 






Baishya (2012)                  
India 
NR NR X-ray, U/S of the KUB 
region at one month 
NR 




NR CT NR 
Geavlete (2017)       
Romania      
Flexible 
ureteroscope 
Laser lithotripsy NR NR 
Ng (2000)                 
United States 
NR Laser for 1 of 2 patients Plain x-ray film and renal 
U/S or non-contrast CT 
NR 
Singh (2019)       




Holium YAG laser Plain x-ray KUB and U/S 
KUB 
60 (30- 90)  




Holium YAG laser lithotripsy 
performed via 200um 
(Dornier Lightguide Super 
200) core-sized fiber until 
only very small pieces 
(<1mm) remained. 
U/S 46 (36-60)  





After a single session, 73% to 100% of the patients were stone-free.13,28,33 In four case 
series, no patients required a second procedure to facilitate complete stone 
removal,14,24,32,33 whereas another case series reported 15% undergoing a second 
ureteroscopy one week following the first procedure.13 The percentage of patients that 
underwent a second procedure was unclear or not reported in one case series.28 Three case 
series reported that none of the patients experienced any post-operative 
complications.14,32,33 About 20% to 27% of the patients experienced at least one post-
operative complication, such as fever, hematuria, and pain in the remaining three case 
series.13,24,28 One case series reported that not a single patient experienced any 
intraoperative outcomes during ureteroscopy13, whereas the remaining five case series did 
not report about any intraoperative outcomes.14,24,28,32,33  
3.3.4 Percutaneous nephrolithotomy (PCNL) 
Sixteen case series14,19,21–25,27,34–41 and one cohort study29 reported the use of PCNL for 
stone removal in adults with ADPKD, with 3 to 29 patients per series (3 to 30 kidneys) 





























Modality Used to 








Khorrami (2012)                    
Iran 
NR Fluroscopy Metal 
telescoping 
dilator 
NR NR NR NR NR 
Al-Kandari 
(2009)      Kuwait 






















• At time of 
nephrostomy tube 











(2008)                
United States 
NR NR NR NR NR NR NR NR 
Baishya (2012)       
India      




NR NR NR NR X-ray, 
ultrasonography of 





























Modality Used to 








Bendigeri (2016)       
India      
NR NR NR NR NR NR NR NR 
Boaz (2016)       
India      
NR NR NR NR NR NR NR 85 
Enganti (2017)       
India      
NR NR NR NR NR NR NR NR 
Ismayil (2014)                      
Azerbaijan 
NR NR NR NR NR NR CT NR 
Khadgi (2016)                       
Kuwait 
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Sabnis (2016)                        
United States 
NR U/S or 
Fluroscopy 
NR NR NR NR NR NR 
Singh (2013)                   
India 
31 Fluroscopy Alkene 
metallic 







































Modality Used to 








Singh (2019)       
India      
NR U/S and 
fluoroscopy 
Serial Dilator Unclear laser or 
pneumatic 
lithoclast 
NR Plain x-ray KUB 
and U/S KUB 
112 (NR; 
70-145)  
Srivastava (2012)          
India 
Unclear NR Amplatz 
sequential 















Forceps  Non-contrast CT NR 
Umbreit (2010)                   
United States          































Wang (2017)     
United States                    
18 U/S  Amplatz 
fascial dilators 
Rigid Pneumatic and 
U/S 
disintegration 
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Zhang (2014)                    
China 










Graspers Ultrasound/ KUB 
film 
77 (23.5; 
45- 128)  






The stone-free status of patients after a single session ranged from 45% to 100%, and 0% 
to 64% of the patients required a follow-up procedure for residual stones among the 12 
studies that reported it.14,19,21–23,25,27,34–36,38–41 Two studies reported no patients 
experiencing any post-operative complications21,34, seven case series did not report the 
percentage of patients with complications19,24,27,35,39–41, and 15% to 100% of patients 
experienced at least one complication among the remaining seven case series.14,23–25,36–38 
The post-operative complications of PCNL included fever, pain, hematuria, bleeding, 
urinary tract infection, cyst infection, perirenal hematoma collection, hydrothorax, 
hemothorax, pneumothorax, paralytic ileus, worsening of pre-existing renal failure, blood 
transfusion, renal pelvic perforation, urinary leakage from nephrostomy tube, and 
sepsis.14,19,22–25,27,35–41 None of the patients described by Umbreit et al. experienced any 
intraoperative complications.21 In three other case series, at least one patient experienced 
an intraoperative complication, including bleeding, renal pelvic tear and 
hypotension34,36,39; the remaining studies did not clearly report any intraoperative 
complications. 14,19,22–25,27,35,37,38,40,41 
Khorrami et al. conducted a cohort study of patients undergoing PCNL, comparing eight 
patients with ADPKD to 100 patients without ADPKD.29 There were no significant 
between-group differences in stone-free status, the rise in the concentration of serum 
creatinine after the procedure, or the decline in concentration of hemoglobin after the 
procedure.29 However, urinary leakage lasted significantly longer in patients with 
ADPKD compared to patients without ADPKD.29 
 
3.4 DISCUSSION 
We conducted a systematic review of 25 studies describing at least one post-operative 
outcome of SWL, ureteroscopy, and PCNL in patients with ADPKD to summarize the 





and between study variability in patient characteristics, stone characteristics, and 
treatment protocol. This concern notwithstanding, based on the literature published to 
date, the percentage of patients who were stone free after one session ranged from none 
to 69% for SWL, 73% to 100% for ureteroscopy, and 45% to 100% for PCNL. The 
overall complication rate ranged from none to 33% for SWL, none to 27% for 
ureteroscopy, and none to 100% for PCNL. Post-operative complications experienced by 
patients with ADPKD after any intervention included residual stones, pain, and fever. 
Post-operative hematuria was observed after ureteroscopy and PCNL. Other PCNL 
complications included urinary leakage, bleeding, renal pelvic perforation, perirenal fluid 
collection, urinary tract infection, cyst infection, worsening renal failure, hydrothorax, 
hemothorax, pneumothorax, and paralytic ileus.  
The post-operative complication and stone free rates of all three stone interventions were 
highly variable. The variability in post-operative complication and stone free rates can be 
explained by between-study variability in the definitions used for stone free status, 
sample size, treatment protocol, timing when imaging was performed post-intervention, 
and the type of imaging performed to assess stone free status post-intervention. For 
example, among all imaging modalities used to assess stone free status, computed 
tomography (CT) is the most sensitive modality to detect residual stones.42,43 Ultrasound 
and kidney, ureter, and bladder (KUB) radiograph cannot detect radiolucent stones, such 
as uric acid stones, and the ultrasound performance is poor for patients who are obese and 
patients with residual fragments less than 5 millimeters42,43, and would be expected to be 
less sensitive in the setting of ADPKD. As a result, studies that use CT post-operatively 
would report a lower stone free rate compared to studies that use ultrasound or KUB. 
Patient and stone characteristics, including ADPKD-specific characteristics such as 
residual renal function and cyst volume and location, influence intervention choice and 
subsequent success and complication rates. In general, symptomatic stones that are 
between one to two centimeters would be treated with either SWL or ureteroscopy, and 
PCNL would be reserved for stones greater than two centimeters, or in patients where 
retrograde access is not possible. The success rate of all three intervention is dependent 





characteristics across studies also explain the variability in reported success and 
complication rate.  
It is difficult to determine whether SWL, ureteroscopy, and PCNL are truly efficacious 
and safe in patients with ADPKD because the variability described above also limits 
indirect comparison of stone interventions success and complication rates between that 
reported in patients with ADPKD and the general population. Furthermore, the ADPKD 
cases described in the studies were likely more selected than the general population 
because of their complex kidney anatomy. Future randomized controlled trials or 
observational studies that use a representative sample of patients with ADPKD and 
address potential confounding factors are required to elucidate whether ADPKD is truly 
associated with poor outcomes following SWL, ureteroscopy, and PCNL.  
Our findings must be interpreted with caution due to several limitations. First, except for 
one cohort study, all studies were clinical case series. Although case series give some 
insight into the outcomes of stone interventions, and are useful for generating new 
hypotheses, the observations are not necessarily generalizable to the broader ADPKD 
population. Based on our systematic, comprehensive search, the conference proceeding 
published by Khorrami et al. (2009) is the only cohort study in the literature.39 Although 
they compared the outcomes of PCNL in patients with ADPKD to patients without 
ADPKD, they did not adjust for any covariates. Second, the sample size of all included 
studies, including the cohort study was small so the reported estimates were imprecise. 
Third, most of the data were retrospectively collected. As a result, the conclusions were 
highly dependent on the accuracy of medical records. Fourth, the inclusion and exclusion 
criteria were not explicitly reported in all identified studies. Lastly, all studies published 
to date did not describe the cystic volume in patients with ADPKD. As a result, it was 
difficult to elucidate whether and how cystic volume influences post-operative 
complication and success rates.  
Aside from inherent limitations of the information in the primary studies, with respect to 
the quality of this review, we used a very comprehensive search strategy to identify 









Our systematic review shows that empirical evidence on the efficacy and safety of SWL, 
ureteroscopy, and PCNL in ADPKD is limited. Our findings corroborate Mallett et al’s 
suggestion to undertake methodologically rigorous studies to understand the 
consequences of these procedures in patients with ADPKD.8 
3.6 ADDENDUM 
We updated our search to identify whether additional studies were published between 
February 2019 (when the initial search was conducted) and July 2020. We identified one 
additional study that described 21 patients with ADPKD who underwent ureteroscopy, 
and 11 patients with ADPKD who underwent PCNL.46 The methods quality score of the 
additional study was 12. The percentage of patients who were stone free after one session 
was 85.9% for patients who underwent ureteroscopy, and 90.9% for those who 
underwent PCNL. 46 The percentage of patients who experienced one complication was 
28.6% for patients who underwent ureteroscopy, and 45.5% for patients who underwent 
PCNL. 46 The percentage of patients who experienced at least one post-operative 
complication following ureteroscopy now ranges from 0% to 29% instead of 0% to 27% 
according to all studies published in the literature; however, the findings from this study 
do not change the conclusion of this chapter that empirical evidence on the efficacy and 
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4.1 Limitations of the existing literature 
We conducted two systematic reviews to identify knowledge gaps, and to gain a current 
state of knowledge on the prevalence and incidence of upper urinary tract stones and 
stone interventions, and on the safety and efficacy of SWL, ureteroscopy, and PCNL in 
patients with ADPKD.  
Our first systematic review revealed that there is still poor consensus on the prevalence of 
upper urinary tract stones and stone interventions in patients with ADPKD. Most studies 
published to date on stones in ADPKD were conducted in a single center, and are of poor 
methodological quality. The ADPKD and stone definitions were variable across studies. 
Additionally, only six studies compared the prevalence of stones in patients with ADPKD 
to controls.1–6 Among the six studies, two statistically compared the prevalence of stones 
between the two group, and none of these studies adjusted for confounders.3,4  
Our second systematic review showed that empirical evidence of the efficacy and safety 
of SWL, ureteroscopy, and PCNL in ADPKD is limited. Except for one cohort study, all 
studies were clinical case series. Although case series give some insight into the 
outcomes of stone interventions, and are useful for generating new hypotheses, the 
observations are not necessarily generalizable to the broader ADPKD population. Based 
on our systematic, comprehensive search, the conference proceeding published by 
Khorrami et al. (2009) is the only cohort study in the literature.7 Although they compared 
the outcomes of PCNL in patients with ADPKD to patients without ADPKD, they did not 
adjust for any covariates. The sample size of all included studies, including the cohort 
study, was small so the reported estimates were imprecise. Most of the data were 
retrospectively collected. As a result, the conclusions were highly dependent on the 
accuracy of medical records. Lastly, the inclusion and exclusion criteria were not 
explicitly reported in all identified studies.  
Our systematic reviews show that the epidemiological data to support the assertion that 
patients with ADPKD are at higher risk of upper urinary tract stones is weak. 
Additionally, there is limited evidence on how stones are currently managed in patients 





interventions, such as lithotripsy, for their upper urinary tract stones. We also do not 
know if patients with ADPKD who underwent stone interventions experience a higher 
risk of post-operative outcomes. More methodologically robust studies are needed to 
better characterize the association between ADPKD and upper urinary tract stones, and 
between stone interventions and post-operative outcomes. This information will help 
patients with ADPKD and physicians guide prognostication, and might inform the use of 
interventions; it will also help inform future clinical practice guidelines. 
Conducting a retrospective cohort study using healthcare administrative databases would 
allow us to conduct large studies and give us insight into rate of hospital encounters with 
upper urinary tract stones and stone interventions in patients with ADPKD, and into the 
risk of post-operative outcomes of stone intervention in patients with ADPKD. However, 
we must first ensure that we can reliably identify patients with ADPKD using 
administrative codes. Patients with ADPKD can be identified using Ontario Health 
Insurance Plan (OHIP) diagnosis codes, codes submitted by physicians for the services 
they provide, or by using the International Classification of Diseases, 9th revision (ICD-9) 
codes, and International Classification of Diseases, 10th, revision (ICD-10) codes 
(healthcare encounter codes). Healthcare encounter codes are assigned per the ICD-9 
(used in Canada prior to 2002) and ICD-10 (used in Canada in 2002 onwards) 
classification system by highly trained coders.9 These data are collected for 
administrative purposes rather than research purposes.10 Physician misdiagnosis, 
incomplete documentation in medical records, or errors by personnel who assign the 
administrative codes to each hospital encounter can potentially lead to misclassification.9 
Thus, patients who truly have ADPKD may not be assigned the code and patients with 
ICD-9 or ICD-10 codes related to ADPKD may not truly have ADPKD. Based on a 
comprehensive literature search of bibliographic databases, there is only a single study 
which validated an administrative code related to ADPKD.11 Blanchette et al. validated 
the ICD-9 code for unspecified PKD (753.12) by using medical chart review as the 
reference standard.11 The positive predictive value of the ICD-9 code 753.12 was 94.7%, 
indicating it identified patients who truly had ADPKD.11 No study, to date, has formally 
validated the more recent ICD-10 code. Additionally, coding practices differ by 





codes related to ADPKD in Ontario. Validating administrative codes related to ADPKD 
will provide assurance of the robustness of our cohort and the internal validity of our 
studies. 
I will address the limitations in the current literature by conducting one validation study, 
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Autosomal dominant polycystic kidney disease (ADPKD) is a genetic condition 
characterized by focal cyst development leading to bilateral enlargement of both 
kidneys.1 Approximately, half of these patients will require end-stage kidney disease care 
by the age of 50.2 ADPKD has an estimated prevalence of 1 in 1000 to 1 in 400 (0.1 to 
0.25%) persons worldwide.3 Since ADPKD is a relatively uncommon disease, using large 
healthcare administrative databases may allow a large number of patients with ADPKD 
to be identified and studied in a time-efficient and cost-effective manner. 4 However, this 
approach requires assurances that ADPKD is coded accurately in these data sources, and 
an appreciation of the number of patients with ADPKD who had at least one hospital 
encounter can be accurately identified in this way. This is because information available 
from administrative databases are collected primarily to monitor healthcare use and to 
assess healthcare needs, without the same rigour used in clinical research studies to assess 
conditions of interest.5 Physician misdiagnoses, incomplete documentation in medical 
records, or errors by personnel who assign codes to each hospital encounter can all 
potentially lead to misclassification of a condition.6  
We conducted a comprehensive search of bibliographic databases (search last updated to 
December 2015), and found only a single study in the United States that described any 
aspect of the accuracy of healthcare administrative database codes for ADPKD. 
Blanchette and colleagues assessed the positive predictive value of a single International 
Classification of Disease, 9th revision (ICD-9) code for any kind of polycystic kidney 
disease (PKD) (753.12), where a medical chart review was used to ascertain whether 
PKD was truly present or not.7 In this study, the clinical criterion used to define PKD in 
the medical chart was not defined. In addition, despite knowing that the population 
comprised of members of commercial health plans, it was not clear whether the charts 
were from an outpatient and/or hospital-based setting.7 In 132 patients, the positive 
predictive value of ICD-9 code 753.12 was 95%, indicating that most patients identified 
with the ICD-9 code 753.12 had ADPKD according to their medical chart review.7 
We undertook two studies. Frist, we determined if different coding algorithms containing 





assigned during hospital encounters (emergency room visits or hospital admissions) can 
be used to identify adult patients who meet the clinical criteria for ADPKD in the 
province of Ontario, Canada. This was done to estimate the positive predictive value of 
various coding algorithms considering the manual chart review and a rigorous definition 
of ADPKD as the reference standard. Second, we used Ontario-wide healthcare databases 
to assess the number of patients identified with different sets of ADPKD codes to 
determine the proportion of the general public identified with ADPKD with each of the 
coding algorithms (where an expected prevalence is 0.1 to 0.25%). 
 
5.2 METHODS 
5.2.1 Study design 
We completed two studies to evaluate the performance of ICD-10 coding algorithms for 
the identification of ADPKD patients and to understand the frequency of ICD-10 coding 
algorithms. For our first study, we manually reviewed inpatient and outpatient medical 
records (including both electronic medical records and paper charts) to assess the positive 
predictive values of different ICD-10 coding algorithms for ADPKD. For our second 
study, we conducted analyses of large healthcare databases housed at ICES, to understand 
the frequency of ICD-10 coding algorithm use in the province of Ontario, Canada.8 
5.2.2 Ethics approval and consent to participate 
The institutional review board at Western University, London, Ontario, Canada approved 
the chart abstraction study, and the one at Sunnybrook Health Sciences Centre, Toronto, 
Ontario, Canada approved the second study using the healthcare administrative data 
housed at the ICES. The institutional review boards waived the need for patient consent. 
The Institute for Clinical Evaluative Sciences is a designated prescribed entity under 
Section 45 of the Personal Health Information Protection Act (PHIPA), and as such the 
need for patient consent is waived (as confirmed by the institutional review board that 





5.2.3 Data sources and database algorithms  
The World Health Organization (WHO) developed the ICD-10 codes collaboratively with 
ten international centres to promote comparability in mortality data across countries. In 
Canada, the National Implementation Advisory Committee (established by the Canadian 
Institute for Health Information, CIHI) modified and enhanced some of the ICD-10 codes 
developed by WHO to better accommodate Canadians’ administrative, epidemiological, 
and public health research needs prior to implementation. ICD-10-CA is the Canadian 
modification of the ICD-10 codes. The ICD-10 codes related to ADPKD used in Canada 
were not modified and are identical to those developed by the WHO. 
ICD-10 and ICD-10-CA codes are used in Canadian administrative databases such as the 
CIHI Discharge Abstract Database (CIHI-DAD) and the CIHI National Ambulatory Care 
Reporting System (CIHI-NACRS). The CIHI-DAD houses administrative, demographic 
and clinical information on hospital discharge and day surgery procedures, and the CIHI-
NACRS database contains information on all emergency room visits.12  Neither CIHI-
DAD nor CIHI-NACRS houses information on outpatient physician office visits. Trained 
personnel at each hospital in Ontario review the medical charts of all patients with 
healthcare encounters. Based on rules and guidelines provided by CIHI, these trained 
personnel code all diagnoses and procedures using the ICD-10 coding system, and then 
enter these codes into the CIHI-DAD and CIHI-NACRS databases.6 These trained 
personnel only consider physician-recorded diagnoses in a patient’s medical chart when 
assigning the codes, and do not review or interpret diagnostic imaging reports, laboratory 
values, family history, or signs and symptoms of ADPKD. 
In our two  studies, we compiled a list of relevant ICD-10 codes for ADPKD (Table 5-1) 
and developed nine unique algorithms using two databases (CIHI-DAD and CIHI-
NACRS) and two ICD-10 codes, Q61.2 (polycystic kidney disease, autosomal dominant) 






Table 5-1. International classification of diseases, 10th revision codes relevant for 
autosomal dominant polycystic kidney disease. 
Database Code Description 
CIHI-DAD Q61.3 polycystic kidney disease - unspecified 
CIHI-DAD Q61.2 polycystic kidney disease - autosomal dominant 
CIHI-NACRS Q61.3 polycystic kidney disease - unspecified 
CIHI-NACRS Q61.2 polycystic kidney disease - autosomal dominant 
Abbreviations: Canadian Institute of Health Information Discharge Abstract Database, CIHI-DAD; 




Table 5-2. Combination of International Classification of Diseases, 10th revision of the 
nine administrative coding algorithms evaluated to identify patients with autosomal 
dominant polycystic kidney disease. 
Administrative Code Algorithms 
1 Q61.2 in CIHI-DAD 
2 Q61.3 in CIHI-DAD 
3 Q61.2 in CIHI-NACRS 
4 Q61.3 in CIHI-NACRS 
5 Q6.2 or Q61.3 in CIHI-DAD 
6 Q61.2 or Q61.3 in CIHI-NACRS 
7 Q61.2 in either CIHI-DAD or CIHI-NACRS 
8 Q61.3 in either CIHI-DAD or CIHI-NACRS 
9 Q61.2 or Q61.3 in either CIHI-DAD or CIHI-NACRS 
Abbreviations: Canadian Institute of Health Information Discharge Abstract Database, CIHI-DAD; 
Canadian Institute of Health Information National Ambulatory Care Reporting System, CIHI-NACRS 
5.3 METHODS SPECIFIC TO CHART ABSTRACTION 
STUDY 
 
5.3.1 Patient selection 
For the chart abstraction study, we compiled a list of adult patients (age > 18 years) with 
emergency department visits and/or hospital admissions (CIHI-DAD or CIHI-NACRS) 
and the presence of one or more ICD-10 code Q61.2, Q61.3 between April 1st, 2002 and 





and University Hospital). ICD-10 codes are only available after April 1st, 2002, and thus 
defined our accrual start date. The main purpose of this study was to determine whether 
we could confidently use the ICD-10 codes related to ADPKD to identify patients with 
ADPKD using ICES data. The data was only available until March 31st, 2014 at the time 
the study was conducted, and thus defined our accrual end date. We assigned a unique 
Subject identification number (ID) to each patient, and saved a list of all patients’ 
medical record numbers and Subject IDs in a password protected Microsoft Excel file, 
which was stored on a secure hospital network, as prescribed by our REB. If a patient had 
more than one code or more than one hospital and/or ambulatory care encounter, we 
assigned the unique subject ID to the first hospital or ambulatory care encounter because 
that was the first time the individual was recognized as affected with ADPKD during our 
study period. We included all patients with an ICD-10 code Q61.2. For the observations 
with ICD-10 code Q61.3, we stratified all patients by database (CIHI-DAD or NACRS) 
and by year of hospital encounter, and randomly sampled within strata to review the 
medical records of a total of 201 patients from a list of 305 patient charts eligible for 
review.  
5.3.2 Data collection 
We manually reviewed the medical records of the 201 patients. We abstracted 
information on physician report of ADPKD, family history of ADPKD, indication of 
ADPKD from surgical pathology reports or autopsy reports, and information from 
imaging reports (reason for examination, number of cysts in each kidney, and dimensions 
of each kidney). Certain imaging reports did not specify the exact number of cysts. In 
these instances, we interpreted “multiple cysts bilaterally” as at least three cysts in each 
of the two kidneys, and “innumerable cysts bilaterally” as at least four cysts in each of 
the two kidneys after consultation with an experienced nephrologist and radiologist. 
Sensitivity analysis were performed to determine whether interpreting “multiple cysts 
bilaterally” as at least four cysts in each kidney meaningfully changed the results. If 
information was missing in an electronic medical record, we obtained the paper in-patient 
chart. If information was still missing after reviewing the paper chart, we reviewed the 





(M.R.) retrieved and reviewed available diagnostic images for patients with missing or 
ambiguous information. We recorded all abstracted information onto a detailed data 





Table 5-3. Data abstraction form to collect relevant clinical information required to elucidate whether patients have ADPKD or not 















































































































Abbreviations: family history, Fam Hx; International Classification of Diseases, 
10th revision, ICD-10; left kidney, LK; polycystic kidney disease, PKD; right 
kidney, RK; ultrasound, U/S  
 





5.3.3 Clinical definition of ADPKD 
In the chart abstraction study, two reviewers (V.K. and R.M.) independently determined 
whether each of the 201 patients had ADPKD or not using strict criteria (described in 
next paragraph). These criteria were developed in consultation with two experienced 
nephrologists (A.G. and Y.P.). To determine final ADPKD status, any disagreements 
between the two reviewers were resolved by consensus. Having two reviewers helped to 
reduce human error and personal bias.  
A reference standard is a method used to diagnose a disease with the most acceptable 
accuracy and provides a standard to which new screening or diagnostic test can be 
compared. Currently, physicians use the ultrasound diagnostic criteria developed by Pei 
et al. to diagnose patients with ADPKD.13 This criteria requires the presence of a positive 
family history of ADPKD, and evidence of the following number of cysts on a 
conventional kidney ultrasound: i) at least three cysts when counting the total number of 
cysts in both kidneys combined for patients 15 to 39 years old; ii) at least two cysts in 
each kidney for patients 40 to 59 years old; and iii) at least four cysts in each kidney for 
patients 60 years of age or older.13 We used this internationally accepted diagnostic 
criteria as our primary clinical definition for ADPKD. One of the disadvantages of 
retrospectively collecting data for the reference standard is that some information 
required to elucidate ADPKD status based on our primary definition may have been 
missing. To reduce the number of patients with indeterminant ADPKD status, we 
developed less stringent criteria to identify patients with ADPKD. First, we classified 
patients with a negative or indeterminate family history of ADPKD as affected if they 
had innumerable cysts in both kidneys with each kidney greater than 13 cm in length. 
Median (10th and 90th percentile) is 11.2 (10.1 to 12.3) cm for the left kidney and is 10.9 
(9.6 to 12.2) cm for the right kidney; hence, we chose 13 cm as a cutoff point to consider 
a kidney as enlarged.14  Second, we classified all patients who had a nephrectomy 
performed and with a diagnosis of ADPKD in a surgical pathology or autopsy report as 
affected irrespective of their ADPKD family history status. Finally, we classified patients 
with missing imaging reports as affected with ADPKD if they had a family history of 





still ambiguous, an experienced nephrologist (A.G.) reviewed all medical records to make 
a determination of whether ADPKD was present or not according to clinical criteria.  
When there was insufficient information to make a determination of whether ADPKD 
was present or not, patients were excluded from analysis. Sensitivity analyses were 
performed to determine if classifying the excluded patients as having ADPKD, or as not 
having ADPKD, meaningfully changed the results.  
5.3.4 Data analysis 
For the chart abstraction study, we expressed continuous variables as median and 
interquartile ranges (IQR) and binary variables as percentages. We calculated the positive 
predictive value for each of the nine coding algorithms and calculated their respective 
95% confidence intervals using the Wilson Score method (Figure 5-1).15 Given the way 
the study was designed, we only had data from patients with hospital encounter with 
ICD-10 codes for ADPKD. We did not have data from patients without the codes; as a 
result, we could only calculate positive predictive value and could not calculate other 
measures of validity, such as sensitivity, specificity, and negative predictive value.   
  Reference Standard: ADPKD 
defined by the clinical definition 
specified in Section D.3.3 
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Note: Positive Predictive Value = TP/(TP+FP). Positive predictive value is defined as the percentage of 
patients who truly have ADPKD according to our clinical definition of ADPKD detailed in Section D.3.3 
among everyone with at least one administrative code related to ADPKD. The cells highlighted in dark 
grey are data that was not available. 
5.4 METHODS SPECIFIC TO ICES STUDY 
5.4.1 Patient Selection 
We linked and analyzed CIHI-DAD and CIHI-NACRS using unique encoded identifiers 
at ICES. We identified all patients over the age of 18 years who were assigned either an 
ICD-10 Q61.2 code or Q61.3 code during an emergency department visit or hospital 
admission between April 1st, 2002 and March 31st, 2014. As with our first study, we only 
considered the first encounter for patients with more than one hospital encounter.   
5.4.2 Data analysis 
We estimated the number of patients with ADPKD in Ontario by calculating the 
percentage of the adult Ontario population with the different coding algorithms in CIHI-
DAD and CIHI-NACRS described in Table D-1. We conducted all statistical analyses 
using SAS 9.3 (SAS Institute Inc., Cary, North Carolina, USA).  
 
5.5 RESULTS 
5.5.1 Chart abstract study sample 
We obtained a list of unique patients with ICD-10 codes Q61.3 and Q61.2 using the 
CIHI-DAD and CIHI-NACRS database. We then included all patients with the ICD-10 
code Q61.2, and stratified random sampled patients with ICD-10 code Q61.3 to sample a 
total of 201 patients. We abstracted information using electronic medical records for all 
201 patients, inpatient charts for 117 patients, and nephrology outpatient charts for 52 
patients. A senior radiology resident (M.R.) reviewed the images of 65 patients with 
ADPKD because imaging reports did not clearly provide all the required information. 
After excluding 14 patients because of insufficient information to determine ADPKD 





5.5.2 Chart abstraction patient characteristics 
Among the 187 patients identified in our cohort through database codes, median 
(interquartile) patient age was 61 (53 to 70), and 95 (50%) were men. Family history of 
ADPKD was positive in 116 (62%) patients, negative in 42 (22%) patients, and was 
missing or indeterminate in 29 (16%) patients. A total of 158 (85%) patients met the 
clinical criteria of ADPKD. The number and percent of patients that satisfied each 
ADPKD criteria is presented in Table 5-4.  
Table 5-4. Number and percentage of patients that satisfied each criterion for autosomal 
dominant polycystic kidney disease. 
Autosomal Dominant Polycystic Kidney Disease Criteria 
Number of Patients 
(%) 
Current Ultrasonographic Diagnostic Criteria: Family 
History and age-dependent, ultrasonographic diagnostic 
criteria: 
a) Ages 15 to 39: at least 3 cysts in one or both kidneys 
b) Ages 40 to 59: at least 2 cysts in each kidney 
c) Ages 60 and over: at least 4 cysts in each kidney 
108 (53.73) 
No family history, both kidneys > 13 cm and age-dependent 
minimal number of cysts: 
a) Ages 15 to 39: at least 3 cysts in one or both kidneys 
b) Ages 40 to 59: at least 2 cysts in each kidney 
c) Ages 60 and over: at least 4 cysts in each kidney 
37 (18.41) 
Indication of ADPKD in surgical pathology report or 
autopsy report 
7 (3.48) 
Physician report of ADPKD and family history of ADPKD 
or patient has ADPKD based on nephrologist adjudication 
6 (2.98) 
Did not meet any criteria 29 (14.43) 
Excluded from the study given a lack of information to make 
a determination of whether ADPKD was present or not 
14 (6.97) 
*Note: These data were obtained from chart review. In accordance with privacy regulations, cell sizes 
less than or equal to five cannot be reported.  






5.5.3 Coding algorithm positive predictive value and frequency 
The positive predictive values, their respective 95% confidence intervals (from our chart 
abstraction study), and the number of Ontarians with the 9 different coding algorithms 
(from our ICES study) are presented in Table 5-5. The presence of either ICD-10 code 
Q61.2 or Q61.3 in either the CIHI-DAD or CIHI-NACRS database had a positive 
predictive value of 85% (95% CI 79% to 89%) and identified 2981 adults in Ontario 
(0.02% of the Ontario adult population). The presence of ICD-10 code Q61.2 in either the 
CIHI-DAD or CIHI-NACRS database had a positive predictive value of 97% (95% CI 
86% to 100%) and identified 394 adults in Ontario (0.003% of the Ontario adult 
population). Sensitivity analyses did not meaningfully change the results. 
Table 5-5. Positive predictive values and the number of Ontarians identified by each 












CIHI-DAD Q61.2 96.97% [84.68, 99.46] 342 0.0028 
CIHI-DAD Q61.3 80.00% [71.35, 86.53] 1901 0.0154 
CIHI-NACRS Q61.2 100.00% [43.85, 100.00] 52 0.0004 
CIHI-NACRS Q61.3 84.78% [71.78, 92.43] 686 0.0056 
CIHI-DAD Q61.2 or Q61.3 84.06% [77.04, 89.23] 2243 0.0182 
CIHI-NACRS Q61.2 or 
Q61.3 
85.71% [73.33, 92.90] 738 0.0060 
Q61.2 in either CIHI-DAD 
or CIHI NACRS 
97.22% [85.83, 99.51] 394 0.0032 
Q61.3 in either CIHI-DAD 
or CIHI-NACRS 
81.46% [74.51, 86.85] 2587 0.0210 
Q61.2 or Q61.3 in either 
CIHI-DAD or CIHI-NACRS 
84.49% [78.62, 88.98] 2981 0.0242 
Abbreviations: Canadian Institute for Health Information Discharge Abstract Database, CIHI-DAD; 
National Ambulatory Care Reporting System, NACRS 
 
5.6 DISCUSSION 
Although past studies have assessed the positive predictive value of different ICD-10 
codes or coding algorithms for other diseases or conditions, there is a lack of information 





predictive value is reported as a number from 0 to 100%, where a high value indicates 
that individuals who are identified with the coding algorithm truly have the condition.  
We manually reviewed a random sample of medical charts from two tertiary care 
hospitals in London, Ontario where the medical coders in routine care had assigned a 
code for polycystic kidney disease. Using rigorous clinical criteria, we then determined 
whether ADPKD was present or not. We found that the presence of the ICD-10 code 
Q61.2 in hospital admissions or emergency visits had an excellent positive predictive 
value of 97% (95% CI: 86% to 100%). The positive predictive value of the presence of 
either the ICD-10 code Q61.2 or Q61.3 in either hospital admissions or emergency visit 
was also good at 85% (95% CI: 79% to 89%). Therefore, our study shows that 
administrative coding algorithms for ADPKD successfully identifies patients who truly 
have ADPKD, which is consistent with the findings from a study conducted by 
Blanchette and colleagues.7 These values in the ADPKD setting are similar or better than 
the positive predictive value of ICD-10 codes or ICD-10 coding algorithms for shock 
(86%; 95% CI: 80% to 91%), infant respiratory distress syndrome (81%; 95% CI: 73% to 
80%), and heart failure (84%; 95% CI: 81% to 87%).16–18 While our study has several 
strengths, results of this study must be interpreted with caution given the limitations. 
First, since we only reviewed the medical charts of patients with assigned ICD-10 
database codes for ADPKD, we cannot estimate other measures of validity such as 
negative predictive value, sensitivity, and specificity. We expect the sensitivity of the 
ICD-10 codes for ADPKD to be low. Since the prevalence of ADPKD is estimated to be 
1 in 1000 to 1 in 400, we would expect 13,000 to 32,500 Ontarians to be affected with 
ADPKD 1. However, the expansive coding algorithm (any of the two ICD-10 codes in 
CIHI-DAD or CIHI-NACRS) only identified approximately 3000 patients. Thus, 
although the two ICD-10 codes appear to have a high positive predictive value, it is 
possible only 9% to 23% of the patients with ADPKD in the province were captured with 
the algorithm.  
Second, by its design, we would expect the ICD-10 coding algorithm would 
preferentially identify a spectrum of ADPKD patients with moderate to advanced disease 
requiring hospital encounters, rather than ADPKD patients managed in the community 





such as patients with ADPKD admitted for uncomplicated pregnancy. Therefore, these 
algorithms should only be used to assemble and study cohorts of adult patients with 
ADPKD and hospital encounters, rather than all patients in the province with ADPKD. 
Unfortunately, there are no relevant codes that can be used to identify the presence of 
ADPKD in the Ontario outpatient billing system.  
Third, we reviewed medical charts from two hospitals at the London Health Sciences 
Centre. While coding practices are standardized across hospitals, any differences in 
coding between these two hospitals and other hospitals would influence generalizability 
of our study results.  
Fourth, there were no reports from genetic testing in any of the patient charts, which 
could have helped further ascertain the presence of ADPKD in cases when a family 
history is absent or not available.19  
Fifth, we are not sure that all imaging or other ancillary information for a given patient 
was found. For example, a patient may have had an ultrasound performed in an outpatient 
lab, and the nephrologist may not have a record of it. Therefore, the positive predictive 
value may be underestimated. Additionally, this also may explain why the percentage of 
our cohort is lower than the estimates reported in the published literature. 
Finally, our adjudicators were aware that all reviewed records had ICD-10 codes assigned 
for polycystic kidney disease in the healthcare database records. While this may have 
influenced their adjudication of the records, we minimized the risk of information bias 
through the use of pre-defined diagnostic criteria for ADPKD, where two reviewers 
independently adjudicated each case.  
 
5.7 CONCLUSION 
In conclusion, the positive predictive value of the various coding algorithms for ADPKD 





patients with ADPKD and hospital encounters, but are expected to miss the majority of 
the milder forms of ADPKD where patients are healthy without hospital encounters.  
5.8 ADDENDUM 
5.8.1 Rationale for sampling 201 patients 
At the time the study was conducted, we sampled 201 patients from 305 eligible charts 
for review. This was done for convenience. If we were to redo the study, we would have 
reviewed the charts of all 305 charts. The positive predictive value (95% CI)  of the 
algorithm Q61.2 and Q61.3 using both databases (CIHI-DAD and NACRS) was 84.49% 
(78.62 to 88.98). Assuming the point estimate would remain unchanged, the 
corresponding number would be 84.49% (79.98 to 88.13) with 305 patients charts. In 
other words, reviewing all 305 charts would have not have materially improved the 
precision of the estimate.  
5.8.2 Recommended algorithm for future studies 
Although the Q61.2 code and the emergency department visit database has a perfect 
positive predictive value, I used a combination of the Q61.2 and Q61.3 codes and both 
databases (CIHI-DAD and NACRS) to assemble a robust ADPKD cohort for my cohort 
studies (Chapter 6 and 7). The latter coding algorithm identifies the most patients 
compared to the other eight coding algorithms examined and still has a positive 
predictive value of 84%; therefore, more patients would be identified and the internal 
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Autosomal dominant polycystic kidney disease (ADPKD) is the most commonly 
inherited kidney disease and is characterized by focal cyst development.1 In ADPKD, 
cysts develop in the kidney that increase in size and number over time.2 This causes 
structural deformation of the kidney, which, along with metabolic abnormalities, is 
believed to predispose patients with ADPKD to upper urinary tract stones.3 Specifically, 
the structural damage to the kidney results in more urinary stasis, which favors urinary 
crystals to form and stagnate.4,5 Prior cross-sectional studies suggest upper urinary tract 
stones are more prevalent in patients with ADPKD compared to unaffected family 
members. However, none of the between-group comparisons in prior studies were 
statistically different.6–11 Additionally, no prior study adjusted for important covariates, 
or longitudinally compared the risk of stones in patients with ADPKD to patients without 
ADPKD.6–11 Finally, most inferences about the difference in stone risk in patients with 
ADPKD were indirect comparisons with the general population.  
Upper urinary tract stones in patients with ADPKD are associated with significant pain 
and morbidity.12 In the chronic kidney disease population, patients with stones are at 
higher risk of end-stage kidney disease compared to patients without stones, with the 
suggestion that this is also true in patients with ADPKD.13,14 For these reasons, stones 
should be optimally managed in patients with ADPKD. However, the structural kidney 
deformation in ADPKD may make optimal stone management challenging. There is 
limited evidence on how stones are currently managed in patients with ADPKD and we 
are unsure how frequently patients with ADPKD receive stone interventions such as 
shockwave lithotripsy (SWL), ureteroscopy, and percutaneous nephrolithotomy (PCNL).  
In this study, we used large healthcare databases to describe the rate of hospital 
encounters (emergency department visits or hospital admissions) with upper urinary tract 
stones in patients with ADPKD, and the rate and type of upper urinary tract stone 
interventions. To put these rates into context we studied a group of patients without 
ADPKD. We also assessed whether risk factors for hospital encounters with upper 






6.2 MATERIALS AND METHODS 
6.2.1 Designs and setting 
The prevalence of ADPKD is between 1 in 1000 and 1 in 400.15–17 In chapter 2 of this 
study, we showed that the prevalence of stone ranges between 3% and 59%8,10,11,18–61, and 
the prevalence of stone intervention ranges between  1% and 8%19,30,41,43,48,54,57. Since the 
prevalence of ADPKD is lower than the prevalence of upper urinary tract stones and 
stone intervention, a retrospective cohort study would allow us to accrue an adequate 
number of patients with ADPKD and allow enough events to accumulate for a well-
powered study. As a result, we conducted a retrospective cohort study using Ontario’s 
healthcare administrative databases held at ICES (a not-for-profit research institute). 
Healthcare services in Ontario are funded through the Ontario Health Insurance Plan 
(OHIP) program; with the exception of outpatient medications, which are only funded for 
segments of the population including those 65 years and older. Healthcare encounters are 
recorded in administrative databases, which are linked using unique encoded identifiers 
and analyzed at ICES. The use of ICES data in this project was authorized under section 
45 of Ontario’s Personal Health Information Protection Act, and did not require review 
by a Research Ethics Board. No informed consent from patients was required. We 
reported this study following guidelines for observational studies conducted using 
routinely-collected data.62,63 
6.2.2 Sample size calculations 
The reported life time prevalence of upper urinary tract stone varies between 1% and 
20%.64 We used the cox proportional hazard model sample size formula, to determine the 
minimum total sample size that would be required to have a statistical power of 80% to 
detect a clinically significant difference between the two groups at a significance level of 
5%.65 Since the effect size is unknown, we determined the sample size by using common 
effect sizes (Hazard Ratio ranging from 1.5 to 5.0). We also explored a range of values 
for the baseline prevalence of upper urinary tract stones (1, 5, 10, 15 and 20%). Sample 
size is inversely proportional to prevalence of event, and to be conservative in our sample 





is 1%.We would need a total sample size of 19,097 to detect even a Hazard Ratio of 1.5 
at a power of 80% and α=0.05 if the prevalence of event is 1% (Figure 6-1). Since our 
total sample size exceeds 19,097, our study was well-powered for this and other potential 
values of the prevalence and effect sizes.   
 
Figure 6-1. Total sample size required to detect a clinically significant difference with an 
effect size (Hazard Ratio) varying between 1.5 to 5.0 when the prevalence of upper 
urinary tract stone is 1%, 5%, 10%, 15%, and 20%. 
6.2.3 Data sources 
We linked seven databases to create the study cohort, describe baseline characteristics, 
and ascertain outcomes. The Canadian Institute for Health Information Discharge 
Abstract Database, Same Day Surgery, and the National Ambulatory Care Reporting 
System (NACRS) databases contain diagnostic and clinical information on hospital 
admissions, same day surgery, and all emergency department visits in Ontario, 
respectively. The OHIP database captures physician-billing claims for all hospital and 
outpatient services for patients covered in Ontario. The Registered Persons Database 
(RPDB) includes reliable demographic information and vital statistics. The ICES 
Physician Database contains physician demographic and practice information. The 



































receiving chronic dialysis and kidney transplants. A detailed description of each of the 
Ontario healthcare administrative databases is described in Table A-1. All variables were 
complete in this study except for average neighbourhood income (<1% missing) and 
urban or rural residency (<1% missing). For patients with missing average 
neighbourhood income quintile and urban or rural residency status, we assigned an 
average neighbourhood income quintile value of 3 and urban residency, respectively. 
6.2.4 Population and timeline 
Our study cohort included Ontarians who had a hospital encounter with ADPKD (i.e. 
admitted to the emergency department or hospital), identified using ICD-10 codes 
between April 1st, 2002 and March 31st, 2016. We used the coding algorithm with the 
highest positive predictive value (ICD-10 codes Q612 and Q613 validated details in 
Chapter 3)  to ensure that the internal validity of our study was not compromised.66  The 
positive predictive value (95% confidence interval [CI]) of the coding algorithm that we 
used was 84.1% (77.0% to 89.2%). A follow-up validation study conducted by our team 
also showed that this coding algorithm differentiates patients with ADPKD from patients 
with very similar conditions (specificity=86.2%; 95% CI 75.7% to 92.5%), but it only 
identified a small subset of the broader ADPKD population (sensitivity=33.7%; 95% CI 
30.1% to 37.7%). ICD-10 codes are only available after April 1st, 2002, and thus defined 
our accrual start date. An accrual end date of March 31st, 2016 ensures that each patient 
had the potential for at least one year of follow-up (March 31st, 2017 was the date of last 
available data at the time that the study was conducted). We excluded the following 
patients:  
(1) Patients aged 18 and under. Autosomal recessive polycystic kidney disease 
(ARPKD) displays very similar clinical characteristics as ADPKD; both patients 
have multiple cysts in their kidneys. However, ARPKD primarily manifests 
during birth or childhood, while ADPKD, although is a congenital condition, 
primarily manifests during adulthood. By excluding patients under 18 years of 






(2) Patients with missing demographic or linkage data, or those who died on or before 
the cohort entry date for data cleaning reasons. 
(3) Non-Ontario residents who received care from a healthcare facility in Ontario to 
limit our study population to Ontarians. We would not have follow-up data on 
Non-Ontario residents who received care from a healthcare facility in Ontario. 
(4) Patients with a history of end-stage kidney disease, as many have no urine output 
making the presence of upper urinary tract stones less relevant.  
Patients with prior upper urinary tract stones and treatments for upper urinary tract stones 
were eligible for study participation; this was treated as an important baseline 
characteristic that was included in the propensity score model and was also considered in 
subgroup analysis. We selected the first hospital encounter during the accrual period for 
patients with more than one hospital encounter.  
We compared the rate of upper urinary tract stones and rate of stone intervention in 
patients with ADPKD to patients without ADPKD with otherwise similar baseline health 
to provide context. Our study population would primarily consist of patients with more 
advanced ADPKD with few milder cases of ADPKD since our study included patients 
who were admitted to the emergency department or who were admitted to the hospital 
with ADPKD. To ensure our control group was as similar as possible to our study 
population, we included patients with at least one hospital admission or emergency 
department visit for any reason between April 1st, 2002 and March 31st, 2016 who were 
not in the ADPKD cohort. For all patients with more than one hospital encounter, we 
selected the first encounter. We applied the same exclusion criteria as we did for the 
ADPKD cohort. In addition, we excluded patients with OHIP diagnosis codes for other 
cystic diseases (OHIP diagnosis code 593) and congenital anomalies of the urinary 
system (OHIP diagnosis code 753), as these codes can occasionally capture patients with 
ADPKD. We then randomly selected 50,000 controls (versus the entire Ontario 
population with hospital encounter) for reasons of computing efficiency. 
The date of discharge for patients identified with hospital admission records and the date 





the date of cohort entry. We followed each patient until March 31st, 2017 (administrative 
censoring), and censored the observational period at time of death or emigration from the 
province.  
6.2.5 Outcomes 
The two outcomes were (a) time to first hospital encounter with upper urinary tract stone; 
and (b) time to first stone intervention, which was a composite outcome of the three 
common stone interventions: shock wave lithotripsy (SWL), ureteroscopy, and 
percutaneous nephrolithotomy (PCNL). The administrative codes used to identify 
outcomes are detailed in Table 6-1. In a validation study, codes similar to the ones we 
used to identify stones had a positive predictive value of 96% compared to chart 
review.67,68 We identified stone intervention events using OHIP fee codes and Canadian 
Classification of Health Intervention (CCI) codes. Although the OHIP fee codes for stone 
intervention have not been formally validated, we expect these codes to have excellent 
validity similar to other fee for service codes.69 Further, the same coding algorithm used 
to identify stone interventions has been used in past studies. 70,71 Any stone-related 
database codes that appeared within 90 days of each other were considered the same 
event, which has been done in past ICES studies.70 For stone intervention, we did not 
restrict to individuals with hospital encounters for upper urinary tract stones (outcome a), 
because we wanted to capture stone interventions in both the inpatient and outpatient 
settings.  
Table 6-1. Databases and coding definitions for restriction criteria, baseline 
characteristics and outcome measurements. 
Variable Database & Administrative Codes 
Study Population Inclusion Criteria 
ADPKD CIHI-DAD & NACRS ICD-10 codes: Q612, Q613 





Ontarians with hospital 
encounter without 
ADPKD 
CIHI-DAD & NACRS 
Exclusion Criteria 
Chronic dialysis CIHI-DAD CCP codes: 5195, 6698 
CIHI-DAD CCI codes: 1PZ21 
OHIP Fee: R849, G323, G325, G326, G860, G862, G865, 
G863, G866, G330, G331, G333, G861, G082, G083, 
G085, G090, G091, G092, G093, G094, G095, G096, 
G294, G295, G864, H540, H740 
CORR  
RECIPIENT_TREATMENT dataset:  select all chronic 
dialysis patients using [Treatment_Code not equal to 171, 
181] in the prior one year. 
Kidney transplantation CIHI-DAD CCP codes: 6759 
CIHI –DAD CCI codes: 1PC85 
OHIP fee codes: S435, S434 
 
CORR 
RECIPIENT_TREATMENT dataset: select all renal 
transplant patients using [Treatment_Code equal to 171] 
and [Transplanted_Organ_Type_Code (1-3) equal to 10, 
11, 12, 18, 19] in the prior five year 
 
Other cystic diseases and 
congenital anomalies of 
the urinary system (only 
for control group 
CIHI-DAD & NACRS ICD-9 codes: 7531 
CIHI-DAD & NACRS ICD-10 codes: Q611, Q612, 
Q613 






Urological Intervention CIHI-DAD, NACRS, & OHIP:  composite of shockwave 
lithotripsy, ureteroscopy, and percutaneous 
nephrolithotomy (refer to codes below) 
Shockwave lithotripsy CIHI-DAD & NACRS CCI: 1PE59KQAP, 
1PE59KQAQ, 1PE59KQAR, 1PG59KQAP, 
1PG59KQAQ, 1PG59KQAR 
 
OHIP Fee Codes: Z630 
 
Ureteroscopy CIHI-DAD & NACRS CCI: 1PE57BAAM, 
1PE57BAGX, 1PE59BAAG, 1PE59BAAS, 1PE59BAAT, 
1PE59BAAZ, 1PG57BAAM, 1PG57BAGX, 
1PG59BAAG, 1PG59BAAS, 1PG59BAAT, 
1PG59BAAZ, 1PG59BAGX, 1PE59BAAS, 1PE59BAAT, 
1PE59BAAZ 
 
OHIP Fee Codes: Z628 AND (E760 or E761 or Z627) 
Percutaneous 
Nephrolithotomy 
CIHI-DAD & NACRS CCI: 1PE57DTAG, 
1PE57DTAM, 1PE57DTAS, 1PE57DTAZ, 1PE57DTBD, 
1PE57DTGX 
 
OHIP Fee Codes: Z624 AND Z627 




Rural location RPDB 
Neighbourhood Income RPDB 
Primary care physician 
visits in the previous one 
year 







visit in the previous one 
year 
NACRS 
Urology clinic visit in the 
previous one year 
IPDB: Mainspeciality= Urology 
OHIP 
Abdominal imaging OHIP Fee codes: J135, J128, X100, X101, X197, X409, 
X410, X126, X451, X455 
Urinary tract obstruction CIHI-DAD & NACRS ICD-9 codes: 591, 5934, 5996 
CIHI-DAD & NACRS ICD-10 codes: N130, N131, 
N132, N133, N138 
OHIP Dx codes: 591 
Urinary tract infection CIHI-DAD & NACRS ICD-9 codes: 5901, '5900, 5908', 
5902, 5909, 5950, 5958, '5959, 5970, 5990, 6016, 6011, 
6012, 6013, 6040, '6049 
CIHI-DAD & NACRS ICD-10 codes: N10, 'N11, 'N12, 
N136, 'N151, N159, N160, N300, N308, N309, N340, 
N390, N410, N411, N412, N413, N431, N45, T835 
Primary 
hyperparathyroidism 
CIHI-DAD & NACRS ICD-9 codes: 2520 
CIHI-DAD & NACRS ICD-10 codes: E210, E211, E213, 
E214, E215 
OHIP Dx: 252 
OHIP Fee: S792, S795, S796, Z772 
CCP: 197, 1971, 1996, 1997 
CCI: 1FV59HAX7, 1FV83NZ, 1FV83NZAG, 1FV83PZ, 
1FV83PZAG, 1FV87NZ, 1FV87NZAG, 1FV87PZ, 
1FV87PZAG, 1FV89NZ, 1FV89NZAG, 1FV89PZ, 
1FV89PZAG 
Gout CIHI-DAD & NACRS ICD-9 codes: 274 
CIHI-DAD & NACRS ICD-10 codes: M10 





Obesity CIHI-DAD & NACRS ICD-9 codes: 2780 
CIHI-DAD & NACRS ICD-10 codes: E65, E660, E661, 
E662, E668, E669 
OHIP Dx codes: 278 
Diabetes Mellitus CIHI-DAD & NACRS ICD-9 codes: 250 
CIHI-DAD & NACRS ICD-10 codes: E10, E11, E13, 
E14 
OHIP Dx codes: 250 
OHIP Fee codes: K045, K046, K029, K030, Q040 
Hypertension CIHI-DAD & NACRS ICD-9 codes: 401, 402, 403, 404, 
405 
CIHI-DAD & NACRS ICD-10 codes: I10, I11, I12, I13, 
I15 
OHIP Dx codes: 401, 402, 403 
Osteoporosis CIHI-DAD & NACRS ICD-9 codes: 7330 
CIHI-DAD & NACRS ICD-10 codes: M80, M81, M82 
OHIP Dx codes: 733 
Prior hospital encounter 
or intervention for stone 
CIHI-DAD, NACRS, & OHIP:  composite of prior 
hospital encounter for stone and prior intervention for 
stone removal 
Prior hospital encounter 
for stone 
CIHI-DAD & NACRS ICD-9 codes: 592,5920, 5921, 
5929 
CIHI-DAD & NACRS ICD-10 codes: N20, N132 
OHIP Dx codes: 592 
Prior intervention for 
stone removal 
CIHI-DAD & NACRS CCI codes: 1PE59KQAP, 
1PE59KQAQ, 1PE59KQAR, 1PG59KQAP, 
1PG59KQAQ, 1PG59KQAR, 1PE57BAAM, 
1PE57BAGX, 1PE59BAAG, 1PE59BAAS, 1PE59BAAT, 
1PE59BAAZ, 1PG57BAAM, 1PG57BAGX, 
1PG59BAAG, 1PG59BAAS, 1PG59BAAT, 





1PE59BAAZ, 1PE57DTAG, 1PE57DTAM, 1PE57DTAS, 
1PE57DTAZ, 1PE57DTBD, 1PE57DTGX 
 
OHIP Fee codes: Z630 OR [Z628 AND (E760 or E761 or 





CIHI-DAD & NACRS ICD-9 codes: 5550, 5551, 5552, 
5559, 556 
CIHI-DAD & NACRS ICD-10 codes: K50, K51 
OHIP Dx: 555, 556 
Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; CCI, Canadian Classification of 
Health Interventions; CCP, Canadian Classification of Diagnostic, Therapeutic, and Surgical Procedures; 
CIHI-DAD Canadian Institute for Health Information Discharge Abstract Database; CORR, Canadian 
Organ Replacement Register; ICD-9, International Classifications of Diseases, 9th revision codes; ICD-10, 
International Classification of Diseases, 10th revision codes; IPDB, ICES Physician Database; NACRS, 
National Ambulatory Care Reporting System; ODB, Ontario Drug Benefit; OHIP Dx, Ontario Health 
Insurance Plan diagnosis codes; OHIP Fee, Ontario Health Insurance Plan fee for service codes; OLIS, 
Ontario Laboratories Information System; RPDB, Registered Persons Database 
 
6.2.6 Data analysis 
In traditional regression analysis, there must be ten events for every covariate adjusted.72 
Since we anticipated the number of covariates to outnumber the number of events that 
may be observed, we eliminated the difference in baseline distribution between the two 
group using propensity scores. There are four common propensity score methods to 
account for confounding: 1) propensity score matching; 2) inverse probability treatment 
weighting (IPTW) based on propensity scores; 3) adjusting for propensity score in the 
model; and 4) stratifying on propensity score. Propensity score matching eliminates a lot 
more of the systematic differences between the study and control group compared to 
stratifying on propensity score, and adjusting for propensity score as a covariate in a 
regression model.73 Prior studies have shown that propensity score matching eliminates 





to IPTW based on propensity.73 For these reasons, we first attempted propensity score 
matching to ensure that the two groups had comparable baseline health. We matched each 
patient with ADPKD on age (± two years), sex, start date of follow-up (± one years), and 
log propensity score (± 0.2 standard deviation) a control to select patients with similar 
indicators for baseline health, and discarded all unmatched patients. However, more than 
20% of our ADPKD population was not matched to any control because our control 
population was very different from our ADPKD cohort; we lost more than 20% of our 
ADPKD population. As such, propensity score matching was not feasible given the loss 
in our ADPKD population. As a result, we used IPTW based on propensity scores and 
used average treatment effect in the treated weights to ensure the distribution of 
indicators for baseline health were similar between controls and patients with ADPKD. 
IPTW based on propensity scores involves assigning a weight of one to everyone in the 
ADPKD group, and a weight of [propensity score/ (1-propensity score)] to the control 
group (i.e. the inverse of the propensity score) so that the distribution of baseline 
characteristics in the control group is similar to that in the ADPKD group.74 This method 
results in a pseudo-control population that has a similar distribution of measured baseline 
characteristics as the ADPKD population while retaining all the individuals in the 
original cohort. In the context of the study, propensity score is the likelihood that a 
patient would be diagnosed with ADPKD conditional on their baseline characteristics. 
We calculated propensity scores using logistic regression with ADPKD as the dependent 
variable, and the following 20 covariates as the independent variables: 
(1) Factors associated with stone and stone intervention: There are four sets of 
variables that can be included in a propensity score model: a) all measured 
baseline covariates; b) covariates associated with exposure; c) covariates 
associated with outcome only (potential confounders); and d) covariates 
associated with both the outcome and exposure.73 Adjusting for potential and/or 
true confounders results in a more precise estimate.73 We included and adjusted 
for potential confounders instead of true confounders as independent variables in 
our propensity score model since it is difficult to identify all true confounders. 
Factors associated with our outcomes and those that can be identified using our 





obstructions, urinary traction, primary hyperparathyroidism, obesity, diabetes 
mellitus, hypertension, osteoporosis, prior hospital encounter with upper urinary 
tract stone, prior stone intervention, and inflammatory bowel disease. Studies 
have shown that lower education level, increased distance from the referral center, 
income, and urologist density was associated with stone burden.75 As a result, we 
also adjusted for average neighbourhood income quintile, rural vs. urban 
residency, and health service region of Ontario (Local Health Integration 
Network) as proxies for these risk factors.     
(2) Abdominal imaging in the prior five years: If one group undergoes abdominal 
imaging more often than the other group, then stones will be more likely be 
incidentally found in the group that undergoes abdominal imaging more, and 
surveillance bias would be introduced. We adjusted for abdominal imaging in the 
prior five years to minimize the risk of surveillance bias.  
(3) Urology clinic visits in the prior one year: People who visit the urology clinic 
would be more likely to be incidentally diagnosed with urological conditions, 
such as upper urinary tract stones. We adjusted for prior urology clinic visits to 
minimize the surveillance bias introduced when one group visits the urology 
clinic more than the other group.  
(4) Primary care physician visits and emergency department visits in the prior one 
year: These are indicators for propensity to seek care. Those who are likely to 
seek care would be more likely to get diagnosed with any conditions; therefore, 
surveillance bias would be introduced if one group visited the primary care 
physician and emergency department more than the other group. We adjusted for 
primary care physicians and emergency department visits as a proxy for 
propensity to seek care. 
When using IPTW based on propensity score, extreme weights can be problematic 
because few individuals will drive results. According to Stürmer (2014), it is reasonable 
to considers weights >10 as a sign of concern.76 A patient in our control group had a 
weight of > 10 so we truncated the extreme weights to ensure that the weights were stable 





weights greater than 99th percentile as the 99th percentile weight, and every control with 
weights less than the first percentile as the first percentile weight.77  
We described baseline characteristics for patients with and without ADPKD as mean and 
standard deviation for continuous variables, and as frequencies and percentages for 
binary or categorical variables before and after weighting. We assessed the imbalances in 
baseline characteristics between the two groups using standardized differences, which are 
insensitive to sample size. The standardized difference is the differences in means or 
proportions divided by the pooled standard deviation, and a value of greater than 10% 
suggests important imbalance.78  
 We plotted the cumulative incidence function for stones censoring the observational time 
for death, end of follow-up, or emigration from the province. While cumulative incidence 
function provides a visual representation of the rate of outcomes in both groups, it does 
not quantify the extent to which the rate of outcomes is similar or different between the 
two groups. In our primary analysis, we compared the rate of outcomes between the 
ADPKD and control groups using a Cox proportional hazards regression model censoring 
on end of follow up, death or emigration from the province given the follow-up period 
was variable and patients died or emigrated from the province during the follow-up. 
Competing risk is an event that hinders or alters the chance of an event of interest from 
occurring.79 Not accounting for competing risk often overestimates the proportion of 
patients experiencing an event.79 As a result, in an additional analysis, we treated death as 
a potential competing event and calculated the subhazard ratio using Fine and Gray’s 
model.80 The applicability of the Fine and Gray model when using inverse probability 
exposure weighting remains unclear; therefore, we only conducted this analysis to 
explore the potential impact of death as a competing event and confirm the 
reproducibility of the results in our primary analysis.81 Based on the results of our 
primary outcomes, accounting for death as a competing event did not alter the hazard 
ratio estimates. Therefore, we did not account for death as a potential competing event for 





We estimated the 95% confidence intervals using bootstrapping-based methods rather 
than traditional methods because traditional methods do not account for the within 
subject correlation introduced by weighting; this results in biased variance estimate and 
95% confidence intervals with inaccurate coverage rates.82 Past studies show that 
bootstrapping-based approach was the best method to estimate 95% confidence intervals 
with approximately accurate coverage rate.82 We estimated the absolute between-group 
difference in the rate of our outcomes by fitting a Poisson model using the PROC 
NLMIXED procedure in SAS.  
In exploratory subgroup analyses, we tested whether the associations between ADPKD 
and our outcomes were modified by baseline age groups (18 to 40 years, 41 to 60 years, 
and >60 years), sex, and prior stone history using Cox proportional hazards models. We 
also assessed the association between age, sex, income quintile, and date of cohort entry 
with both outcomes separately in patients with and without ADPKD using multivariable 
Cox proportional hazards models. We assessed for multi-collinearity among the potential 
risk factors by determining the variance inflation factors; all variance inflation factors 
were less than 2 indicating this was of minimal concern. 
Patients with ADPKD generally receive more abdominal imaging than patients without 
ADPKD, which could explain why upper urinary tract stones may be detected more 
frequently in patients with ADPKD. To gain insight into this potential surveillance bias, 
we compared the rate of abdominal imaging during follow-up in patients with ADPKD 
compared to controls using Cox proportional hazards regression. 
We performed all analyses using SAS 9.4 (SAS Institute, Inc., Cary, North Carolina). We 
present the 95% confidence intervals for all estimates, which corresponds to a level of 
significance of 0.05. Prior to using each Cox proportional hazards model, we ensured the 
proportional hazards assumption was met. First, we used log-minus-log curve (a 
graphical method) to visually assess whether the proportional hazard assumption was 
met. If the log-minus-log curves were not parallel or did not overlap, then the 
proportional hazard assumption was considered violated. This method is subjective so we 





dependent covariate test (statistical test), which includes a time-independent variable and 
time interaction term. If the p-value for the time-dependent variable and time interaction 
term was <0.05, then there was no statistical evidence against proportional hazards 
assumption.  When proportional hazard assumption was violated and the hazards of both 
groups did not cross during following-up, we reported the results as an average hazard 
ratio over a 15-year period.83  
 
6.3 RESULTS 
6.3.1 Cohort selection & baseline characteristics 
From 4,361 potentially eligible patients with ADPKD, the final cohort included 2,094 
patients with ADPKD identified in Ontario (Figure 6-2). From 7,153,842 potentially 
eligible non-ADPKD controls, 4,547,371 met the eligibility criteria. From the eligible 
controls, we randomly sampled 50,000 controls which corresponded to 1,902 patients in 
the weighted cohort after truncating weights (Figure 6-3). Table 6-2 summarize the 
baseline characteristics of the two groups. After weighting, the mean (standard deviation, 
SD) age was 57 (18) years for patients with ADPKD, and 57 (4) years for patients 
without ADPKD, and 49% of patients with ADPKD and 52% of patients without 
ADPKD were women. The two groups were similar in the mean number of visits to their 
primary care physician, emergency department, and urologist in the prior year, and were 






Figure 6-2. Cohort selection of patients with autosomal dominant polycystic kidney 






Figure 6-3. Cohort selection of patients without autosomal dominant polycystic kidney 





Table 6-2. Characteristics of the autosomal dominant polycystic kidney disease (ADPKD) cohort and controls at the time of cohort 
entry before and after inverse probability exposure weighting based on propensity scores and truncating extreme weights. 














Mean (SD) age (years) 57 (18) 52 (20) 25 57 (18) 57 (4) 1 
Women, n (%) 1,069 (49) 18,810 (38) 23 1,069 (49) 984 (52) 1 
Income fifthb       
   Quintile 1 (lowest) 436 (21) 10,223 (20) 1 436 (21) 399 (21) 0 
   Quintile 2 420 (20) 10,234 (21) 1 420 (20) 381 (20) 0 
   Quintile 3 425 (20) 10,287 (21) 1 425 (20) 386 (20) 0 
   Quintile 4 368 (18) 9,985 (20) 6 368 (18) 336 (18) 0 
   Quintile 5 (highest) 445 (21) 9,271 (19) 7 445 (21) 400 (21) 0 
Rural Town, n(%)c 238 (11) 6,870 (14) 7 238 (11) 222 (12) 1 
LHIN, n (%)       
   Erie St. Clair 112 (5) 2,692 (5) 0 112 (5) 104 (5) 2 
   South West 141 (7) 3,903 (8) 4 141 (7) 131 (6) 2 
   Waterloo Wellington 94 (4) 2,566 (5) 3 94 (4) 88 (4) 1 
   Hamilton Niagara Haldimand  
   Brant 
259 (12) 5,641 (11) 3 259 (12) 232 (11) 4 
   Central West 98 (5) 2,933 (6) 5 98 (5) 90 (4) 2 
   Mississauga Halton 134 (6) 3,905 (8) 5 134 (6) 123 (6) 2 
   Toronto Central 209 (10) 4,317 (9) 5 209 (10) 188 (9) 4 
   Central 256 (12) 5,890 (12) 1 256 (12) 229 (11) 4 
   Central East 271 (13) 5,601 (11) 5 271 (13) 243 (12) 4 
   South East 74 (4) 2,128 (4) 4 74 (4) 70 (3) 1 
   Champlain 247 (12) 4,619 (9) 8 247 (12) 222 (11) 4 





   North East 90 (4) 2,740 (6) 6 90 (4) 84 (4) 2 
   North West 33 (2) 1,172 (2) 5 33 (2) 32 (2) 0 
No of visits to primary care 
physician in previous year (%) 
      
   0 95 (5) 2,053 (4) 2 95 (5) 84 (4) 1 
   1 to 2 258 (12) 6,567 (13) 2 258 (12) 229 (12) 1 
   3 to 4 246 (12) 7,919 (16) 12 246 (12) 228 (12) 1 
   5 to 6 265 (13) 7,692 (15) 8 265 (13) 243 (13) 0 
   7 to 8 251 (12) 6,442 (13) 3 251 (12) 231 (12) 0 
   9 to 10 180 (9) 4,927 (10) 4 180 (9) 169 (9) 1 
   > 10 799 (38) 14,440 (28) 20 799 (38) 719 (38) 1 
No of visits to emergency 
department in the previous year (%) 
      
   0 350 (17) 18,275 (37) 46 350 (17) 340 (18) 3 
   1 to 3 1,427 (68) 28,780 (58) 22 1,427 (68) 1,308 (69) 1 
   4 to 6 252 (12) 2,381 (5) 26 252 (12) 201 (11) 5 
   7 to 9 44 (2) 350 (1) 12 44 (2) 35 (2) 2 
   10 to 12 13 (1) 135 (0) 4 13 (1) 12 (1) 0 
   > 12 8 (0) 79 (0) 4 8 (0) 6 (0) 1 
No of visits to urologist visit in the 
previous year (%) 
      
   0 1,495 (71) 45,296 (91) 5 1,495 (71) 1,406 (74) 6 
   1 to 2 344 (16) 2,503 (5) 38 344 (16) 282 (15) 4 
   3 to 4 122 (6) 1,107 (2) 18 122 (6) 105 (6) 1 
   5 to 6 71 (3) 615 (1) 15 71 (3) 59 (3) 2 
   7 to 8 34 (2) 278 (1) 1 34 (2) 29 (2) 1 
   9 to 10 13 (1) 104 (0) 6 13 (1) 10 (1) 1 
   > 11 15 (1) 97 (0) 7 15 (1) 11 (1) 2 
Abdominal imaging in the past five 
years, n (%) 
1,885 (90) 20,810 (42) 119 
1,885 (90) 1,693 (89) 3 





   Acute kidney injury 17 (1) 69 (0) 10 17 (1) 10 (1) 4 
   Urinary tract obstruction, n (%) 111 (5) 516 (1) 25 111 (5) 85 (4) 4 
   Urinary Tract Infection, n (%) 594 (28) 3,877 (8) 56 594 (28) 465 (24) 9 
   Primary Hyperparathyroidism, n (%) 43 (2) 249 (0) 14 43 (2) 27 (1) 5 
   Gout, n (%) 290 (14) 1,428 (3) 40 290 (14) 208 (11) 9 
   Obesity, n (%) 155 (7) 3,653 (7) 0 155 (7) 144 (8) 1 
   Diabetes Mellitus, n (%) 509 (24) 8,036 (18) 15 509 (24) 460 (24) 0 
   Hypertension, n (%) 1,662 (79) 19,459 (39) 90 1,662 (79) 1,471 (77) 5 
   Osteoporosis, n (%) 209 (10) 3,274 (6) 13 209 (10) 178 (9) 2 
   Prior hospital encounter or   
   intervention for stone, n (%) 
281 (13) 1,324 (3) 41 
281 (13) 209 (11) 7 
     Prior hospital encounter for stone,  
     n (%) 
278 (13)  1,315 (3) 40 
278 (13) 208 (11) 7 
     Prior intervention for stone, n (%) 58 (3) 403 (1) 15 58 (2) 49 (3) 1 
   Inflammatory Bowel Disease, n (%) 72 (3) 899 (2) 10 72 (3) 62 (3) 1 
Abbreviations: autosomal dominant polycystic kidney disease, ADPKD; standard deviation, SD 
Discharge date was date of entry into cohort for those identified with hospital admission records and was registration date for those identified with emergency 
department records.  
a Standardized difference is the difference in means or proportions divided by the pooled standard deviation. Unlike hypothesis testing, standardized difference is 
not influenced by sample size. A standardized difference of <10% indicates negligible difference.  
b Income was categorized by fifths of average neighborhood income. Income quintile was missing for <1% of the cohort. For these individuals we assumed that 
their household income was part of the third quintile. 





6.3.2 Follow-up period for stone event 
The median length of follow-up for an upper urinary tract stone event was 5.4 years (5.0 
years in patients with ADPKD, 5.8 years in controls, maximum 15.5 years). A total of 
436 patients with ADPKD and 441 controls in the weighted cohort were followed for a 
period of 10 years or more. The median (IQR) age at the time of last follow-up for the 
entire cohort was 65 years (51 to 77). Of the 3,996 total individuals, 2,598 (65%) were 
alive and event-free at the end of study follow-up (March 31st, 2017), 76 (2%) were 
censored at time of emigration from the province, 1,170 (29%) died and 152 (4%) had the 
event of interest during follow up. The total person-years of follow-up was 24,223 
(12,254 for patients with ADPKD, 11,969 for non-ADPKD controls). Less than 2% of 
the ADPKD and control groups experienced two or more stone events or stone 
intervention events in follow-up (and we only considered the time to the first event). 
6.3.3 Follow-up period for stone intervention event 
The median length of follow-up was 5.5 years (5.2 years in patients with autosomal 
dominant polycystic kidney disease [ADPKD], 5.8 years in controls, maximum 15.5 
years). A total of 450 patients with ADPKD and 444 controls in the weighted cohort were 
followed for a period of 10 years or more. The median (interquartile range [IQR]) age at 
the time of last follow-up for the entire cohort was 65 (50-77). Of the 3,996 individuals 
(2,094 patients with ADPKD, 1,902 controls), 2,635 (66%) were alive at the end of study 
follow-up (31 March 2017) and had not experienced a stone intervention event, 76 (2%) 
were censored at a time of emigration from the province, 1,186 (30%) died and 99 (3%) 
had the event of interest during follow-up. The total person years of follow-up was 
24,483 (12,472 patients with, 12,011 control). 
 
6.3.4 Outcomes 
Figure 6-4 and Table 6-3 present the main outcomes. The proportional hazard assumption 
test was assessed graphically using log-minus-log curves (Figure 6-5 and Figure 6-6) and 





parallel or overlap each other, and if the time-dependent covariate p-value was <0.05, 
then there is statistical evidence against the proportional hazard assumption. There was 
no statistical evidence against proportional hazards assumption  for the outcome of 
hospital encounter with upper urinary tract stones both for the main analysis and when 
death was treated as a competing event (ADPKD status and time interaction term, P=0.2 
and P=0.2, respectively). The same was also true for the outcome of stone intervention 






Figure 6-4. Cumulative incidence function of (A) time to first hospital encounter with 





Table 6-3. Comparison of the hazards of (i) time to first hospital encounter with stone, and (ii) time to first stone intervention between 
patients with autosomal dominant polycystic kidney disease cohort (ADPKD) and patients without ADPKD with similar baseline 
health. 
 Hospital encounter for stone Stone intervention 
  ADPKD  Non-ADPKD  ADPKD 
Non-
ADPKD  
Median (IQR) follow-up, years 5.0 (2.2 to 9.1) 5.8 (2.7 to 9.7) 5.2 (2.3 to 9.2) 5.8 (2.7 to 
9.7) 
Total follow-up, person-years 12,254 11,969 12,472 12,011 
No. who died, (%) 676 (32) 494 (26) 688 (33) 498 (26) 
No. who emigrated, (%) 37 (2) 39 (2) 37 (2) 39 (2) 
No. of unique patients with event, (%) 92 (4) 60 (3) 52 (2) 47 (2) 
   Type of Intervention 
    
       Shockwave lithotripsy or percutaneous  
       nephrolithotomy or combination of two  
       or more intervention performed on the  
       same day or within the same hospital  
       admission 
N/A N/A 17 (1) 19 (1) 
       Ureteroscopy N/A N/A 35 (1) 28 (1) 
No. of events per 1000 person-years 7.5 5.0 4.2 3.9 
Hazards ratio (95% CI)* 1.5 (1.2 to 1.9) 1.0 
(Reference) 
1.0 (0.8 to 1.4) 1.0 
(Reference) 
Subhazards ratio (95% CI) 1.4 (1.1 to 1.8) 1.0 
(Reference) 
1.0 (0.7 to 1.4) 1.0 
(Reference) 
Risk difference per 1000 person-years 
(95% CI) 
2.5 (0.5 to 4.5) 0.0 
(Reference) 






Abbreviations: autosomal dominant polycystic kidney disease, ADPKD; confidence interval, CI; interquartile range, IQR; not applicable, N/A 
a Hazards ratio was obtained by censoring for death, end of follow-up, and emigration from Ontario. The estimates were weighted using inverse probability 
exposure weighting based on propensity scores. There was no statistical evidence against proportional hazards assumption, for both the hospital encounter with 
stone outcome (ADPKD status and time interaction term, P=0.2) and stone intervention outcome (ADPKD status and time interaction term, P=0.7). 
b Hazards ratio was obtained by censoring for emigration and end of follow-up from Ontario, and accounting for death as a competing event. The estimates were 
weighted using inverse probability exposure weighting based on propensity scores. There was no statistical evidence against proportional hazards assumption for 






a) primary analysis 
 
b) additional analysis 
 






a) primary analysis 
 
b) secondary analysis 
 





There was no statistical evidence against proportional hazards assumption for all exploratory 
subgroup analyses, and all risk factors except sex for the control group for both the healthcare 
encounter with stones outcome (ADPKD status and time interaction term, P=0.02) and stone 
intervention outcome (ADPKD status and time interaction term, P=0.0045). The reported hazard 
ratio in instances where the proportional hazards assumption is violated is the average hazard 
ratio over a 15-year period. 
The rate of a hospital encounter with upper urinary tract stones was significantly higher in the 
ADPKD group than the control group (92 of 2,094 patients with ADPKD [4.4%] vs 60 of 1,902 
patients without ADPKD [3.2%]; 7.5 vs. 5.0 events per 1000 person-years; hazard ratio [HR] 
1.5, 95% confidence interval [CI] 1.2 to 1.9). The results were similar when accounting for death 
as a competing event (average subHR over 15 years 1.4, 95% CI 1.1 to 1.8).   
There was no statistically significant difference, on average, in the rate of stone intervention in 
patients with ADPKD compared to controls (52 of 2,094 [2.4%] vs 47 of 1,902 [2.5%]; 4.2 vs. 
3.9 events per 1000 person-years; average HR over 15 years 1.0; 95% CI 0.8 to 1.4). The results 
were similar when treating death as a competing event (average subHR over 15 years 1.0, 95% 
CI 0.7 to 1.4). Ureteroscopy was the most common type of intervention in both groups.  
Sex, age, and stone event in the prior five years did not significantly modify the effects of 
ADPKD on the rate of stones, or stone intervention (Table 6-4).   
The rate of abdominal imaging was significantly higher in patients with ADPKD compared to 
controls (1,826 of 2,094 [87.2%] vs 1,310 of 1,902 [68.9%]; 169.5 vs 121.7 events per 1000 







Table 6-4 Hazard ratio of hospital encounter with upper urinary tract stone and stone 
intervention among patients with autosomal dominant polycystic kidney disease versus 
patients without ADPKD with similar indicators for baseline health in various subgroups. 
 
No. of events/ No. at 
risk 
No. of events per 









Hospital encounter with upper urinary tract stone 
   Overall  92/2,094 60/1,902 7.5 5 1.5 (1.2 to 1.9) 
   Sex           
      Male 58/1,025 36/918 10.7 6.6 1.6 (0.8 to 1.7) 
      Female 34/1,069 25/984 5 3.8 1.3 (0.5 to 1.4) 
   Age, years 
     
      18 to 40 38/440 16/422 11.6 5.1 2.3 (1.5 to 3.3) 
      41 to 60 35/748 23/571 6.8 5.8 1.2 (0.8 to 1.7) 
      > 60 19/906 21/909 4.9 4.3 1.1 (0.6 to 1.8) 
   Stone intervention or hospital encounter with stone in the prior five years 
      Yes 53/281 32/209 36.5 24.8 1.4 (1.0 to 1.9) 
      No 39/1,813 28/1693 3.6 2.6 1.4 (1.0 to 2.0) 
Stone intervention 
   Overall  52/2,094 47/1,902 4.2 3.9 1.0 (0.8 to 1.4) 
   Sex           
      Male 33/1,025 27/918 5.9 5.0 1.2 (0.8 to 1.7) 
      Female 19/1,069 20/984 2.7 3.0 0.9 (0.5 to 1.4) 
   Age, years 
     
      18 to 40 18/440 8/422 5.3 2.5 2.2 (1.2 to 3.8) 
      41 to 60 21/748 18/571 4.0 4.6 0.9 (0.5 to 1.4) 
      > 60 13/906 21/909 3.4 4.3 0.7 (0.4 to 1.4) 
   Stone intervention or hospital encounter with stone in the prior five years 
      Yes 34/281 32/209 21.6 24.5 0.8 (0.6 to 1.2) 
      No 18/1,813 15/1,693 1.7 1.4 1.2 (0.7 to 1.9) 
a Hazards ratio was obtained by censoring for death, end of follow-up, and emigration from Ontario. The 
estimate was weighted using inverse probability exposure weighting based on propensity scores. The 







6.3.5 Multi-variable risk factor analysis 
The adjusted hazard ratios for each of the studied risk factors are summarized in Table 6-
5. Older age was significantly associated with a lower rate of a hospital encounter with 
stones in patients with ADPKD only, and a higher rate of stone interventions in patients 
without ADPKD only.  Male sex was associated with a higher risk of hospital encounter 
with upper urinary tract stone and stone intervention in both the ADPKD and non-





Table 6-5. Risk factors for hospital encounter with upper urinary tract stones and stone interventions in patients with 
autosomal dominant polycystic kidney disease (ADPKD) and patients without ADPKD with similar indicators for baseline 
health when each group was analyzed separately. 
Risk Factors 
Hospital encounter with stone Stone Intervention 
ADPKD Non-ADPKD ADPKD Non-ADPKD 
Age 
    
   41 to 60 (vs. 18 to 40) 0.5 (0.3 to 0.7) 1.0 (0.7 to 1.4) 0.6 (0.3 to 1.3) 1.7 (1.1 to 2.5) 
   60+ (vs. 18 to 40) 0.3 (0.2 to 0.5) 0.7 (0.5 to 1.0) 0.4 (0.2 to 1.0) 1.5 (1.0 to 2.2) 
Male (vs. female) 2.5 (1.6 to 4.0) 1.7 (1.3 to 2.2) 2.4 (1.3 to 4.4) 1.5 (1.1 to 2.0) 
Income quintiles 
    
   Quintile 2 (vs. quintile 1) 0.9 (0.5 to 1.8) 1.4 (0.9 to 2.2) 1.2 (0.5 to 2.9) 1.2 (0.8 to 2.0) 
   Quintile 3 (vs. quintile 1) 0.9 (0.5 to 1.7) 1.4 (0.9 to 2.1) 0.8 (0.3 to 2.2) 1.4 (0.9 to 2.4) 
   Quintile 4 (vs. quintile 1) 0.9 (0.4 to 1.8) 1.4 (0.9 to 2.2) 0.8 (0.3 to 2.2) 1.6 (1.0 to 2.7) 
   Quintile 5 (vs. quintile 1) 1.0 (0.6 to 1.9) 1.2 (0.8 to 1.9) 1.1 (0.4 to 2.7) 1.2 (0.7 to 2.1) 
Date of Entry into Cohort         
   April 1st, 2007 to March 31st, 2012 (vs.  
   before April 1st, 2007) 
1.1 (0.7 to 1.9) 1.0 (0.8 to 1.3) 1.5 (0.7 to 3.1) 0.9 (0.6 to 1.3) 
   After March 31st, 2012 (vs. before  
   April 1st, 2007) 
0.8 (0.4 to 1.5) 1.5 (1.0 to 2.4) 1.1 (0.4 to 3.0) 1.2 (0.8 to 1.9) 
Abbreviation: autosomal dominant polycystic kidney disease, ADPKD 
Separate multivariable Cox proportional hazards regression models created for ADPKD group and non-ADPKD group with similar indicator for 
baseline health. 
The date of entry into cohort was discharge date for those identified using hospital admission records and registration date for those identified with 
emergency department records. 
Hazards ratio was obtained by censoring for death, end of follow-up and emigration from Ontario. The estimate was weighted using inverse probability 







It is uncertain whether the incidence of hospital encounters with upper urinary tract 
stones and stone interventions in patients with ADPKD differs from patients with similar 
baseline health status without ADPKD. It is also not clear whether some factors 
associated with these events are similar between the two groups. Our study addresses 
these knowledge gaps. We found the rate of first hospital encounter with upper urinary 
tract stones was significantly higher in patients with ADPKD compared to similar 
patients without ADPKD, although the rate of stone interventions was not significantly 
differ between the two groups. Ureteroscopy was also the most prevalent intervention 
type for both patients with and without ADPKD.  
There are several possible explanations for the increased rate of hospital encounters with 
stones in patients with ADPKD. Cysts may lead to more urinary stasis, which favours 
urinary crystals to form, cause stones to stagnate, and promotes stone growth leading to 
more upper urinary tract stones. Given their ongoing renal concerns, patients with 
ADPKD may also be more likely to present to hospital when they develop a stone 
compared to patients without ADPKD. We found no statistical difference in the rate of 
stone intervention between patients with ADPKD and similar patients without ADPKD. 
It is possible urologists were less inclined to perform interventions in patients with 
ADPKD with complex anatomy, choosing to favour medical treatments. Uric acid stones 
are the most prevalent stone in patients with ADPKD, and urologists may use dissolution 
treatment to treat these stones first, even in situations where the stones are large.84,85  
Studies examining the burden of upper urinary tract stones in patients with ADPKD 
relative to a non-ADPKD population are scarce. To date, only six cross-sectional studies 
report the prevalence of upper urinary tract stones in both patients with ADPKD and their 
unaffected family members.6–11 Two of six studies that performed statistical comparisons 
found that the prevalence of stones was not different between the two groups.7,8  The 
prior studies also did not adjust for any covariates in their analyses. To the best of our 
knowledge, our study is the first longitudinal study that adjusted for covariates and 





intervention between patients with ADPKD and controls with similar baseline health. It is 
also the largest study to date on this topic, and loss to follow-up was minimal with only 
about 2% of persons in the cohort emigrating from Ontario. We expect patients identified 
with ADPKD with the administrative coding algorithm truly had ADPKD given the high 
positive predictive value of ICD-10 codes that we used to identify patients with 
ADPKD.66 Additionally, we used inverse probability exposure weighting based on 
propensity scores to ensure our two groups had similar baseline indicators of health 
status; this allowed us to adjust for a large number of covariates prior to conducting 
statistical analyses.73 
Our study is not without limitations. A small number of events meant some estimates 
were imprecise. We did not have information on upper urinary tract stone events outside 
of the hospital, which represents a large proportion of stone events not captured in this 
study. This deficiency should be addressed in future studies. Some relevant information 
such as the amount of daily water consumed was also not available in our healthcare data 
sources, and some measures in our data sources could be miscoded. We also did not have 
information on the type of stone. These factors along with the observational design of our 
study raise the possibility of residual confounding. With our data sources we could only 
enter ADPKD patients with a history of at least one hospital encounter into the cohort, so 
the results may generalize less well to healthier segments of the ADPKD population. We 
could not ascertain which type of procedure was performed first in a small subset of our 
patients in both groups, because two or more different types of interventions were 
performed on the same day or within the same hospitalization.   
 
6.5 CONCLUSION 
Overall, our results suggest that ADPKD increases the rate of hospital encounters with 
upper urinary tract stones, and that urologists are not more or less aggressively managing 
stones in patients with ADPKD than in patients without ADPKD with otherwise similar 
baseline health. Future studies should focus on further quantifying the burden of upper 





development and minimize their impact on patient health. Additionally, future studies 
should explore whether additional, important subgroups, such as patients with larger total 
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Autosomal dominant polycystic kidney disease (ADPKD) is a genetic kidney disorder 
with no cure.1,2 It is characterized by focal cyst development which leads to progressive 
enlargement of both kidneys, and eventual kidney function loss.3–5 Much of the current 
research on patients with ADPKD is focused on delaying time to the onset of end-stage 
kidney disease (ESKD). However, ADPKD is a systemic disorder with other morbidities 
that warrant attention to prevent loss of health-related quality of life.6 One such morbidity 
is upper urinary tract stones.7 Stones in patients with ADPKD are a significant 
determinant of pain, and may be associated with a higher risk of ESKD.7,8 Currently, 
there is limited evidence on how best to manage upper urinary tract stones in patients 
with ADPKD.  
In the general population, stones less than four millimeters in size usually do not require a 
surgical intervention, and will often pass within four weeks of symptom onsets.9 Pain 
may be managed with narcotics or nonsteroidal anti-inflammatory drugs (NSAIDs).9 
However, urgent intervention is often required in the presence of infection/urosepsis, 
intractable pain, vomiting, impending acute renal failure, and/or significant obstruction.10 
Currently, shockwave lithotripsy (SWL), ureteroscopy, and percutaneous 
nephrolithotomy (PCNL) are potential treatment options; however, ureteroscopy is the 
most common intervention used in both patients with and without ADPKD.11 
A comprehensive systematic review conducted by our team confirms there is limited 
information on the risk of ureteroscopic complications in patients with ADPKD.12  All 
studies were either clinical case series or reports, and most studies reported data from a 
single center. Overall, these limitations lead to uncertainty in how to counsel patients 
with ADPKD on expected post-operative ureteroscopic complications. In this study, we 
described the 30-day cumulative incidence of selected ureteroscopic complications, all-
cause hospital presentation, all-cause hospital admission, and all-cause emergency 






7.2 PATIENTS AND METHODS 
7.2.1 Design and setting 
We conducted a retrospective cohort study using linked healthcare administrative 
databases held at ICES (a not-for-profit research institute). Healthcare services in Ontario 
are funded through the Ontario Health Insurance Plan (OHIP) program, with the 
exception of outpatient medications, which are only funded for segments of the 
population, including all people 65 years of age and older. These healthcare encounters 
are recorded in administrative databases, which are linked using unique, encoded 
identifiers and held at ICES. The use of ICES data in this project was authorized under 
section 45 of Ontario’s Personal Health Information Protection Act, which does not 
require review by a Research Ethics Board. No informed consent from patients was also 
required. We reported this study following guidelines set up for studies conducted using 
observational routinely-collected data. 
7.2.2 Data sources 
We created the study cohorts, described baseline characteristics, defined the exposure, 
and ascertained outcomes using administrative codes detailed in Table 7-1 and seven 
databases: CIHI-DAD, SDS, NACRS, OHIP, RPDB, CORR, and ODB. A detailed 
description of each of the Ontario healthcare administrative databases is described in 
Table A-1. All variables were complete, except for average neighbourhood income 
(missing in 0.18%) and urban or rural residency status (missing in 0.05%); we assigned 
the middle average neighbourhood income quintile and urban residence for these missing 
values, respectively.  
Table 7-1. Database and coding definitions for restriction criteria, baseline characteristics 
and outcome measurements. 
Variable Database & Administrative Codes 
Study Population  
Ureteroscopy CIHI-DAD & NACRS CCI: 1PE57BAAM, 1PE57BAGX, 
1PE59BAAG, 1PE59BAAS, 1PE59BAAT, 1PE59BAAZ, 
1PG57BAAM, 1PG57BAGX, 1PG59BAAG, 1PG59BAAS, 







OHIP Fee Codes: Z628 AND (E760 or E761 or Z627) 
Exposure 
Autosomal dominant 
polycystic kidney disease 
CIHI-DAD & NACRS ICD-10 codes: Q612, Q613 
Exclusion Criteria 
Shockwave lithotripsy 
performed in the previous 
90 days 
CIHI-DAD & NACRS CCI: 1PE59KQAP, 1PE59KQAQ, 
1PE59KQAR, 1PG59KQAP, 1PG59KQAQ, 1PG59KQAR 
 
OHIP Fee Codes: Z630 
Percutaneous 
nephrolithotomy performed 
in the previous 90 days 
 
CIHI-DAD & NACRS CCI: 1PE57DTAG, 1PE57DTAM, 
1PE57DTAS, 1PE57DTAZ, 1PE57DTBD, 1PE57DTGX 
 
OHIP Fee Codes: Z624 AND Z627 
Open stone surgery 
performed in the previous 
90 days 
CIHI-DAD & NACRS CCI: 1PE57LAAM, 1PE57LAGX, 
1PE57QWGX, 1PE59LAAG, 1PG57LAAM, 1PG57LAGX, 
1PG59LAAG, 1PG59LAGX 
Kidney transplant CIHI-DAD & NACRS CCP: 6759 
CIHI-DAD & NACRS CCI: 1PC85 
OHIP fee code: S435, S434 
CORR – RECIPIENT_TREATMENT dataset 
[Treatment_Code]: 171 
[Treatment_Date] 
[Transplanted_Organ_Type_Code] [1-3]: 10, 11, 12, 18, 19 
ADPKD (only for control 
group 
CIHI-DAD & NACRS ICD-9 codes: 7531 
CIHI-DAD & NACRS ICD-10 codes: Q611, Q612, Q613 
OHIP Dx codes: 753, 593 
Outcomes 
Acute kidney injury CIHI-DAD & NACRS ICD-10 codes: N17 
Urinary tract infection CIHI-DAD & NACRS ICD-10 codes: N10, 'N11, 'N12, N136, 
'N151, N159, N160, N300, N308, N309, N340, N390, N410, 
N411, N412, N413, N431, N45, T835 
Sepsis CIHI-DAD & NACRS ICD-10 codes: A021, A392, A393, A394, 
A400, A401, A402, A408, A409, A410, A411, A412, A403, 
A414, A4159, A413, A4150, A4151, A4152, A4158, A4180, 
















visits in the previous one 
year 
NACRS 
Primary care physician 
visits in the previous one 
year 
IPDB: Mainspecialty= GP/FP 
Hospital admission in the 
previous one year 
CIHI-DAD 
ICU admission in the 
previous one year 
CIHI-DAD CCP codes: 1361, 1362 
CIHI-DAD CCI codes: 1GZ31CAND, 1GZ31CRND, 
1GZ31GPND 





Acute interstitial nephritis CIHI-DAD & NACRS ICD-9 codes: 5837, 5838, 5839 
CIHI-DAD & NACRS ICD-10 codes: N10, N12 
Acute kidney injury CIHI-DAD & NACRS ICD-9 codes: 584 
CIHI-DAD & NACRS ICD-10 codes: N17 
Anemia CIHI-DAD & NACRS ICD-9 codes: 280, 281, 282, 283, 284, 
285 
CIHI-DAD & NACRS ICD-10 codes: D50, D51, D52, D53, 
D55, D58, D59, D61, D62, D63, D64 
OHIP dx codes: 280, 281, 282, 283, 284, 285 
Atrial Fibrillation CIHI-DAD & NACRS ICD-9: 4273 
CIHI-DAD & NACRS ICD-10: I48 
Chronic liver disease CIHI-DAD & NACRS ICD-9 codes: 4561, 4562, 070, 5722, 
5723, 5724, 5728, 573, 7824, V026, 2750, 2751, 7891, 7895, 571 
CIHI-DAD & NACRS ICD-10 codes: B16, B17, B18, B19, I85, 
R17, R18, R160, R162, B942, Z225,  E831, E830, K70, K713, 
K714, K715, K717, K721, K729, K73, K74, K753, K754, K758, 
K759, K76, K77 
OHIP dx codes: 571, 573, 070 
OHIP fee codes: Z551, Z554 
Chronic lung disease CIHI-DAD & NACRS ICD-9 codes: 491, 492, 493, 494, 495, 
496, 500, 501, 502, 503, 504, 505, 5064, 5069, 5081, 515, 516, 
517, 5185, 5188, 5198, 5199, 4168, 4169 
CIHI-DAD & NACRS ICD-10 codes: I272, I278, I279, J40, J41, 
J42, J43,J44, J45, J47, J60, J61, J62, J63, J64, J65, J66, J67, J68, 
J701, J703, J704, J708, J709, J82, J84, J92, J941, J949, J953, J961, 
J969, J984, J988, J989, J99 
OHIP dx codes: 491, 492, 493, 494, 496, 501, 502, 515, 518, 519 
OHIP fee codes:  J889, J689 
Coronary artery disease CIHI-DAD & NACRS ICD-9 codes: 412, 410, 413, 414, 4292, 





CIHI-DAD & NACRS ICD-10 codes: I20, I21, I22, I23, I24, I25, 
Z955, Z958, Z959, R931, T822 
CIHI-DAD & NACRS CCI codes: 1IJ26, 1IJ27, 1IJ54, 1IJ57, 
1IJ50, 1IJ76 
CIHI-DAD & NACRS CCP codes: 4801, 4802, 4803, 4804, 
4805, 481, 482, 483 
OHIP fee codes: R741, R742, R743, G298, E646, E651, E652, 
E654, E655, G262, Z434, Z448 
OHIP dx codes: 410, 412, 413 
Cystoscopy OHIP fee codes:  Z606, Z607, Z628, Z632, Z633, Z634 
Depression CIHI-DAD & NACRS ICD-9 codes: 2962, 2963, 3000, 3002, 
3003, 3004, 3091, 311 
CIHI-DAD & NACRS ICD-10 codes: F063, F064, F320, F321, 
F322, F323, F328, F329, F330, F331, F332, F333, F334, F338, 
F339, F341, F400, F401, F402, F408, F409, F410, F411, F412, 
F413, F418, F419, F420, F421, F422, F428, F429, F430, F431 
OHIP dx codes: 311 
OMHRS DSM-IV codes: 29189, 29284, 29289, 29383, 29384, 
29620, 29621, 29622, 29623, 29624, 29625, 29626, 29630, 29631, 
29632, 29633, 29634, 29635, 29636, 30000, 30001, 30002, 30021, 
30022, 30023, 30029, 30030, 30040, 30113 
Diabetes Mellitus CIHI-DAD & NACRS ICD-9 codes: 250 
CIHI-DAD & NACRS ICD-10 codes: E10, E11, E13, E14 
OHIP Dx codes: 250 
OHIP Fee codes: K045, K046, K029, K030, Q040 
Hemorrhage CIHI-DAD & NACRS ICD-9 codes: 430, 431, 432, 5307, 5310, 
5312, 5314, 5316, 5320, 
 5322, 5324, 5326, 5330, 5332, 5334, 5336, 5340, 5342,  
5344, 5346, 5780, 5781, 5693, 5789, 7191, 7192, 4590,  
5997, 5307, 5310, 5312, 5314, 5316, 5320, 5322, 5324,  
5326, 5330, 5332, 5334, 5336, 5340, 5342, 5344, 5346, 
 5693, 53501, 53511, 53521,7847, 7863, 6238, 6262 
CIHI-DAD & NACRS ICD-10 codes: I600, I601, I602, I603, 
I604, I605, I606,  
I607, I609, I61, I62, I850, I9820, I983, K2210, K2211,  
K2212, K2214, K2216, K226, K228, K250, K252, K254, K256, 
 K260, K262, K264, K266, K270, K272, K274, K276, K280,  
K282, K284, K286, K290, K3180, K6380, K920, K921, K5520, 
 K625, K922, M2509, M2501, M2502, M2503, M2504, M2505,  
M2506, M2507, M2508, M2500, M1229, M1221, M1222, M1223,  
M1224, M1225, M1226, M1227, M1228, M1220, R58, N020,  
N021, N022, N023, N024, N025, N026, N027, N028, N029,  
R310, R311, R318, K226, K250, K252, K254, K256, K260,  
K262, K264, K266, K270, K272, K274, K276, K280, K282,  






CIHI-DAD & NACRS CCP codes: 1302, 1303, 1304, 1305, 
1306, 1307, 1308, 1309 
CIHI-DAD & NACRS CCI codes: 1LZ19HMU1, 1LZ19HMU2, 
1LZ19HMU9, 1LZ19HHU9A, 1LZ19HHU9J,  
1LZ19HHU1A, 1LZ19HHU1J, 1LZ19HHU3J, 1LZ19HHU4J, 
1LZ19HHU2A,  
1LZ19HHU2J, 1LZ19HHU5J 
Hypertension CIHI-DAD & NACRS ICD-9 codes: 401, 402, 403, 404, 405 
CIHI-DAD & NACRS ICD-10 codes: I10, I11, I12, I13, I15 
OHIP Dx codes: 401, 402, 403 
Kidney tumor CIHI-DAD & NACRS ICD-9 codes: 1890, 1891, 2230 
CIHI-DAD & NACRS ICD-10 codes: C64, C65, D300 
OHIP Dx: 189, 2230 
Obesity CIHI-DAD & NACRS ICD-9 codes: 2780 
CIHI-DAD & NACRS ICD-10 codes: E65, E660, E661, E662, 
E668, E669 
OHIP Dx codes: 278 
Percutaneous tube/Ureteral 
stent 
OHIP Fee codes: E773, E776, E818, Z623, J046, Z629 
Prostatic hyperplasia CIHI-DAD & NACRS ICD-9 codes: N40 
CIHI-DAD & NACRS ICD-10 codes: 600 
OHIP Dx codes: 600 
Surgery OHIP Fee codes: S002, S003, S004, S005, S006, S007, S010, 
S011, S012, S013, S014, S015, S018, S019, S020, S021, S023, 
S024, S025, S028, S030, S031, S032, S033, S034, S035, S036, 
S042, S043, S044, S045, S046, S047, S049, S050, S057, S058, 
S059, S061, S062, S063, S065, S066, S067, S068, S069, S103, 
S104, S113, S114, S115, S116, S118, S119, S208, S209, S222, 
S223, S225, S226, S227, S228, S229, S231, S233, S234, S236, 
S237, S241, S242, S243, S246, S247, S248, S249, S251, S253, 
S256, S257, S258, S259, S260, S265, S266, S267, S268, S269, 
S270, S271, S272, S273, S274, S275, S276, S278, S280, S281, 
S282, S283, S284, S285, S287, S291, S292, S293, S294, S295, 
S297, S298, S299, S300, S301, S302, S303, S304, S305, S306, 
S307, S308, S309, S310, S311, S312, S313, S314, S315, S316, 
S317, S318, S319, S320, S321, S322, S323, S325, S326, S328, 
S329, S330, S332, S333, S334, S335, S336, S337, S338, S339, 
S340, S342, S343, S344, S345, S346, S347, S348, S349, S355, 
S372, S400, S401, S402, S403, S404, S405, S406, S407, S408, 
S409, S410, S411, S412, S413, S415, S416, S417, S418, S420, 
S421, S422, S423, S424, S426, S427, S428, S429, S430, S431, 
S432, S433, S434, S435, S436, S437, S438, S440, S441, S442, 
S443, S444, S445, S446, S447, S448, S449, S450, S451, S452, 
S453, S454, S455, S456, S457, S458, S459, S460, S461, S462, 
S463, S465, S466, S467, S468, S470, S471, S476, S477, S478, 





S490, S491, S502, S512, S513, S518, S519, S520, S521, S522, 
S523, S524, S525, S530, S531, S532, S533, S534, S535, S536, 
S537, S538, S539, S540, S541, S542, S543, S544, S545, S546, 
S547, S548, S549, S550, S551, S552, S553, S554, S555, S556, 
S557, S558, S559, S560, S561, S562, S563, S564, S566, S567, 
S568, S569, S570, S571, S572, S573, S574, S575, S576, S577, 
S578, S579, S580, S581, S588, S589, S590, S591, S592, S593, 
S595, S596, S597, S598, S599, S600, S601, S602, S606, S611, 
S616, S618, S619, S623, S625, S626, S630, S631, S636, S640, 
S641, S642, S643, S644, S645, S646, S647, S648, S649, S650, 
S651, S652, S653, S654, S655, S656, S700, S701, S702, S703, 
S704, S705, S706, S707, S708, S709, S710, S711, S712, S713, 
S714, S715, S716, S717, S718, S719, S720, S721, S722, S723, 
S724, S725, S726, S727, S728, S729, S730, S731, S732, S733, 
S734, S735, S736, S737, S738, S739, S740, S741, S742, S743, 
S744, S745, S746, S747, S748, S749, S750, S751, S752, S753, 
S754, S755, S756, S757, S758, S759, S760, S761, S762, S763, 
S764, S765, S766, S767, S768, S769, S770, S771, S772, S773, 
S774, S775, S776, S777, S778, S779, S780, S781, S782, S783, 
S784, S785, S786, S787, S788, S789, S790, S791, S792, S793, 
S795, S796, S797, S798, S799, S800, S805, S806, S807, S808, 
S810, S811, S812, S813, S815, S816, S900, R107, R108, R109, 
R110, R111, R112, R113, R114, R115, R116, R117, R118, R119, 
R120, R121, R122, R123, R124, R143, R144, R145, R146, R147, 
R148, R149, R150, R151, R152, R153, R154, R155, R156, R181, 
R182, R191, R192, R193, R194, R195, R196, R197, R198, R199, 
R200, R201, R202, R203, R204, R205, R206, R207, R208, R209, 
R210, R211, R212, R213, R214, R215, R216, R217, R218, R219, 
R220, R221, R222, R223, R224, R225, R226, R227, R228, R229, 
R230, R231, R232, R233, R234, R235, R236, R237, R238, R239, 
R240, R241, R242, R243, R244, R245, R246, R247, R248, R249, 
R250, R251, R252, R253, R254, R255, R256, R257, R258, R259, 
R260, R261, R262, R263, R264, R265, R266, R267, R268, R269, 
R270, R271, R272, R273, R274, R275, R276, R277, R278, R279, 
R280, R281, R282, R283, R284, R285, R286, R287, R288, R289, 
R290, R291, R292, R293, R294, R295, R296, R297, R298, R299, 
R301, R302, R303, R304, R305, R306, R307, R308, R309, R310, 
R311, R312, R313, R314, R315, R316, R317, R318, R319, R320, 
R321, R322, R323, R324, R325, R326, R327, R328, R329, R330, 
R331, R332, R333, R334, R335, R336, R337, R338, R339, R340, 
R341, R342, R343, R344, R345, R346, R347, R348, R349, R350, 
R351, R352, R353, R354, R355, R356, R357, R358, R359, R360, 
R361, R362, R363, R364, R365, R366, R367, R368, R369, R370, 
R371, R372, R373, R374, R376, R377, R378, R379, R380, R381, 
R382, R383, R384, R385, R386, R387, R388, R389, R390, R391, 





R402, R403, R404, R405, R406, R407, R408, R409, R410, R411, 
R412, R413, R414, R415, R416, R417, R418, R419, R420, R421, 
R422, R423, R424, R425, R426, R427, R428, R429, R430, R431, 
R432, R433, R434, R435, R436, R437, R438, R439, R440, R441, 
R442, R443, R444, R445, R446, R447, R448, R449, R450, R451, 
R452, R453, R454, R455, R456, R457, R458, R459, R460, R461, 
R462, R463, R464, R465, R466, R467, R468, R469, R470, R471, 
R472, R473, R474, R475, R476, R477, R478, R479, R480, R481, 
R482, R483, R484, R485, R486, R487, R488, R489, R490, R491, 
R492, R493, R494, R495, R496, R497, R498, R499, R500, R501, 
R502, R503, R504, R505, R506, R507, R508, R509, R510, R511, 
R512, R513, R514, R515, R516, R517, R518, R519, R520, R521, 
R522, R523, R524, R525, R526, R527, R528, R529, R530, R531, 
R532, R533, R534, R535, R536, R537, R538, R539, R540, R541, 
R542, R543, R544, R545, R546, R547, R548, R549, R550, R551, 
R552, R553, R554, R555, R556, R557, R558, R559, R560, R561, 
R562, R563, R564, R565, R566, R567, R568, R569, R570, R571, 
R572, R573, R574, R575, R576, R577, R578, R579, R580, R581, 
R582, R583, R584, R585, R586, R587, R588, R589, R590, R591, 
R592, R593, R594, R595, R596, R597, R598, R599, R600, R601, 
R602, R603, R604, R605, R606, R607, R608, R609, R610, R611, 
R612, R613, R614, R615, R616, R617, R618, R619, R620, R623, 
R621, R627, R628, R629, R632, R633, R634, R635, R636, R637, 
R638, R639, R640, R641, R642, R643, R644, R645, R646, R647, 
R648, R649, R650, R651, R652, R653, R654, R655, R656, R657, 
R658, R659, R675, R676, R677, R678, R679, R680, R681, R682, 
R683, R684, R685, R686, R687, R688, R689, R690, R691, R692, 
R693, R694, R695, R696, R697, R698, R706, R709, R710, R711, 
R751, R752, R753, R775, R776, R778, R781, R818, R819, R820, 
R821, R822, R823, R824, R825, R826, R827, R828, R829, R834, 
R835, R836, R837, R838, R839, R840, R841, R842, R843, R844, 
R846, R848, R849, R850, R851, R852, R853, R854, R866, R867, 
R868, R869, R870, R872, R873, R874, R878, R879, R885, R905, 
R907, R910, R911, R912, R913, R914, R915, R916, R940, R941, 
R942, R943, R944, R945, R946, R950, R951, R952, R953, R954, 
R956, R957, R958, R959, R960, R961, R962, R963, R964, R965, 
R966, R967, R968, R969, R970, R971, R972, R973, R974, R975, 
R976, R977, R978, R979, R990, R991, R993, R999, F000, F001, 
F002, F218, F627, Z219, Z220, Z221, Z273, Z279, Z280, Z281, 
Z290, Z291, Z296, Z297, Z298, Z299, Z301, Z302, Z303, Z304, 
Z305, Z306, Z308, Z309, Z310, Z311, Z312, Z313, Z314, Z315, 
Z316, Z317, Z318, Z319, Z320, Z321, Z322, Z323, Z324, Z325, 
Z326, Z327, Z328, Z329, Z330, Z331, Z332, Z333, Z334, Z335, 
Z336, Z337, Z338, Z339, Z340, Z341, Z342, Z343, Z344, Z345, 
Z346, Z347, Z348, Z349, Z350, Z351, Z353, Z354, Z355, Z356, 





Z411, Z412, Z413, Z414, Z415, Z422, Z423, Z424, Z425, Z426, 
Z427, Z428, Z429, Z430, Z431, Z432, Z433, Z434, Z435, Z436, 
Z437, Z438, Z439, Z440, Z441, Z442, Z443, Z444, Z445, Z446, 
Z447, Z448, Z449, Z450, Z451, Z452, Z453, Z454, Z455, Z456, 
Z457, Z458, Z459, Z460, Z461, Z462, Z463, Z464, Z465, Z466, 
Z470, Z475, Z477, Z478, Z480, Z496, Z497, Z498, Z499, Z512, 
Z513, Z514, Z515, Z520, Z523, Z524, Z525, Z526, Z527, Z528, 
Z529, Z530, Z531, Z532, Z533, Z534, Z535, Z536, Z537, Z538, 
Z539, Z540, Z541, Z542, Z543, Z544, Z545, Z546, Z547, Z548, 
Z549, Z550, Z551, Z552, Z553, Z554, Z555, Z556, Z557, Z558, 
Z559, Z560, Z561, Z562, Z563, Z564, Z565, Z566, Z567, Z568, 
Z569, Z570, Z571, Z572, Z573, Z574, Z575, Z576, Z577, Z578, 
Z579, Z580, Z581, Z582, Z583, Z584, Z585, Z586, Z587, Z590, 
Z591, Z592, Z593, Z594, Z595, Z596, Z597, Z600, Z601, Z602, 
Z603, Z604, Z605, Z606, Z607, Z608, Z609, Z610, Z611, Z612, 
Z615, Z616, Z617, Z618, Z619, Z620, Z621, Z622, Z623, Z624, 
Z625, Z626, Z627, Z628, Z629, Z630, Z631, Z632, Z633, Z634, 
Z635, Z636, Z637, Z638, Z640, Z662, Z700, Z701, Z702, Z703, 
Z704, Z705, Z706, Z707, Z708, Z709, Z710, Z711, Z712, Z713, 
Z714, Z715, Z716, Z717, Z718, Z719, Z720, Z721, Z722, Z723, 
Z724, Z725, Z726, Z727, Z728, Z734, Z735, Z736, Z737, Z738, 
Z739, Z740, Z741, Z742, Z743, Z744, Z745, Z746, Z747, Z748, 
Z749, Z750, Z751, Z752, Z753, Z754, Z755, Z756, Z757, Z758, 
Z759, Z760, Z761, Z762, Z763, Z764, Z765, Z766, Z767, Z768, 
Z769, Z771, Z772, Z773, Z774, Z775, Z776, Z777, Z778, Z779, 
Z780, Z781, Z782, Z783, Z784, Z785, Z787, Z788, Z800, Z801, 
Z802, Z803, Z804, Z805, Z806, Z807, Z808, Z809, Z810, Z811, 
Z812, Z813, Z814, Z815, Z816, Z817, Z818, Z819, Z820, Z821, 
Z823, Z824, Z825, Z826, Z827, Z869, Z870, Z873, Z941, Z942, 
Z943, Z944 
Urinary tract infection CIHI-DAD & NACRS ICD-9 codes: 5901, 5900, 5908, 5902, 
5909, 5950, 5958, 5959, 5970, 5990, 6016, 6011, 6012, 6013, 
6040, '6049 
CIHI-DAD & NACRS ICD-10 codes: N10, N11, N12, N136, 
N151, N159, N160, N300, N308, N309, N340, N390, N410, 
N411, N412, N413, N431, N45, T835 
Urinary tract obstruction CIHI-DAD & NACRS ICD-9 codes: 591, 5934, 5996 
CIHI-DAD & NACRS ICD-10 codes: N130, N131, N132, N133, 
N138 
OHIP Dx codes: 591 
Angiotensin-converting 
enzyme inhibitors or 









Calcium channel blocker ODB 
Diuretic ODB 
Proton pump inhibitors ODB 
Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; CCI, Canadian Classification of 
Health Interventions; CCP, Canadian Classification of Diagnostic, Therapeutic, and Surgical Procedures; 
CIHI-DAD Canadian Institute for Health Information Discharge Abstract Database; CORR, Canadian 
Organ Replacement Register; ICD-9, International Classifications of Diseases, 9th revision codes; ICD-10, 
International Classification of Diseases, 10th revision codes; IPDB, ICES Physician Database; NACRS, 
National Ambulatory Care Reporting System; OHIP Dx, Ontario Health Insurance Plan diagnosis codes; 
OHIP Fee, Ontario Health Insurance Plan fee for service codes; Registered Persons Database, RPDB 
 
7.2.3 Population and timeline 
We identified all patients who underwent ureteroscopy between April 1st, 2002 and 
March 31st, 2018 using OHIP fee and Canadian Classification of Health Intervention 
(CCI) codes. OHIP fee codes are submitted by physicians so they are paid for the 
interventions/procedures they perform. The OHIP fee codes for ureteroscopy have been 
extensively used in prior studies, and are expected to have excellent validity similar to 
other fee-for-service codes.13–15 CCI is a health-related intervention classification system 
developed by Canadian Institute for Health Information for administrative purposes. An 
accrual end date of March 31st, 2018 ensures that each patient had the potential for at 
least 30 days of follow-up. We excluded the following patients:  
(1) Missing or invalid encrypted unique identifiers, missing date of birth or sex, 
patients aged over 105 years, and those who died before cohort entry date for data 
cleaning purposes;  
(2) Visiting non-Ontarians who received care from a healthcare facility in Ontario to 
limit our study population to Ontarians. We will not have follow-up data on non-
Ontarians; 
(3) Patients aged 18 and under to exclude patients with autosomal recessive 
polycystic kidney disease who may have been misclassified as patients with 
ADPKD;  
(4) Patients with database codes for open stone surgery, SWL, and PCNL in the 
previous 90 days to ensure that ureteroscopy was the first stone intervention 





(5) Kidney transplant recipients to ensure the ureteroscopy was performed in the 
polycystic kidneys.  
Any stone intervention codes that appeared within 90 days of each other were considered 
interventions performed for the same stone.  
The cohort entry date, to reflect the time of the ureteroscopic procedure, was either the 
hospital discharge date (for patients who underwent ureteroscopy in a hospital), 
registration date (for patients who underwent ureteroscopy at the emergency department), 
or the date of the ureteroscopy (for patients who had the procedure performed in the 
outpatient setting). We looked back from cohort entry date until April 1st, 2002 (earliest 
date when could identify patients with ADPKD using our administrative databases and 
hence also defined our accrual start date) for International Classification of Diseases, 10th 
revision (ICD-10) codes related to ADPKD, and classified patients as having or not 
having ADPKD.16 ICD-10 codes related to ADPKD in our province have a positive 
predictive value of 85% (95% confidence interval [CI]: 79% to 89%), only identify 
patients who presented at the hospital with ADPKD, and differentiate patients with 
ADPKD from patients with other cystic kidney diseases.16,17 After classifying each 
patient as affected or not affected with ADPKD, we excluded patients with OHIP 
diagnosis codes for congenital anomalies of the urinary system (753) and other renal 
cystic disease (593) from the patients without ADPKD cohort only; although these OHIP 
diagnosis codes identify a lot of patients with ADPKD, the codes also indiscriminately 
capture a lot of patients with similar conditions.17 Therefore, excluding patients with 
OHIP diagnosis 753 and 593 would ensure that there are no patients with ADPKD in the 
control group. We also excluded patients with baseline characteristics that were present 
in one group but not the other as an approach to account for confounders (see Table 6-2). 
For patients who underwent more than one ureteroscopy, we included only the first 
ureteroscopy event. We followed each patient for 30 days from cohort entry date to 
ascertain outcomes. A follow-up of 30 days would ensure that there is sufficient time to 






Table 7-2. List of baseline characteristics that were present in one study group but not the 
other group.  
Category Variables 
Health care usea  Intensive care unit admission 
Comorbiditiesb Brain injury, cirrhosis, chronic obstructive pulmonary disease, 
hepatic failure, hepatorenal syndrome, HIV, microangiopathy, 
multiple sclerosis, neurogenic bladder, peripheral vascular disease, 
pneumonia, renal vein thrombosis, rheumatoid arthritis, 
schizophrenia or other psychotic disorders, sclerosis, sickle cell 
disease, spinal cord injury, urinary diversion, vasculitis, 
vesicoureteral reflux, vitamin D deficiency 
Medicationsc Aliskiren, anti-convulsant, anti-histamine, anti-neoplastic 
medications, carmustine, cisplatin, cyclosporine, glucocorticoid, 
gold compounds, methotrexate, leucovorin calcium, lithium, 
tacrolimus, or TMP-SMX antibiotics 
a The look-back period for health care use was 1-year. 
b The look-back period for comorbidities was 5-years. 
c The look-back period for medications was 120 days.  
7.2.4 Outcomes 
Outcomes assessed in the 30-days following ureteroscopy were hospital presentation with 
ureteroscopic complications (which was a composite outcome of either emergency 
department visit or hospital admission with acute kidney injury [AKI], urinary tract 
infection [UTI], or sepsis), all-cause hospital presentation (which is either emergency 
department visit or hospital admission for any reason), all-cause hospital admission, and 
all-cause emergency department visit. We identified hospital presentation with AKI, UTI, 
and sepsis using ICD-10 codes.18–20 The sensitivity and specificity of ICD-10 codes for 
each of the components of the composite outcome is as followed: 
• Sepsis presented during hospital admission or emergency department visit: 
Sepsis is a life-threatening condition characterized by a systemic inflammatory 
response to a severe infection.21 I will identify all hospital encounters for sepsis 
using the validated ICD-10 codes using CIHI-DAD and CIHI-NACRS (Table F-
1). Based on a previous validation study of ICD-10 codes related to sepsis, the 
sensitivity ranged from 5.9 to 51.1%, specificity > 92%, positive predictive value 






• AKI presented during hospital admission or emergency department visit: 
AKI is characterized by a sudden increase in serum creatinine.23 It is associated 
with increased mortality and longer hospital stay.23 I will identify patients with 
AKI using the validated ICD-10 codes with moderate sensitivity for patients who 
present with AKI at the emergency department (37.9%; 95% CI 32.1% to 43.1%), 
and hospital admission (61.1%; 95% CI: 57.5% to 65.5%), and high specificity 
(>95%) in both settings. 
• UTI presented during hospital admission or emergency department visits: I 
will identify all urinary tract infections presented at hospital admissions (CIHI-
DAD), or emergency department visits (CIHI-NACRS) using the validated ICD-
10 codes with a sensitivity of 49.5% (95% CI: 39.5% to 59.5%), specificity of 
96.6% (95% CI: 94.5% to 98.1%), and a positive predictive value of 77.3% (95% 
CI: 65.3% to 86.7%) (Table F-1).24 I will consider all recurrent events.24 
However, two or more codes billed within seven days will be considered as 
hospital encounters for a single infection.25 
Since the sensitivity of each of the ICD-10 codes for each of the component of the 
composite outcome is low, the estimated 30-day risk of ureteroscopic complication would 
be underestimated. However, the specificity of each of the ICD-10 codes for the three 
component is >95%, indicating that the codes differentiate patients with the conditions 
from those without the conditions. Although the risk of 30-days ureteroscopic outcome 
would be underestimated, the ICD-10 codes are likely capturing the more severe cases of 
AKI, UTI, and sepsis.  
7.2.5 Data analysis 
We assessed the baseline characteristics of both cohorts as mean and standard deviation 
for continuous variables, and as frequencies and percentages for binary or categorical 
variables. We used standardized difference, which are insensitive to sample size, to 
compare the baseline characteristics between patients with and without ADPKD. A 





We assessed the unadjusted and adjusted relative and absolute risk difference of 
outcomes and its respective 95% confidence intervals using modified Poisson regression 
with robust variance estimator, and binomial regression model with an identity link 
function, respectively. Although logistic regression is the most common model used to 
analyze binary outcome, we used modified Poisson to compare relative risk because 
modified Poisson model provides relative risk directly which is more easily interpretable 
than odds ratio. The outcomes were the dependent variable and the variables listed in 
Table 6-3 (risk factors of our outcome) were independent variables. 






Date of cohort entry, age, sex, neighbourhood income quintile, 
rural vs. urban residency, health service region of Ontario (local 
health integration network), 
Health care usea  Hospital admission, emergency department visit, and primary care 
physician visit 
Comorbiditiesb Acute interstitial nephritis, acute kidney injury, anemia, atrial 
fibrillation, chronic liver disease, chronic lung disease, coronary 
artery disease, depression, diabetes mellitus, hemorrhage, 
hypertension, kidney tumor, obesity, prostatic hyperplasia, urinary 
tract infection, urinary tract obstruction 
Proceduresb Cystoscopy, stent placed on cohort entry date, surgery 
Medicationsc Angiotensin converting enzyme inhibitor or angiotensin receptor 
blockers, proton pump inhibitors, diuretics, anti-diabetic 
medications, antibiotics, and calcium channel blocker 
Lab Values Estimate glomerular rate greater than or less than 60 
mL/min/1.73m2 
a The look-back period for health care use was 1-year. 
b The look-back period for comorbidities was 5-years. 
c The look-back period for medications was 120 days.  
We assessed for multicollinearity between all considered covariates using variance 
inflation factor (a variance inflation factor of >2 indicates presence of multicollinearity. 
The variance inflation factor was greater than two for proton pump inhibitors, diuretics, 
anti-diabetic medication, antibiotics, and calcium channel blockers. After omitting the 
latter four variables, the variance inflation factor was less than two for all remaining 





As post-hoc analysis, we examined the most common reasoning for presenting to 
the emergency department and median [interquartile range, IQR] time to the outcomes 
for both patients with and without ADPKD. All statistical analyses were performed using 
SAS 9.4 (SAS Institute, Inc, Cary, NC). We present the 95% confidence interval for all 
estimates, which corresponds to a significance level of 0.05.       
7.3 RESULTS 
7.3.1 Cohort selection and baseline characteristics 
Our cohort included 73 patients with ADPKD, and 81,445 patients without ADPKD who 
underwent ureteroscopy (Figure 7-1). Ureteroscopy was performed across 40 unique 
institutions for patients with ADPKD, and across 228 unique institutions for patients 
without ADPKD. The characteristics of both groups are summarized in Table 7-4. 
Compared to patients without ADPKD, patients with ADPKD were younger (median age 
44 vs. 53 years), and equally likely to come from a rural area (12% vs. 12%). About 40% 







Figure 7-1. Cohort selection. 
*Control groups were restricted to baseline characteristics present in ADPKD group to improve 





Table 7-3. Characteristics of patients with and without autosomal dominant polycystic 
kidney disease at the time of cohort.  
ADPKD  Standardized 
Differencea 
(%) 
  Yes                      
(n=73) 
No                         
(n= 81,445) 
Median (IQR) age, years 44 (38-60) 53 (42-64) 37 
Women, n (%) 29 (40) 31,521 (39) 2 
Income fifth:b 
   
  Quintile 1 (lowest) 16 (22) 15,034 (19) 0 
   Quintile 2  18 (25) 16,669 (21) 0 
   Quintile 3 14 (19) 16,610 (20) 0 
   Quintile 4 6 (8) 17,007 (21) 0 
   Quintile 5 (highest) 19 (26) 16,125 (20) 0 
Rural Townc, n (%) 9 (12) 9,891 (12) 1 
Median no. of visits to primary 
care physician in prior year (IQR) 
8 (3-12) 8 (3-13) 11 
No. of hospital admissions in the 
prior year (%) 
   
   0 37 (51) 65,359 (80) 64 
   1 24 (33) 12,687 (16)  40 
   2+ 12 (16) 3,399 (4) 41 
Median no. of visits to emergency 
department in the prior year 
(IQR) 
1 (1-3) 1 (1-2) 11 
Procedures in the prior five years 
unless specified otherwise, n (%) 
      
   Cystoscopy 61 (84) 68,631 (84) 2 
   Any type of surgery 41 (56) 33,795 (41) 30 
Comorbidities, in the prior five 
years, n (%)  
      
   Acute interstitial nephritis 10 (14) 3,006 (4) 36 
   Acute kidney injury 14 (19) 2,261 (3) 54 
   Anemia 10 (14) 7,919 (10) 12 
   Atrial fibrillation 6 (8) 6,645 (8) 0 
   Chronic liver disease 7 (10) 3,130 (4) 23 
   Chronic lung disease 9 (12) 15,303 (19) 18 
   Coronary artery disease 12 (16) 12,209 (15) 4 
   Depression 7 (10) 7,925 (10) 0 
   Diabetes mellitus 13 (18) 18,422 (23) 12 
   Hemorrhage (any type) 24 (33) 14,013 (17) 37 
   Hypertension 42 (58) 33,057 (41) 34 
   Kidney tumor 6 (8) 1524 (2) 29 
   Obesity 7 (10) 7,417 (9) 2 
   Prostatic hypertrophy 7 (10) 9,905 (12) 8 






ADPKD  Standardized 
Differencea 
(%) 
  Yes                      
(n=73) 
No                         
(n= 81,445) 
   Urinary tract obstruction 33 (45) 26,261 (32) 27 
Medication use in the prior 120 
days, n (%)d 
   
   ACE inhibitors or ARBs 10 (31) 9,803 (31) 0 
   Antibiotics 15 (47) 14,800 (47) 0 
   Calcium channel blockers 7 (22) 4,985 (16) 15 
   Diabetic medicationse 6 (19) 5,564 (18) 3 
   Proton pump inhibitors 6 (19) 4,694 (15) 11 
Kidney function, n (%)f 
   
   > 60 mL/min/1.73m² 34 (83) 33,402 (88) 14 
   < 60 mL/min/1.73m² 7 (17) 4,753 (12) 14 
Abbreviations: angiotensin II receptor blockers, ARBs; angiotensin converting enzyme inhibitors, ACE 
inhibitors; autosomal dominant polycystic kidney disease, ADPKD; interquartile range, IQR 
Date of cohort entry is discharge date for patients that underwent ureteroscopic procedure during same day 
surgery, or inpatient setting, registration date for patients that underwent ureteroscopy in the emergency 
department, and procedure date for patients who underwent ureteroscopy in an outpatient setting.  
a Unlike hypothesis testing, standardized difference is not influenced by sample size. A standardized 
difference of <10% indicates negligible difference. 
b Average neighbourhood income was categorized into fifths on index date. Income quintile was missing 
for 0.18% of the entire study cohort. For these individuals, middle income quintile was assigned. 
c Rural/urban residency status was missing for 0.05% of the entire study cohort. For these individuals we 
assumed they resided in an urban area 
d Data on prescription filled was only available in 32 patients with ADPKD, and 31,411 patients without 
ADPKD.  
e Diabetic medications represent a combination of insulin and anti-glycemic medications. 








None of the 73 (0%) patients with ADPKD and 142 of 81,445 (0.2%) patients without 
ADPKD died during 30-day follow-up.  
7.3.3 Outcome 
The risk of ureteroscopic complications was not significantly different between patients 
with and without ADPKD, although the estimates were imprecise (6 of 73 [8%] patients 
with ADPKD vs. 3,537 of 81,445 [4%] patients without ADPKD; adjusted RR 1.52, 95% 
CI 0.72 to 3.24) (Table 7-5). Median [IQR] time to ureteroscopic complication among 
those who had one was 16 (5 to 20) days in patients with ADPKD vs. 8 (4 to 15) days in 
patients without ADPKD.  
Compared to patients without ADPKD, patients with ADPKD were more likely to 
present to hospital after their procedure (26 of 73 [36%] patients with ADPKD vs. 16,345 
of 81,445 [20%] patients without ADPKD; adjusted RR 1.62, 1.19 to 2.20), which 
included a statistically significant increase in the risk of presenting to the emergency 
department (33% vs. 19%; adjusted RR 1.58, 95% CI 1.15 to 2.19) but not hospital 
admissions (8 of 73 [11%] vs. 4,076 of 81,445 [5%]; adjusted RR 1.78, 0.92 to 3.43) 
(Table 7-5). The most common diagnosis for those coming to the emergency room was 
renal colic or abdominal pain; nine patients with ADPKD and 3,908 patients without 
ADPKD presented to the emergency department with one of these diagnoses. Median 
[IQR] time to emergency department visit (6 [2 to15) days in patients with ADPKD vs 5 
(2 to 11) days in patients without ADPKD) is approximately the same between patients 





Table 7-4. Unadjusted, and adjusted 30-days risk of ureteroscopic complications, hospital presentation, hospital admission, 
and emergency department visits in patients with compared to patients without autosomal dominant polycystic kidney disease 
(ADPKD). 
 

















Outcome           
Ureteroscopic complication 6 (8) 3,537 (4) 1.89                  
(0.88 to 4.08) 
0.04                  
(-0.02 to 0.10) 
1.52  
(0.72 to 3.24) 
All-cause hospital 
presentation 
26 (36) 16,345 (20) 1.77                    
(1.30 to 2.42) 
0.16                
(0.05 to 0.27) 
1.62 
 (1.19 to 2.20) 
All-cause hospital 
admission 
8 (11) 4,076 (5) 2.19                  
(1.14 to 4.21) 
0.06                                 
(-0.01 to 0.13) 
1.78  
(0.92 to 3.43) 
All-cause emergency 
department visits 
24 (33) 15,479 (19) 1.73 
 (1.25 to 2.40) 
0.14                 
(0.03 to 0.25) 
1.58  
(1.15 to 2.19) 
 Abbreviations: autosomal dominant polycystic kidney disease, ADPKD; confidence interval, CI 
a Estimates were obtained using modified Poisson regression with outcomes as the dependent variable and ADPKD as the independent variable. 
b Estimates were obtained using binomial regression with identity link function with outcomes as the dependent variable and ADPKD as the 
independent variable. 
c Estimates were obtained using modified Poisson regression with outcomes as the dependent variable and the following as the independent variables: 
ADPKD, date of cohort entry, age, sex, rural residency status, income quintile, LHIN, healthcare encounter in the prior one year (hospital admission, 
emergency department visit, primary care physician visit, and intensive care unit visit), comorbid conditions (acute interstitial nephritis, acute kidney 
injury, anemia, atrial fibrillation, chronic liver disease, chronic lung disease, coronary artery disease, depression, diabetes mellitus, hemorrhage, 
hypertension, kidney tumor, obesity, prostatic hyperplasia, urinary tract infection, urinary tract obstruction), procedures performed in the prior five years 
(cystoscopy, percutaneous stent, and surgery), prescription filled in the prior 120 days (angiotensin converting enzyme inhibitor or angiotensin receptor 







The distorted kidney anatomy in patients with ADPKD may make performing 
ureteroscopy challenging compared to the general population. We described the 30-day 
risk of ureteroscopic complications, all-cause hospital presentation, all-cause hospital 
admission, and all-cause emergency department visit in patients with ADPKD, and 
compared it to patients without ADPKD. In general, all outcomes were common 
(although not necessarily statistically significant) in the ADPKD population. Specifically, 
the 30-days risk of ureteroscopic complications was not significantly different between 
patients with and without ADPKD, however, patients with ADPKD were more likely to 
present to hospital after ureteroscopy, which was driven by a statically significant 
increase in risk of presenting to the emergency department.  
Our group recently conducted a thorough systematic review summarizing the outcomes 
of the three commonly used stone interventions in patients with ADPKD. Currently, there 
are only six case series describing the post-ureteroscopy outcome in a total of 43 patients 
with ADPKD with the largest case series consisting of 13 patients with ADPKD.26–32 
According to the six published case series, the overall risk of complication ranged 
between 0% and 27%; post-operative complications described in the literature includes 
fever, pain, and hematuria.26–32 While case series and report provide insight into post-
operative outcomes of ureteroscopy experienced by patients with ADPKD, it does not 
provide strong empirical evidence into whether ADPKD is truly associated with 
ureteroscopic complications. Our cohort study is the first and largest study to date to 
examine this association (approximately six times larger than the largest published case 
series). Additionally, our study had minimal loss to follow-up; no patient with ADPKD 
died, and it is unlikely that many people would have travelled out of Ontario during the 
30-day follow-up.  
There may be reasons why patients with ADPKD presented to the emergency department 
after ureteroscopy more than patients without ADPKD. It is possible that patients with 
ADPKD may experience a ureteroscopic related complications that is not part of our 





the two case series published in the literature; as this was is nonspecific we did not 
include it in our composite outcome.28,32 Our post-hoc analysis showed that pain is the 
most common reason for presenting to the emergency department and confirm that 
presenting to the emergency department with pain is more prevalent in patients with 
ADPKD compared to patients without ADPKD.  
Our study is not without limitations. First, the codes for ureteroscopy have not been 
formally validated, so we had to rely on clinical expertise and knowledge of billing 
practices to define the outcomes. However, we expect the codes for ureteroscopy to have 
excellent validity similar to other fee-for services codes. The study is also limited by 
what is available in the healthcare administrative databases. We could not adjust for all 
important covariates, such as surgeon characteristics, and the accuracy and validity of 
each covariate was not perfect; this may have introduced residual confounding and 
affected the association between ADPKD and outcomes. We selected ureteroscopy 
complications that we thought would represent common issues encountered post-
operatively, and rare complications such as ureteral perforation, or common 
complications such as retained stone fragments/incomplete stone treatment could not be 
accurately measured with administrative data. Lastly, the low event number led to 
imprecision around the relative risk estimates. As a result, future studies with larger 
number of patients are needed.   
7.5 CONCLUSION 
In this study of patients who underwent ureteroscopy for upper urinary tract stones, those 
with ADPKD did not have a statistically significant higher 30-day risk of selected 
ureteroscopic complications. However, they did have a significantly higher 30-day risk of 
all-cause hospital presentation and all-cause emergency department visits. Past case-
series and reports and the results of this current study do not provide strong evidence 
against the use of ureteroscopy to remove upper urinary tract stones in patients with 
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8.1 SUMMARY OF KEY FINDINGS 
This doctoral thesis identifies knowledge gaps and explores the epidemiology of upper 
urinary tract stone and stone interventions, and the consequences of upper urinary tract 
stone management in patients with ADPKD. Our first systematic review of 49 studies 
showed that the prevalence estimates ranged widely from 3% to 59% for upper urinary 
tract stones and from 1% to 8% for stone interventions in the literature.1 The between-
study difference in prevalence estimates is due to inconsistent stone definitions, different 
distributions of stone risk factors, potential recall bias in studies that relied on patient 
self-reported data to identify stone events, and relying on past imaging reports done for 
reasons other than stone identifications. UTI and flank pain were the predominant 
precursor to diagnosis of stone, and uric acid stones are the most prevalent stone 
compositions in patients with ADPKD. Only six studies compared the prevalence of 
upper urinary tract stones in patients with ADPKD to unaffected family members.2–7 The 
two of six studies with controls that statistically compared the prevalence of upper 
urinary tract stones between the two groups showed no significant difference.2–7 
However, none of the studies adjusted for confounders. The wide-ranging prevalence 
estimates along with the discovery that no published studies clearly reported stone 
incidence confirms that there is poor consensus on how often patients with ADPKD 
develop or undergo intervention for upper urinary tract stones.  
Our second systematic review of 25 studies describing 311 patients (32 patients that 
underwent SWL, 42 patients that underwent ureteroscopy, and 237 patients that 
underwent PCNL) showed that percentage of patients who were stone-free after one 
session ranged from 0-69% after SWL, 73-100% after ureteroscopy, and 45-100% after 
PCNL.8 The percentage of patients with ADPKD that experienced at least one post-
operative complication ranged from 0-33% for SWL, 0-27% for ureteroscopy, and 0-
100% for PCNL. The wide-ranging estimates, which were limited by the sample size, 
shows that the efficacy and safety of stone interventions in patients with ADPKD remains 
uncertain.8 
The methodological quality of the published studies included in both systematic reviews 





better characterize the risk of upper urinary tract stones and stone intervention in patients 
with ADPKD, and to better understand the consequences of these three common stone 
interventions in patients with ADPKD. Conducting large cohort studies using healthcare 
administrative databases can help address this knowledge gap. However, validation of 
whether administrative codes related to ADPKD can reliably identify patients with 
ADPKD is first required. Our validation study shows that most patients with ICD-10 
codes Q61.2 (ADPKD) and Q6.13 (unspecified polycystic kidney disease) truly had 
ADPKD according to our strict clinical criteria.9 Another validation study that we 
conducted showed that ICD-10 codes related to ADPKD differentiate patients with 
ADPKD from patients with similar conditions.10 The second validation study also 
showed that OHIP diagnosis codes for congenital anomalies of the urinary system and 
other cystic kidney diseases identifies most patients with ADPKD but is indiscriminately 
also identifying patients without ADPKD.10 Therefore, we can use the ICD-10 codes 
related to ADPKD to build a robust cohort of patients with ADPKD and hospital 
encounters. We can also use OHIP diagnosis codes for congenital anomalies of the 
urinary system and other cystic kidney diseases as exclusion codes to exclude patients 
with ADPKD from the control group to ensure that the ADPKD and control groups are 
mutually exclusive. We used the ICD-10 codes to assemble our ADPKD cohorts for our 
two cohort studies and OHIP diagnosis codes to exclude patients with ADPKD from the 
control cohort. 
Our first cohort study fills some of the knowledge gap identified in our first systematic 
review. The results show that ADPKD is associated with an increased rate of hospital 
encounter with upper urinary tract stone in patients with ADPKD than patients without 
ADPKD with otherwise similar baseline health.11 The cysts may be compressing the 
collecting system leading to urinary stasis, which favours urinary crystals to form, stones 
to stagnate, and promote stone growth. Given their ongoing renal concerns, patients with 
ADPKD may be more likely to present to hospital when they develop a stone compared 
to patients without ADPKD. The increased surveillance may also explain the increased 
rate of hospital encounter with upper urinary tract stones. The results also showed no 
statistical difference in the rate of stone intervention between patients with ADPKD and 





interventions in patients with ADPKD with complex anatomy, choosing to favour 
medical treatments. Uric acid stones are the most prevalent stone in patients with 
ADPKD, and urologists may use dissolution treatment to treat these stones first, even in 
situations where the stones are large.12,13 Our first cohort study also showed that 
ureteroscopy is the most common type of stone intervention used to treat stone in both 
patients with and without ADPKD.  
Our second cohort study examined the post-operative ureteroscopic complications, all-
cause hospital presentation, all-cause hospital admission, and all-cause emergency 
department visit of the most commonly performed stone intervention, ureteroscopy. The 
results show that risk of ureteroscopic complication did not differ between patients with 
and without ADPKD. Patients with ADPKD were more likely to present to the hospital 
after the intervention, which included an increased risk of presenting to the emergency 
department but not hospital admission.14 There may be reasons why patients with 
ADPKD presented to the emergency department after ureteroscopy more than patients 
without ADPKD. It is possible that patients with ADPKD may experience a 
ureteroscopic related complications that is not part of our composite outcome. For 
example, pain is a post-ureteroscopic complication according to the two case series 
published in the literature; as this was is nonspecific we did not include it in our 
composite outcome.15,16 Our post-hoc analysis showed that pain is the most common 
reason for presenting to the emergency department and confirm that presenting to the 
emergency department with pain is more prevalent in patients with ADPKD compared to 
patients without ADPKD. Interestingly, this does not appear to be driven by stent related 
pain, as the placement of ureteral stents was similar between groups. 
 
8.2 IMPLICATIONS 
8.2.1 Laid the foundation for future research in ADPKD using 
administrative databases 
Understanding the performance of administrative codes related to ADPKD is important 





Chapter 5 of this thesis show that patients with ICD-10 codes related to ADPKD truly 
have ADPKD according to a strict clinical criterion.9 Another validation study conducted 
by our team shows that ICD-10 codes also differentiate patients with ADPKD from 
patients with similar conditions, but only identifies a subset of the ADPKD population.10 
The study also shows that OHIP diagnosis codes for congenital anomalies of the urinary 
system and other cystic kidney diseases capture most patients with ADPKD, but also a lot 
of patients with similar conditions.10 Therefore, future studies that use administrative 
databases can use ICD-10 codes to build a robust cohort of patients with ADPKD and can 
use OHIP diagnosis codes to exclude patients with ADPKD.  
8.2.2 Implications for clinical practice guidelines 
Many popular educational materials and clinical practice guidelines state that upper 
urinary tract stones are common in patients with ADPKD, and its prevalence may be five 
to ten times higher than the general population.17,18 Our systematic review and meta-
analysis of the prevalence and incidence of upper urinary tract stones in patients with 
ADPKD (Chapter 2) revealed that these assertions are based on weak evidence.  
Results from our first cohort study (Chapter 6) did show that rate of hospital encounter 
with upper urinary tract stone is higher in patients with ADPKD compared to patients 
without ADPKD with similar baseline health. However, the percentage of patients with 
ADPKD who experienced at least one hospital encounter with a stone (4%) and stone 
intervention (2%) is still relevantly uncommon. We acknowledge that the way stone is 
defined in the study does not identify many stone events, such as when the stone is 
passed at home or when it only requires care in an outpatient clinic, We recommend 
repeating this study in the future with more rigorous methodology. 
Although clinically significant stones are fairly uncommon in patients with ADPKD, 
stones remain a major determinant of pain.24 Stones are also known to accelerate disease 
progression in patients with CKD and this is suggested to be true in patients with 
ADPKD. 25,26 According to the exploratory risk factor analysis in Chapter 6, male sex is a 
risk factor for hospital encounter with stone and stone intervention. Therefore, a 





for upper urinary tract stones. They may also place a greater emphasis on preventing 
upper urinary tract stone formation by monitoring and managing any metabolic 
abnormalities. For example, hypocitraturia is a prevalent metabolic abnormality observed 
in patients with ADPKD and upper urinary tract stones.19–22 Hypocitraturia is when there 
is a low amount of citrate in the urine, and citrate is an inhibitor of stone formation. 
Screening for hypocitraturia and treating it with potassium citrate may help prevent upper 
urinary tract stones in high-risk stone formers with ADPKD. Nephrologists may also 
consider the use of foam sclerotherapy to eliminate predominant cysts that obstruct upper 
urine flow.23 Foam sclerotherapy is a procedure that reduces cyst volume by removing 
the fluid within the cyst and by instilling sodium tetradecyl sulfate to ablate cyst lining.23  
Even if stones are not frequent in patients with ADPKD, we still need to ensure that 
interventions are safe and efficacious in those patients who require intervention. If upper 
urinary tract stones do develop and grow to the extent that surgical intervention is 
needed, it is clear that we cannot draw conclusions about whether the three common 
stone interventions (SWL, ureteroscopy, and PCNL) are safe and efficacious in patients 
with ADPKD based on the evidence available from the published literature (Chapter 3). 
Our final cohort study (Chapter 7) provided preliminary results on the risk of 
complications after the most common stone intervention.14 The results show that ADPKD 
is not associated with a significant increase in ureteroscopic complications but is 
associated with an increased 30-day risk of all-cause emergency department visits.14 Post-
hoc analysis showed that the most common reason for emergency department is pain, 
which can be managed with medications. Therefore, based on the preliminary insight 
from our final cohort study, there are not sufficient evidence against performing 
ureteroscopy in patients with ADPKD. However, this needs to be further investigated in 
future studies. 
8.2.3 Clinical prognostication 
Identifying risk factors for upper urinary tract stones in patients with ADPKD can help 
target patients who may warrant closer monitoring and increased efforts to prevent upper 
urinary tract stone formation. Our exploratory analysis from Chapter 6 shows that men 





undergo stone interventions. Nephrologists may wish to monitor males with ADPKD 




The strength of this thesis is described in detail in the discussion section of each chapter 
of the thesis. However, the key strengths are highlighted below. 
First, we conducted two comprehensive systematic review to gain a thorough 
understanding of the current literature on the epidemiology and management of upper 
urinary tract stones in patients with ADPKD. We used a very comprehensive search 
strategy to identify relevant literature, and two reviewers independently screened and 
abstracted data carefully using a robust form in duplicate to minimize human error and 
bias. 
Second, we validated administrative codes related to ADPKD and our study showed that 
patients identified ADPKD-related ICD-10 codes truly have ADPKD (Chapter 5). The 
same codes also differentiate patients with ADPKD from patients with conditions similar 
to ADPKD. We used the codes validated in Chapter 5 to assemble our study population 
for chapter 6 and 7; therefore, our study populations were robust and internal validity of 
the studies were not compromised by the administrative codes used to assemble our study 
population.  
Third, to the best of our knowledge, Chapter 6 was the first and largest, longitudinal 
study that adjusted for covariates, and compared the rate of hospital encounter with upper 
urinary tract stones and stone intervention between patients with ADPKD and controls 
with similar baseline health. Additionally, Chapter 7 was the first and largest cohort study 
to date examining the association between ADPKD and complications post-ureteroscopy. 







Limitations of the thesis is described in details in the discussion section of each data 
chapter, and are reiterated in this section of the thesis. 
First, our two systematic reviews only included conference proceedings and original 
journal articles published in English.  
Second, we only reviewed medical charts from two hospitals within the London Health 
Sciences Center for our validation study (Chapter 4). While coding practices are 
standardized across hospitals in Ontario, there still may be slight difference in coding 
practices between the two hospitals and other hospitals across Ontario. Additionally, 
coding practices vary across the world. For example, in Ontario, physician fee diagnostic 
and fee-for service codes (OHIP codes) are submitted by physicians for the remuneration 
for the services they provide. ICD-10 codes are traditionally used for administrative 
purposes, such as assessing healthcare use and needs in hospital settings. In other regions, 
ICD-10 codes are used in outpatient settings as well. Therefore, findings from our 
validation study must be generalized to other regions with caution.  
Third, ICD-10 codes for ADPKD only identifies patients with a hospital encounter with 
ADPKD and does not identify patients with ADPKD who did not have any hospital 
encounter. Therefore, findings from chapter 6 and 7 must be generalized to patients with 
ADPKD without any hospital encounter with caution.  
Fourth, codes for stone interventions has not been formally validated, so we had to rely 
on clinical expertise and knowledge from billing practices to define stone intervention. 
However, we expect the codes for stone intervention to have excellent validity similar to 
other fee-for service codes.  
Fifth, chapters 6 and 7 were limited by what is available in healthcare administrative 
databases held at ICES. Therefore, we could not adjust for all important covariates, such 
as stone size and location, water intake for chapter 6, and surgeon characteristics for 
Chapter 7. Additionally, the validity of all the included covariates is not perfect, and 





Sixth, the number of upper urinary tract stones events is under-reported in chapter 6 
because we used ICD-10 codes to identify upper urinary tract stone events. ICD-10 codes 
only identify patients who had a hospital encounter with upper urinary tract stones and 
does not capture upper urinary tract stone events presented at an outpatient clinic or that 
simply passed at home.  
Last, the small number of events in both chapters 6 and 7 led to some imprecise 
estimates.  
 
8.5 FUTURE DIRECTIONS 
While this thesis addressed many knowledge gaps, and addressed many questions about 
the epidemiology of upper urinary tract stones in patients with ADPKD, there still 
remains many unanswered questions.  
First, linking a registry of a large number of patients with ADPKD and their unaffected 
family members with precise collection of baseline and outcome measures will provide a 
better estimate of risk. In our studies, we were limited by what was available through 
healthcare administrative databases held at ICES. As a result, we could not identify 
patients with ADPKD with a wide spectrum of disease. We also could not adjust for 
important confounders such as diet and water intake. By comparing the outcomes to an 
unaffected family member, we would be indirectly adjusting for lifestyle and by linking a 
registry with prospectively collected baseline data we can supplement the data from 
administrative databases with registry data to minimize residual confounding. 
Second, while we know that upper urinary tract stones accelerate disease progression in 
patients with CKD, this is only suggested to be true in patients with ADPKD.25,26 Future 
studies should determine whether upper urinary tract stones truly accelerate disease 
progression to ESKD in patients with ADPKD.  
Third, while Chapter 6 gives some insights into risk factors for upper urinary tract stone 





stones, such as total kidney volume and mutation type, should be explored. Identifying 
risk factors for upper urinary tract stones would help clinicians identify which particular 
patients should be monitored more closely and targeted for preventative therapy for upper 
urinary tract stones.  
Fourth, while chapter 7 provided preliminary insight into the complication rates of 
ureteroscopy in patients with ADPKD compared to patients without ADPKD with 
otherwise similar baseline health, the estimates were imprecise. The same study should 
be repeated with a larger sample size achieved by conducting national level study or a 
longer accrual period in the future to get a better understanding of the complication rates 
of ureteroscopy in the future.  
Last, this thesis did not explore the success and complication rates of SWL and PCNL. 
Chapter 3 confirms that evidence for the success and complication rates of SWL and 
PCNL is limited. Therefore, future, large, multi-center, prospective or retrospective 
cohort studies should be conducted to understand the safety and efficacy of SWL and 
PCNL in patients with ADPKD.  
 
8.6 CONCLUSION 
Kidney failure is not the only manifestation of ADPKD. ADPKD is a systemic disorder 
with many other manifestations that warrant attention to maintain or improve quality of 
life. This thesis confirms that hospital encounters with upper urinary tract stones are a 
manifestation of ADPKD. The urologists are not more or less likely to manage stones 
compared to patients with otherwise similar baseline health. The distorted kidney 
anatomy may make performing stone interventions more challenging. Of all three 
commonly used interventions (SWL, ureteroscopy, and PCNL), ureteroscopy is the most 
prevalent intervention used to manage stones in both patients with and without ADPKD. 
Our final thesis study shows that ADPKD is not associated with a statistically significant 
increase in ureteroscopic complications and all-cause hospital admission but is associated 





department visits. Currently, there is insufficient evidence to show that we should 
discontinue using ureteroscopy to manage upper urinary tract stones. The knowledge 
gained from this thesis identifies this knowledge gap and lays the foundation for future 
studies on ADPKD using healthcare administrative databases. It clarifies the rate of 
hospital encounters with upper urinary tract stones and the rate of stone interventions, and 
provides the best evidence we have to date to inform clinical practice.  
 
8.7 TAKE HOME MESSAGE 
• We can reasonably identify patients with a hospital encounter with ADPKD using 
ICES data 
• Incidence and prevalence of upper urinary tract stone and stone intervention in 
ADPKD, and the safety and efficacy of the three common stone interventions 
(SWL, ureteroscopy, and PCNL) are unclear. 
• The rate of a hospital encounter with upper urinary tract stone is higher in patients 
with ADPKD than patients without ADPKD with similar baseline health. The 
percentage of patients with ADPKD who experience a clinically significant stone 
event remains relatively uncommon (4%) 
• Urologists are not more or less aggressive in their management of stones in 
patients with ADPKD compared to patients without ADPKD.  
• Patients with ADPKD are more likely to visit to the emergency department within 
30 days of ureteroscopy for stone disease compared to patients without ADPKD 
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APPENDIX A: Detailed descriptions of ICES data 






Table A-1. Detailed description of ICES data sources used in Chapters 5 to 7. 
DATABASE DESCRIPTION 
Canadian Institute for Health Information 
(CIHI) Discharge Abstract Database 
(DAD), CIHI Same Day Surgery (SDS), and 
CIHI National Ambulatory Care Reporting 
System (NACRS) 
CIHI-DAD contains administrative, demographic, and clinical information 
on hospital discharges of patients admitted to acute care hospitals in Ontario, 
SDS contains information on same day surgery, and NACRS contains 
information on all emergency department visits. The diagnostic and 
procedural information are coded using the 9th edition of the Canadian 
Modified International Classification of Diseases (ICD-9-CM) and the 
Canadian Classification of Diagnostic, Therapeutic, and Surgical Procedures 
(CCP) codes, respectively, prior to April 1st, 2002, and coded using the 10th 
edition of the Canadian Modified International Classifications of Diseases 
(ICD-10-CM) and the Canadian Classification for Health Interventions 
(CCI) codes, respectively, from April 1st, 2002 and onwards.119  
Ontario Health Insurance Plan (OHIP) 
Database 
OHIP contains most claims covered under the provincial health insurance 
plan. Approximately 95% of the specialist and 50% of the family care 
physicians in Ontario get paid on a fee for service basis.  
Ontario Registered Persons Database 
(RPDB) 
RPDB contains reliable demographic and vital statistics, such as birth and 
death data, of all Ontarians with a valid health card number.  
ICES Physician Database (IPDB) IPDB is created by ICES and contains information about all physicians, 
including practice location, and clinical specialties. It comprises information 
from the OHIP Corporate Provider Database (CPDB), the Ontario Physician 
Human Resource Data Centre database, and the OHIP database of physician 
billing. 
Canadian Organ Replacement Register 
(CORR) 
CORR is a national information system that contains detailed information on 
everyone who has received an organ transplantation or is on chronic 
dialysis.120 At ICES, we only have access to data from Ontario. 
Ontario Drug Benefits (ODB) ODB contains information on outpatient prescriptions dispensed to patients 
aged 65 years and older, patients who live in a Long-Term Home or Home 
for Special Care, patients enrolled in Home Care Program, patients enrolled 
in the Trillium Drug Program, and patients who receive social assistance 
from Ontario Works or the Ontario Disability Support program. The data 





The health card number of Ontarians is encoded using a unique ICES key number, which is used as a common identifier to link databases at ICES 
together.  
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